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Abstract
The success of cancer gene therapy is hindered by various physiological barriers to 
therapeutic vector transport from the site of injection to the nucleus of all the tumor cells. 
The application of replicating viruses for the treatment of cancers can overcome this 
problem. But this approach is limited by normal tissue tolerance of toxicity determined 
by local concentration of transgene products and viral proteins. Major improvements in 
vector targeting technology are required before any clinical success. On this basis, this 
thesis tests the hypothesis to target transformed tumor cells by using a novel post- 
translational mRNA stabilizing mechanism, which is occasionally deregulated in cancer. 
The overexpression of various proteins associated with rapid responses to inflammation 
and/or proliferation can be controlled at the level of mRNA stability. Since tumor cells 
continually recapitulate intracellular programs of proliferation, we hypothesize that we 
can use the tumor cell selective stabilization of mRNA as a novel means to target 
different malignant diseases.
Cyclooxygenase (COX) is the key enzyme in the conversion of arachidonic acid to 
prostaglandin during inflammation and many studies have linked elevated expression of 
COX-2 to the pathology of breast, colorectal, head and neck and other types of cancer. It 
has been shown that the up-regulation of COX-2 is a downstream effect of RAS- 
mediated transformation. Although the COX-2 over-expression in cancer is associated 
with increased transcription of the COX-2 gene, a large component of RAS-induced up- 
regulation is also mediated by a selective stabilization of the mRNA of the COX-2 gene 
in RAS-transformed cells. In this project, we show tumor selective mRNA stability via 
COX-2 3’ UTR by fusing it with the adenovirus early essential gene El A, thereby
obtaining a conditionally replicating adenovirus vector which will preferentially replicate 
in the RAS transformed cells.
There are wide range of genes reported in the literature with 3'UTR, which confers 
destabilized activity on their cognate mRNA, but whose actions are reversed under 
certain physiological conditions. These include hypoxia responsive 3'UTR, radiation 
responsive elements and 3' UTR, which mediate increased mRNA stability in 
proliferating cells. Therefore, the linkage to 3’UTRs is a general strategy that could be 
used to confer tumor cell specificity to expression of therapeutic and/or replicative genes 
in a wide variety of vectors and to target specific physiological situations within tumors.
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Chapter 1 
Introduction
1
1.1 Gene therapy
1.1.1 Introduction to gene therapy
The basic principle of gene therapy is to introduce a functional gene into a diseased target 
cell and restore the normal physiological function of that gene in order to revert the disease 
state or slowdown the progression of the disease. Over the years, a large number of 
inherited and acquired diseases have been targeted by gene therapy to provide new therapy. 
But success is considerably limited by the inability to develop a safe and effective gene 
transfer vehicle with which to transport genetic material into the target cells. The first 
major success in the field of gene therapy was the retrovirus-based therapy for infants 
suffering from the X-linked severe combined immune deficiency (SCID-X1) and showed 
real promise for long-term and even permanent cure of hereditary diseases (Cavazzana- 
Calvo et al., 2000). However, the field suffered serious setbacks from recent findings that 
two of the SCID-X1 -treated patients developed a leukemia-like condition due to the vector- 
mediated insertional mutagenesis (Hacein-Bey-Abina et al., 2003). It has rapidly become 
obvious that major improvements are required in all aspects of gene delivery vector 
development and targeting of gene expression in order to treat any disease successfully 
using gene therapy. Also, various features of each vector and type of disease need to be 
defined before decisions are made as to which vector should be applied. The purpose of 
this part of the chapter is to describe the development of the field of gene therapy by 
discussing the history, the problems and the premise of this field.
1.1.2 A brief history of human gene therapy.
The concept that genes can be used to treat human diseases goes back several decades. 
In the early 60s, when the fundamentals of molecular genetics and gene transfer technology
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in bacteria were established, gene transfer into animal and human became inevitable. But it 
wasn’t until the discovery of reverse transcriptase and sequence-specific restriction 
endonucleases in the late 60s and 70s that gene therapy became a reality. In this part of the 
chapter, I will briefly review the revolution of molecular genetics and technology that gave 
birth to the field of human gene therapy.
1.1.2.1 The early development of gene therapy
The concept of gene therapy came before the molecular genetics revolution, beginning 
with the discovery by Oswald Avery and his colleagues that a gene could be transferred 
within nucleic acids during the Second World War (Avery and McCarthy 1944). They were 
able to demonstrate that transferring genomic DNA from one strain of bacteria to another 
changes the recipient’s phenotypes into that of the donor’s. The ability of viruses to 
transmit genes was first demonstrated in Salmonella by Zinder and Lederberg, which is 
thought to be a critical point of reference in terms of the development of gene transfer 
technology (Zinder & Lederberg, 1952). Then Elizabeth Szybalska and Wadaw Szybalski 
performed the earliest mammalian gene transfer experiments, where they were able to 
transform mammalian cells with a foreign DNA (Szybalska & Szybalski, 1962). In 1968, 
researchers from Salk Institute were able to immortalize mammalian cells by SV40 viral 
DNA and demonstrated the integration of proviral DNA into the host genome (Sambrook et 
al., 1968) . The ability of virus to transfer foreign genetic materials in the target cells and 
the fact that such genetic information can be stably expressed sparked the idea of treating 
genetic diseases by substituting a normal gene for a defective one.
3
1.1.2.2 Virus as a vehicle of gene transfer
In the late 1960s, Stanfield Rogers and his research group in the Oak Ridge National 
Laboratory in Tennessee were working with the Shope papiloma virus, which had long 
been known to cause warts in rabbits when applied topically to rabbit skin. In the late 
1950s, Rogers’s group reported that Shope papilloma virus infected rabbits skin cells 
contained high levels of active arginase (Rogers, 1959). Because no detectable arginase 
activity was observed in the normal rabbit skin, they concluded that the virus genome 
contained an arginase gene, which was introduced in the skin cells by transduction. At the 
same time several other investigators had demonstrated that the arginase found in the 
Shope papilloma virus infected rabbit skin cells showed very similar physical and chemical 
properties of the arginase found in the normal rabbit liver (Satoh & Ito, 1968). These 
observations were contradictory to Rogers’s conclusions about the Shope papilloma virus- 
mediated arginase induction and were somehow overlooked by his group. However, one 
reproducible observation made by Roger’s group was the decreased serum arginine level 
after the systemic administration of Shope papilloma virus in rabbits. In 1966, they also 
reported that researchers who worked with the Shope papilloma virus in Roger’s laboratory 
had prolonged decreased levels of serum arginine. Based on these observations, in 1970s 
Rogers and his colleagues had become involved in testing the Shope gene transfer model 
for clinical application to cure hyperargininemia, a human disease caused by a defect in 
urea cycle in the liver and characterized by elevated serum arginine levels and deficiency in 
cellular arginase enzyme activity (Terheggen et al., 1972). Large amounts of purified 
Shope papilloma virus were injected systemically into two sick children with 
hyperargininemia (New York Times, 20 September 1970). The clinical argument behind
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this premature and probably very first human gene therapy clinical trial was no alternative 
treatment available at that time for hyperargininemia and aggressive new approaches were 
the only way to help those patients (Rogers & Pfuderer, 1968) (Rogers, 1968). Several 
years later, in their final publication on hyperargininemia gene therapy study, Rogers and 
his collogues reported that the systemic administration of the Shope papilloma virus into 
the patients with hyperargininemia did not reduce the serum arginine levels or alter the 
course of the disease (Terheggen et al., 1975).
The scientific community heavily criticized this clinical study at that time. It is not 
difficult for us to understand why the hyperargininemia clinical trial failed. Rogers’s group 
neither had enough information about the Shope papilloma virus, nor they had any clear 
ideas about the source and the mechanism of the Shope papilloma virus-induced arginase 
activity. Now the Shope papilloma virus genome has been sequenced (Giri et al., 1985) and 
we know that viral genome does not contain any arginine gene. There is no doubt that these 
experiments were attempted too early, before the necessary technologies were developed. 
But one should remember Rogers’s attempt to cure hyperargininemia as we commemorate 
the Wright brothers’ innovation. It was crude, but taught us how to fly, inspired us to 
explore space. As Theodore Friedmann said (Friedmann, 2001), “perhaps the most 
interesting part of this history, even in the face of the flawed design and failure of the 
clinical study, was Rogers’s insight into the potential use of viruses as vectors to add new 
genetic information into human cells for therapy.”
1.1.2.3 The development of viral vector for gene therapy
The controversies surrounding the first human gene therapy clinical trial by Rogers’s 
group concealed their groundbreaking attempt to produce one of the earliest viral vector for
5
gene therapy (Jackson et al., 1972). The tobacco mosaic virus (TMV), which causes 
diseases in tobacco plants was one of the best understood eukaryotic viruses at that time 
and all the assays required for studying this virus were readily available. Rogers and his 
colleagues elected to chemically modify the RNA genome of the TMV virus and to show 
that in Jackson’s word, “ sequences of nucleotides can be added to a virus RNA in vitro 
and the virus used as a vector to transmit the desired information”. They were able to add 
poly (A) sequences to purified TMV RNA genome by using the polynucleotide 
phosphorylase and reported that plants infected with this modified virus contained elevated 
levels of tetra-lysine and penta-lysine oligomers, indicating expression of the modified 
poly(A) added to viral genome.
In the early 1970s, Paul Berg and his group from Stanford University foresaw the potential 
of using virus to introduce the corrective genetic materials into victims of genetic diseases 
and developed the first viral vector system based upon the rhesus polyoma virus (SV40). 
They were able to introduce new genetic information such as the X phage DNA and the 
galactose operon gene from E. coli into the SV40 DNA (Jackson et al., 1972). But the 
alarming ability of the SV40 virus to transform cells in the culture and cause cancer in 
rodent delayed the testing of these vectors (Watson, DNA 2003). In 1976, Burg was able 
to show that the recombinant SV40 vectors carrying lambda phage DNA were able to 
propagate in cultured kidney cells (Goff & Berg, 1976). In the late 1970s, the reverse 
transcriptase enzyme was discovered and Berg and his colleagues were able to show that in 
vitro synthesis of rabbit globin cDNA. Then they exchanged the globin cDNA with the 
major capsid protein, VP1 of the SV40 virus and showed that cells infected with this 
recombinant virus expressed the rabbit-globin protein (Mulligan et al., 1979). Both Roger’s
6
and Berg’s experiments were milestones for the development of viral vectors in gene 
therapy.
1.1.2.4 Early gene transfer studies in animals and human
In 1980, the head of the department of hematology at UCLA, Martin Cline and his 
group successfully transferred the DHFR gene by using calcium phosphate transfection into 
mouse bone marrow cells in vitro. Then they transplanted the modified cells into irradiated 
mice and showed that the recipient animals had an increased percentage of donor marrow 
cells with elevated DFHR enzymatic activity (Cline et al., 1980). Based on this 
experimental data, Cline and his colleagues transferred the p-globin gene in human bone 
marrow with a calcium phosphate transfection method, which was then transplanted back 
into the thalassaemia patients in Italy and Israel (Beutler, 2001). Although the patients 
suffered no adverse effects from the therapy, this clinical trial was criticized for both the 
scientific and the procedural design. Cline was disciplined by his home institution and by 
NIH (Wade, 1981) for breaking the institution guidelines, therefore, NIH established a new 
rule for all new gene therapy trials to be approved by the Recombinant DNA Advisory 
Committee (RAC).
In the early 1980s, two other successful gene transfer experiments in animal models are 
worth mentioning in this overview. In the first study carried out by Rubin et al., where they 
transferred a normal xanthine dehydrogenase gene, which is responsible for wild-type eye 
color in Drosophila, into embryos containing the defective gene by using transposon and 
were able to restore the wild-type eye color (Rubin et al., 1982). The second experiment 
was a retrovirus-mediated growth factor transferred into transgenic dwarf mice, which 
mimicked human pituitary dwarfism and resulted in the correction of murine dwarfism
7
(Hammer et al., 1984). But the mice grew 50% larger than the normal size due the 
deregulated expression of the corrective gene.
1.1.2.5 Gene therapy begins to come of age
Steven Rosenberg and French Anderson did the first approved clinical trial for human 
gene therapy on May 22, 1989, where they used a retrovirus to transduce the tumor- 
infiltrating lymphocytes (TIL) with the neomycin resistance gene as a marker for the 
infused cells (Morecki et al., 1991). The aim of this trial was not therapy, but to evaluate 
the applicability and side effects of this method. Five patients received the gene-modified 
TIL. The presence and expression of the neomycin-resistance gene were detected in TIL 
from all the patients with southern blot and cells from four out of five patients grew 
successfully in high concentration of a neomycin analogue, G418. This study was able to 
demonstrate the safety of the retroviral vector-mediated gene transduction for human gene 
therapy. The first RAC-approved human gene therapy trial with a therapeutic aim began 18 
month later. This time, Anderson and his colleagues at NIH attempted to cure severe 
combined immune deficiency (SCDD), a monogenic disease caused by the lack of the 
enzyme adenosine deaminase (ADA). They were able to insert an ADA gene into T cells of 
two children suffering from SCID (Blaese et al., 1995). Although the infusion of corrective 
gene-modified T cells did not fully reverse the disease symptoms, it did significantly 
reduce the amount of the drug PGE-ADA needed to treat them (Blaese et al., 1995).
1.1.3 Viral Vectors for Gene Therapy
Viruses have evolved for thousands of years to become a biological machine that 
efficiently gains access to host cells and hijacks the cellular machinery to support their 
replication. The idea behind virus-based vectors for gene therapy application utilizes the
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viral infection pathways to deliver desired genetic information, but avoids the subsequent 
expression of viral genes, which leads to viral replication and toxicity. This is achieved by 
replacing all, or some, of the coding regions from the viral genome with the genetic 
information of a desired therapeutic gene, but leaving intact those genes that are required 
for the packaging of vector genome with the therapeutic gene into the viral capsid. The 
deleted genes encoding proteins are usually essential for virus replication or 
capsid/envelope proteins, which are included in a separate construct in the 
packaging/producer cells to provide helper function in trans. The recombinant 
nonreplication vector particles carrying a therapeutic gene can be produced by introducing 
the modified vector sequence into the producer cells (Figure 1.1). The ability to insert 
desired genetic information into a replication defective viral vector is the backbone of 
developing virus-based gene transfer technology.
All the currently available viral vectors for gene therapy are based on the different 
which viruses can be categorized into two groups: I) integrating vectors and II) 
nonintegrating vectors (Verma & Weitzman, 2005) Vectors based on oncoretrovirus, 
lentivirus and adeno-associated virus can integrate packaged sequences into the host cell 
chromosomal DNA and maintain lifelong gene expression. Adenovirus and herpes simplex 
virus based vectors are nonintegrating vectors. The packaged genetic information delivered 
by these vectors remains episomal in the nucleus of the target cells. In this part of the 
chapter, I will give a brief overview of the development of all the major gene therapy 
vectors derived from different viruses.
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Figure 1.1 Principle of generating a viral vector for gene therapy, (a) Different viral 
genes that are involved in replication, production of the virion, and pathogenicity after viral 
infection. The packaging constract contains only genes that requires for replication and 
structural proteins. The vector construct contains the essential cis-acting packaging signals 
and the transgene cassette that contains the therapeutic gene, (b) The packing and vector 
constructs are introduced into the packaging cells by transfection, which stably expressed 
proteins required for replication and assembly for the recombinant vectors. Adapted from 
Kootstra (2003).
1.1.3.1 Retrovirus
Retroviruses are a large family of enveloped viruses, which contain two copies of the 
RNA viral genome flanked by 5’ and 3’ terminal repeats (LTR) (Pages & Bru, 2004). The 
RNA genome holds three essential genes: the gag gene that encodes for the core proteins
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capsid, matrix and nucleocapsid; the pol gene which encodes for the viral enzymes 
protease, reverse transcriptase and integrase; and the env gene encodes for envelope 
glycoproteins, which mediate virus entry. After binding to its receptor, the viral capsid 
containing the RNA genome enters the cell through membrane fusion and the RNA 
genome converts into double-stranded proviral DNA by the viral enzyme reverse 
transcriptase. The proviral DNA then translocates to the nucleus with the preintegration 
complex during mitosis and integrates into the host cell genome by the viral integrase.
Retrovirus based vectors are amongst the earliest and most widely used viral vectors for 
gene therapy (Shimotohno & Temin, 1981). These vectors were initially based on gamma 
retrovirus genus, mainly Moloney murine leukaemia virus (MoMuLV). To generate 
recombinant retroviral vectors, the gag, pol and env genes are replaced by the cDNA of 
therapeutic gene up to 6-7 kb in a vector, which only contains the packaging signals and 
two LTRs. All three deleted viral genes are constitutively expressed in a cell line known as 
packaging cell, which provides the necessary helper function for the propagation and 
production of retroviral vector. Because these vectors are capable of integrating the 
therapeutic gene into the host genome, they are the ideal vectors for the long-term gene 
expression to correct monogenic diseases. But the main concern in using retroviral vector is 
the insertional mutagenesis caused by accidental random integration into the host 
chromosome resulting in the activation of certain protooncogenes. Another limitation is the 
proviral integration and gene expression required for active cell division (Verma & 
Weitzman, 2005).
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1.1.3.2 Lentiviruses
Lentiviruses are members of retrovirus family, which encode three to six more viral 
proteins in addition to gag, pol and env (Kootstra & Verma, 2003). I will focus on the 
human immunodeficiency virus type 1 (HlV-l)-based vectors because, they have been 
most extensively used for gene therapy. In addition of all the advantages described above, 
which are common to all retroviral vectors, vectors derived from lentiviruses offer one 
great advantage over their oncoretroviral counterparts: they can transduce nondividing 
cells, an important requirement for genetically modifying tissues for potential targets for 
gene therapy. Vectors derived from HIV-1 allow for the efficient in vivo delivery, 
integration, and stable expression of transgenes into cells such as neurons, hepatocytes and 
myocytes (Blomer et al., 1997, Kafri et al., 1997)). But the safety of HIV-based vectors 
requires a most careful evaluation, considering the pathogenicity of the parental virus.
HIV-1 encodes six accessory proteins (Tat, Rev, Vif, Vpr, Nef, and Vpu). Using a 
similar strategy that is used for the production of retroviral vector can generate the HIV- 
based vector. The third-generation packaging unit of HIV-1-based vectors conserves only 
three of the nine genes present in the genome of the parental virus, which eliminates 
possibility of reconstitution of a wild-type virus through recombination. These vectors are 
deleted for all the viral genes except the LTRs, the packaging signal and the Rev responsive 
element (RRE). The Rev proteins, if provided in trans during vector production, ensure 
efficient nuclear export of the viral RNA through binding to the RRE. Initially, the vector 
RNA was derived by the endogenous LTR promoter, but the next generation HIV-based 
vector utilizes a CMV/LTR hybrid promoter to make the vector Tar-independent. The 
presence of the nuclear target signals in the viral accessory protein Vpr allows the
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integration of the viral/therapeutic genome into the host genome in both dividing and non­
dividing cells making them an attractive vector system. However, the safety of the HIV- 
based vectors in the clinical setting is a major concern. This problem is addressed by the 
recent development of self-inactivated vectors, where the 3’ LTR is partially deleted to 
prevent mobilization following infection with HIV-based vector (Miyoshi et al., 1998) and 
minimize the risk of insertional mutagenesis.
1.1.3.3 Adeno-associated virus (AAV)
AAV is a small, no enveloped, nonpathogenic DNA virus that belongs to the 
Parvoviridae family (Kootstra & Verma, 2003). The viral genome is a linear, 4580 base 
pairs single-stranded DNA (ssDNA), which is inserted between two T-shaped ITRs 
carrying two major viral open reading frames (ORF). The cap ORF encodes for the 
structural proteins that form capsid, whereas the Rep ORF produces the regulatory proteins. 
After the virus enters the cell, the ssDNA is converted into the double-stranded DNA and is 
directed to host chromosome by Rep proteins, where it integrates by nonhomologous 
recombination. Successful AAV replication requires coinfection with a helper virus such as 
adenovirus or herpes virus. To generate recombinant AAV vector (rAAV), the cDNA of a 
therapeutic gene is inserted between the two AAV ITRs in an expression plasmid. The 
second plasmid is the helper plasmid that provides all the necessary AAV proteins like Cap 
and Rev in trans. These two plasmids are cotransfected in a permissive cell line such as 293 
followed by helper adenovirus infection. Most recombinant AAV vectors have been 
derived from serotype 2 capsid (Carter & Samulski, 2000). But, so far, a total of eight 
different AAV serotypes have been identified that utilize different cellular receptors for cell 
entry, which give each serotype a unique tropism (Grimm & Kay, 2003). Pesudotyping the
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rAAV2 with capsids from other serotypes to achieve more efficient gene transfer in 
targeted tissues is becoming a common strategy (Grimm & Kay, 2003). One of the major 
problems of using the AAV vectors for gene therapy is contamination with the wild type 
AAV and helper virus in purified rAAV stocks. However, new vector systems and 
packaging cell lines have been designed to overcome these problems.
1.1.3.4 Herpes Simplex Virus
Human herpesviruses are a class of large double-stranded DNA viruses with the ability 
to accommodate a large amount of foreign DNA (Epstein et al., 2005). The viral genome is 
about 152 kb in size and is divided into unique long (U l) and unique short (Us) regions that 
are flanked by terminal repeats. The virus encodes at least 80 viral proteins with very little 
gene splicing. Natural herpes virus infection can be lytic in epithelial cells or persist in a 
latent state in the neuronal cells. All of the gene therapy vectors are derived from type 1 
herpes simplex virus. Two different strategies have been used to generate recombinant viral 
vectors. The first strategy uses the replication defective HSV-1 vectors contained deletion 
of all, or the five immediate early genes (ICP0, ICP4, ICP22, ICP27 and ICP47) that are 
responsible for lytic infection (Berto et al., 2005). They can carry large transgenes up to 30 
kb in size and can be produced in high titers by using complementary cell lines that provide 
the deleted early genes in trans. But these vectors still contain large proportions of wild 
type HSV-1 genome and can express many different viral genes, which induce cytotoxicity 
and immune responses against the therapeutic vector. The second HSV vector system is 
known as the HSV-1 amplicon vector system, which is based on the ability of HSV-1 to 
package defective genomes carrying the cis-acting sequences ori (origin of viral DNA 
replication) and pac (packaging and cleavage signal). Beside the m-acting sequences, all
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other wild type viral genes are deleted from the amplicon vectors. For this reason, 
packaging and production of the amplicon vectors require a replicating helper virus 
infection, which can result in high-level contamination with the helper virus. This problem 
is overcome by the development of a bacterial artificial chromosome carrying all the viral 
genes without the pac signal. The HSV vector systems have been applied to gene therapy 
for multiple diseases, including brain tumors, neurological diseases and spinal nerve 
diseases. The major limitation for recombinant HSV-1 vector is the host immune response. 
But the large packaging capacity of HSV-1 based vectors may be useful for delivering 
complex genes.
1.1.4 Adenovirus
Half a century ago Rowe and his colleagues first isolated adenovirus from culture 
adenoid tissue in the laboratory (Rowe et al., 1953). Since then, this virus has been used as 
a powerful model system to study basic cellular processes such as transcription, RNA 
processing, DNA replication, cell cycle and oncogenesis. In some earlier studies, it was 
observed that adenovirus could recombine in tissue culture setting (Lewis & Rowe, 1970) 
and that became the foundation for the use of the adenovirus as a vector for gene therapy. 
In this part of this chapter, I will briefly discuss the structure and life cycle for the human 
adenovirus and then give an overview of the use of adenovirus vectors as a gene therapy 
vehicle.
1.1.4.1 Adenovirus structure
Adenovirus is a nonenveloped icosahedral particle about 70-90 nm in size with a viral 
capsid that surrounds the viral core containing the large double-stranded DNA genome of
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Figure 1.2 Schematic of the adenovirus particle, showing major component of the capsid 
and the core. Adapted from Shenk (1996).
36 kb (Figure 1.2) (Berk, 2005). The capsid is made of three types of proteins: the hexon 
proteins, which form homotrimers and 240 of these hexomers form the basis of the 
icosahedral structure; the fiber form trimers which is associated with each of the 12 penton 
vertices and is responsible for the initial attachment of virions to the cell surface; and the 
penton base which form 12 pentomers that anchors the fiber. So far, at least 51 distinct 
serotypes of human adenoviruses have been isolated and classified into six groups (A-F) 
based on the sequence homology and their ability to agglutinate red blood cells.
1.1.4.2 Adenovirus binding and entry
Except for the group B adenoviruses, the initial attachment of all other groups to the 
cell surface occurs through binding of the fiber knob to the Coxsackie and Adenovirus 
Receptor (CAR) (Coyne & Bergelson, 2005). CAR is a type 1 transmembrane protein in 
the immunoglobulin superfamily, which normally functions as a cell-to-cell adhesion 
molecule (Honda et al., 2000) and is expressed in many human tissues including heart, 
lung, liver and brain (Howitt et al., 2003). After the initial binding to CAR, the RGD motif
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on the penton base interacts with the otvp3 and oivPs integrin molecules and triggers virus 
internalization by the clathrin-dependent, receptor-mediated endocytosis (Meier et al., 
2002).Then the virions escape from the endosome to cytoplasm by an unknown 
mechanism, traffic toward the nucleus by a dynein-mediated, microtubles dependent 
migration where they subsequently dock with the Nuclear Pore Complex (NCP) (Trotman 
et al., 2001). The viral capsid disassembles at the NPC, transports the viral genome in the 
nucleus and initiates the viral transcriptional program.
1.1.4.3 Adenovirus genome and replication
Adenovirus genes can be divided into three major groups depending on the time course of 
their gene expression during the viral replicative cycle: early (El A, E1B, E2, E3, and E4), 
delayed (IX and Iva2), and the late transcription unit. (Figure 1.3). El A is the first viral 
transcription unit that is expressed after infection, which then fra^s-activates the other 
adenovirus early genes and pushes the infected cells to enter S phase by sequestering the
LP
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Figure 1.3 Map of the adenovirus genome and transcription unit. Position of the left and 
right ITRs, the packing sequence (\j/), the early transcription units (El, E2, E3 and E4) and 
the major late transcription unit (MLP, L1-L5) are shown. Arrows indicate the direction of 
transcription. Adapted from Mcconnell (2004).
17
Rb proteins and subsequently releasing the E2F transcription factor in order to create an 
optimal environment for virus replication (McConnell & Imperiale, 2004). But this E1A 
mediated cell cycle deregulation results in an accumulation of the tumor suppressor p53 
and the activation of p53-dependent apoptosis pathway, which prevents the survival of 
infected cells. The adenoviral ElB-55k protein and the E4 region product E4orf6 together 
block the p53-dependent apoptosis by directly binding p53 and inhibiting its transcription 
activity to express proapoptotic genes (Sarnow et al., 1982). The E2 region contains DNA 
polymerase, preterminal protein (pTP), and the 72-kDa DNA-binding protein, which are 
necessary for the replication of the viral DNA. The pTP acts as a telomere to maintain the 
integrity of the viral DNA. The products of the viral E3 region suppress the host immune 
response by interfering with the antigen processing and presentation in order to allow the 
virus to replicate more efficiently. The E4 gene products have been known to play a role in 
cell cycle control and transformation; however, the mechanisms underlying these functions 
are not well understood.
The adenoviral major late promoter (MLP) derived most of the late genes. This major 
late transcription unit encodes approximately 15 to 20 different mRNAs, all of which are 
derived from a single pre-mRNA by differential splicing. Most of the late gene products are 
viral structural proteins and other proteins involved in virion assembly, which include 
hexon, penton base, knobbed fiber, 100k protein, pIX, pIV and IVa2.
Adenoviruses enter cells by receptor-mediated endocytosis. Once the viral DNA is 
released into the nucleus, the viral early genes are transcribed, leading to DNA replication 
by E2 gene products. The viral DNA replication also initiates the late phase where gene 
expression by the MLP increases, which in turn results in a high production of all the
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structural proteins that assemble together with viral genome in the nucleus. The newly 
synthesized virions are released from the cell by induction of cell lysis.
1.1.4.4 Adenoviral vector development and production
Most of the early generation adenoviral vectors are derived from Ad serotype 5. The 
replication-defective adenovirus (Ad) vector can be generated.by replacing viral sequences 
such as El, E2, E3 or E4 in viral DNA by the foreign cDNA. As described above, the 
adenoviral El A genes are necessary for the activation of most of the viral promoters and 
the expression of both early and late genes. Thus, the removal of the El coding region 
results in replication defective virus. The first generation adenoviral vectors were 
specifically designed to replace their El region with the sequence of the gene of interest, so
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Figure 1.4 Genomic structure of first-generation, second-generation and helper-dependent 
vectors. Regions that have deleted are indicated by open boxes. Adapted from Mcconnell 
(2004).
that the recombinant virus could not replicate but was able to express the inserted transgene 
upon infection. The ability to generate El deleted vectors is made possible by the existence 
of cell lines that provide the El gene products in trans. One of the most frequently used 
cell line for this purpose is the 293A cell line, which is a human embryonic kidney-derived 
line that is immortalized by sheared fragments of adenovirus type 5 DNA (Graham et al., 
1977). Production of El-deleated vectors is usually carried out by homologous 
recombination or site directed recombination in the mammalian cells between constructs 
carrying the left and right end of the adenoviral genome. The cloning capacity of the first 
generation Ad vectors can be further increased by deletion of additional nonessential genes 
such as the E3 region. Combining the El and E3 deletions allows approximately 8.3 kb for 
insertion of therapeutic genes in one recombinant adenovirus. However, recent data has 
suggested that the expression of E3 genes from the recombinant vector may be beneficial in 
vivo because of its ability to dampen the host immune responses against the viral vector 
(Bruder et al., 1997).
Although first-generation vectors have been proven to be highly efficient as vehicles 
for gene delivery, one of the major challenges for using these vectors at a clinical level is 
the host immune response against the therapeutic vector. To overcome this problem, 
vectors deleted for multiple genes have been created to inhibit viral gene expression more 
effectively. These vectors, known as second-generation adenoviral vectors (Figure 1.4), 
are usually deleted in E2 and E4 coding sequences to reduce the host immune response 
against the adenovector and also have the benefit of a large capacity for transgene insertion 
due to the deletion. Experiments in immune-competent mice demonstrate that the transgene 
expression from the second-generation adenovectors was sustained much longer than the
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first-generation vectors (Amalfitano et al., 1998). But the most promising approach for 
long-term gene expression with the adenoviral vectors is that of gutted, or helper-dependent 
adenovirus vectors (Alba et al., 2005), where all of the viral structural genes are deleted 
from the viral chromosome, leaving just the two ITRs and the packing signals. Such 
vectors can accommodate up to 37 kb of transgene sequences. The presence of a helper 
virus that provides the functions that required for replication and assembly of the helper- 
dependent adenovector. The main problem to date is the inability to completely separate 
virions containing the helper-dependent chromosome from those containing the helper 
virus genome (Sandig et al., 2000). However, in vivo studies using helper-dependent 
vectors have produced some promising results (Ehrhardt & Kay, 2002).
1.1.5 Gene therapy application:
1.1.5.1 Gene therapy for genetic diseases
Gene therapy is very attractive particularly for diseases that currently do not have any 
effective treatment options, and it is probably easier for targeting monogenic disorders than 
for complex diseases with multiple defective genes. The most obvious application for gene 
therapy is the replacement of a defective gene with its functional counterpart in order to 
restore normal physiological function and thereby reverse the diseases state. A successful 
gene therapy approach for monogenic diseases requires a stable transfer of the gene into 
target cells to insure the permanent correction of the disorder. There are two types of gene 
therapy approaches for inherited genetic disorders. The first approach is germ cell gene 
therapy, where the corrective gene is inserted into a sperm cell or ova and will therefore be 
incorporated into each cell of the new individual thus upon. However, genetic modification 
of the human germline is not allowed in any country yet. The second method is somatic
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gene therapy. This approach involves a corrective gene transfer into somatic cells of an 
individual in order to restore the normal gene function. So far, about 90 trials for inherited 
monogenic disorders have been reported in the literature (Edelstein et al., 2004). Here, I 
briefly summarize the current advances and the future direction of gene therapy for 
different inherited monogenic diseases.
1.1.5.1.1 Cystic Fibrosis
Cystic fibrosis (CF) is caused by mutations in a gene named cystic fibrosis 
transmembrane regulator (CFTR), which is located on chromosome 7 and acts as a 
membrane chloride channel (Drumm et al., 1991). Mutations in the CFTR gene result in 
chronic lung infection, pancreatic dysfunction and diabetes mellitus. It is the most common 
autosomal recessive disorder in Caucasians, which affects about 1 in 2500 live births. In 
theory, CF states can be improved by restoring the mutant CFTR gene function, which can 
be achieved by transferring a wild type CFTR gene in the target cells with the gene therapy 
vector. In the early days, adenovirus-based vectors were widely used in most of the CF 
gene therapy experiments. But, it has become clear that these vectors are not best suited for 
CF gene therapy due to their poor gene transfer ability into the airway epithelial cells and 
also due to the host immune response against the adenovirus-based vectors (Crystal et al., 
1994). In contrast, AAV-based vectors become more attractive for CF gene therapy 
because of their safety profile, broad tissue tropism, long-term gene expression and their 
ability to escape the host immune surveillance. Early trials for CF gene therapy using AAV 
did not induce inflammation, but showed inadequate amount of CFTR-gene transfer (Flotte 
et al., 1996). Target Genetics Corporation carried out several clinical trials with an AAV-
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based vector tgAAVCF, which contains the complete human CFTR cDNA and uses AAV 
ITR-promoter elements to express the therapeutic gene. They administered this vector in an 
aerosolized form and were able to show that a single administration of the virus was well 
tolerated and safe, but no therapeutic benefits were observed in any patients due to lack of 
CFTR gene expression (Aitken et al., 2001). A recently reported phase I clinical trial using 
second-generation AAV2 vector expressing CFTR gene also showed the limited 
transduction of the therapeutic gene into the airway epithelial cells. The low transduction 
efficiency is thought to result in the increased inflammation and sputum barrier in patients 
with moderate to severe disease. Several nanoparticle formulations have been developed to 
increase the transduction efficiency for the CFTR gene into the target cells (Zabner et al.,
1997). But no treatment efficacy has been noted. For a successful CF gene therapy, we 
have to overcome the problems associated with gene transfer to airway epithelial cells.
1.1.5.1.2 Hemophilia
Hemophilia A and B are inherited bleeding disorders that affect one out of 34,500 men 
(Bell et al., 1995). This disease is caused by a mutation in the Factor VIII and IX gene 
respectively, which are involved in blood clotting. Several characteristics make hemophilia 
an ideal candidate for a gene therapeutic approach: i) only a relatively small amount of 
proteins is required for phenotypic correction, ii) the therapeutic gene is small (Factor IX 
cDNA 1.4kb long) and it can easily be packaged into different viral vectors, and iii) 
because the Factor IX protein is secreted into the blood stream, one can target different 
organs such as muscle or liver to express the therapeutic gene. Most of the earlier attempts 
for gene therapy for hemophilia were based on adenoviral vectors. Adenovectors were 
initially attractive for hemophilia gene therapy because of their natural ability to transduce
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hepatocytes. Although, preclinical studies with the first generation replication incompetent 
adenoviral vectors in both murine and canine hemophilia models showed promising results, 
the host immune response against these vectors compromised their safety and also inhibited 
long term therapeutic gene expression. The third generation gutless adenovector carrying 
Factor VIII gene for hemophilia A has shown a significant reduction in the immune 
response and hepatotoxicity (Ehrhardt et al., 2003), but its long term therapeutic gene 
expression is compromised by the formation of neutralizing antibodies against the 
therapeutic Factor VIII protein. The host immune response against the AAV-based vectors 
is much lower than the adenovectors and produces some very promising preclinical results 
for hemophilia gene therapy. So far, two clinical trials have been reported using AAV2 
vector to deliver Factor IX to the muscle (Manno et al., 2003) and to the liver, via hepatic 
artery infusion (Kaiser, 2004). In the first clinical trial with adenovirus, muscle delivery 
increased the Factor IX expression only about 1%, whereas a 12% increase was detected in 
one of the patient treated by hepatic artery delivery of the rAAV vector. However, this 
increased Factor IX expression was followed by a transient elevation in serum 
transaminase levels and a loss of the therapeutic gene expression; it was speculated that the 
host immune response against the AAV vector lead to the destruction of the transduced 
cells (Sabatino et al., 2005). The main challenge for hemophilia gene therapy is how to 
avoid the induction of the host immune responses after the delivery of the therapeutic gene. 
Reduction of the therapeutic gene expression is often attributed to cell-mediated and 
humoral immune responses against the transduced target cells and transgene produced. 
Viral vectors used to deliver the therapeutic gene act as an immunological adjuvant and
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amplify this response. Several strategies have been investigated for inducing immune 
tolerance to the Factor VIII and IX transgene products (Manno et al., 2006).
1.1.5.1.3 Muscular Dystrophy
Muscular Dystrophy (MD) is caused by a large deletion of the dystrophin gene that 
leads to a destabilization and subsequent degeneration of muscle tissue (Culligan et al.,
1998). MD is a good candidate for gene therapy because the successful transfer of the wild 
type dystrophin gene to the muscle tissue should lead to the correction of the disease’s 
state. But, the dystrophin gene is a very large gene that encodes a 3685 amino acid protein 
and 14 kb cDNA (Nobile et al., 1997). This is a significant challenge for MD gene therapy, 
because only a few viral vectors are currently available that will be able to package such a 
large transgene as dystrophin. A phase I trial has been initiated using a plasmid dystrophin 
DNA directly injected into the muscle to determine the tolerability and safety as well as 
gene expression (Thioudellet et al., 2002). In this trial, a low level of dystrophin expression 
was detected for up to 3 weeks in the muscle fibers of six out of nine patients (Romero et 
al., 2004). Gutless adenoviral vectors have been used to deliver dystrophin genes into the 
muscle of the mdx transgenic model of MD. But the success rate was limited by the host 
immune response against the viral vectors and inefficient infection of mature muscle 
tissues by this vector (Dudley et al., 2004). AAV vector system is very attractive because 
of its tropism to infect muscle cells and it’s ability to escape immunological response in 
vivo. Unfortunately AAV vectors have a cloning capacity of only about 4 kb and cannot 
package full-length dystrophin cDNA. However, recent advances in creating mini- and 
microdystrophin genes have resulted in dystrophin expressing cassettes that can be 
packaged in the AAV vector (Gregorevic et al., 2006). But, it is yet to be determined if
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these minimal dystrophin proteins can fully compensate for the lack of full-length 
dystrophin.
1.1.5.1.4 Severe combined Immunodeficiency
Severe Combined Immunodeficiency (SCID) is a group of rare monogenic disorders, 
which is commonly characterized by a block in T cell differentiation and a direct and 
indirect impairment of B cell immunity. Mutations in ten different genes have been found 
to cause ten distinct SCID phenotypes (Fisher et al., 2005). Recent understanding of the 
molecular basis of different SCID conditions has opened the door toward an alternative 
gene therapy, which is allogeinc hematopoietic stem cell transplantation.
The adenosine-deaminase (ADA) deficiency was the first inherited SCID disease to be 
treated with a gene therapy approach (Culver et al., 1991). This fatal inherited disorder is 
characterized by a defect in purine metabolism pathway that leads to impaired immune 
functions, recurrent infections and systemic metabolic abnormalities. A strong rationale for 
somatic gene therapy and the need for alternative therapy led to the design of the earliest 
human gene therapy clinical trial, which was based on retroviral-mediated gene transfer of 
the normal ADA gene into autologus hematopoietic stem cells (HSCs) or peripheral blood 
lymphocytes (PBLs). Most of these early gene therapy trials, which mainly used retroviral 
vector to transfer ADA gene into HSCs and PBLs, have proven to be safe and feasible 
(Bordignon & al., 1995). However, all patients in these trials received conventional 
enzyme-replacement therapy, which abolished the growth advantage for gene corrected 
cells and interfered with the proper evaluation of the gene transfer efficacy. It is only 
recently that the clinical efficacy of the ADA gene therapy has been examined in the 
absence of enzyme replacement therapy (Aiuti et al., 2002a). Results from these trials
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showed that engineered PBLs were able to restore the T-cell defect, but were insufficient 
for systemic correction and detoxification. However, gene transfer in bone marrow stem 
cells showed a full immunological and metabolic correction of the ADA defect (Aiuti et al., 
2002b).
In 2000, Cavazzana-Calvo and colleagues from the Necker Hospital in Paris 
(Cavazzana-Calvo et al., 2000) used a gene therapy approach to treat ten infants that were 
bom with X-linked SCID. This type of SCID is the most common of all SCID syndromes, 
which is caused by mutations in the jc  subunit of the interleukin 2 cytokines receptor 
family that leads to impairment of T, B and NK-cell development. In their gene therapy 
protocols, the authors used cytokines-stimulated, bone marrow-derived, autologous CD34+ 
cells that were repeatedly transduced with an oncoretroviral vector carrying the normal yc 
gene. Approximately 15-20 X 106 engineered CD34+ cells were infused back to the patient 
without any conditioning. Significant immune reconstitution occurred in all except one 
infant. T-cell levels increased from near undetectable levels to normal limits within 3 
months of infusion and these modified T-cells were able to induce an appropriate immune 
response against a variety of antigens. The therapeutic transgene was detectable in almost 
100% of circulating T cells. Unfortunately, almost 5 years after therapy, three patients that 
were involved in this trial developed T-cell leukaemia, both associated with an insertional 
mutagenesis event (Hacein-Bey-Abina et al., 2003, Marshall el al., 2003, Check et al., 
2005). The activation of the LM02 proto-oncogene at the site of vector integration played a 
key role in the development of leukaemia (Hacein-Bey-Abina et al., 2003), but other 
factors may have contributed as well including the effect of yc transgene (Dave et al., 2004) 
or abnormal proliferative advantage of corrected cells. This serious adverse side effect in a
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trial that initially produced such promising results has slowed down the expansion of 
human gene therapy.
1.1.6 Gene therapy in neoplastic Diseases
Cancer is a multi-stage genetic disease that involves alteration in the multiple molecular 
pathways related to growth control and apoptosis in order to support uncontrolled growth 
of the cancer cells and support their ability to invade and metastasize (Hanahan & 
Weinberg, 2000). The interaction of cancer cells with their microenvironment, including 
stroma, extrcellular matrix, immune system, and cells necessary for induction of 
angiogenesis to support tumor growth is critical for tumorogenesis. Thus, there are many 
genes that have been identified in recent years, which can be a potential target for novel 
cancer therapy. Catalyzed by the finding of these new targets for cancer therapy, there has 
been a dramatic increase in developing gene therapy approaches for the treatment of 
cancer. The new knowledge of the molecular mechanisms underlying oncogenesis and the 
development of viral vector as a vehicle for gene delivery has permitted the formulation of 
the concept of cancer gene therapy. In this part of the chapter, I will discuss various 
strategies of cancer gene therapy.
1.1.6.X Strategies for cancer gene therapy
Strategies for cancer gene therapy adopt ideas and technologies ranging from 
generating the immune response against tumor antigens to directly attacking on tumor cells. 
All the new understandings about the mechanisms of molecular alteration in tumorgenesis 
have contributed a great deal to the various approaches to cancer gene therapies. Some of 
the most popular approaches that have been explored to date are described below.
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1.1.6.1.1 Transfer of tumor suppressor gene
The loss of tumor suppressor gene functions is one of the key characteristics in many 
human malignancies. In the most direct “gene replacements” approach of cancer gene 
therapy, tumor-suppressor genes are delivered and expressed in cancer cells in which these 
genes are defective, resulting in cell death and growth arrest. Several tumor suppressor 
genes have been isolated in recent years. Examples of tumor suppressor genes are -the 
retinoblastoma pRB, APC, PTEN and the p53. The expression of each of these genes in 
tumor cells in vitro causes an acute change in cell physiology and gene expression, 
resulting in cell cycle arrest or death (McCormick, 2001). Vectors expressing tumor 
suppressor genes such as p53 injected directly into the tumor show some promise both in 
vivo and clinically (Roth et al., 1999). But one of the major problems of the gene 
replacement approach of cancer gene therapy is that almost every cell in the tumor would 
need to be infected with vector carrying tumor-suppressor gene in order to achieve 
clinically relevant therapeutic efficacy, which is an enormous technical hurdle with the 
current vector technology in hand.
1.1.6.1.2 Suicide genes-enzyme/pro-drug approach
One of the most popular ways to achieve direct targeting of cancer cells with gene 
therapy is the delivery of suicide genes to cancer cells. In this approach, vectors expressing 
suicide genes allow the cancer cells to metabolize a harmless prodrug, administered 
separately, into a potent cytotoxic that does not only kill the transduced cell with the 
suicide gene, but also can diffuse into the neighboring cells and create a bystander effect. 
Several prodrug-enzyme combinations are evaluated for this approach, but the herpes 
simplex virus thymidine kinase (HSV-tk) has been the most popular and most extensively
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used in the clinic. The HSV-tk gene converts inactive prodrug ganciclovir to the 
phosphorylated active form, which becomes incorporated into DNA during cell division, 
thereby blocking DNA synthesis. The vector carrying suicide genes can be injected directly 
into the tumor mass or delivered systemically and targeted to tumor cells by using the 
tumor-specific expression elements. Clinical studies with suicide gene therapy have proven 
to be safe, but not sufficient enough to show clinically relevant therapeutic efficacy. A 
Phase III clinical study of retrovirus- encoded HSV-tk showed no patients benefit (Roth et 
al., 1996) Adenovirus expressing HSV-tk injected directly into brain looked slightly more 
promising, with some survival benefit in a small number of patients (Sandmair et al.,
1999). However, suicide gene activity needs to be enhanced to improve its efficacy.
1.1.6.1.3 Anti-angiogeneic therapy
In the last twenty years, remarkable progress has been made in understanding the 
molecular mechanisms of angiogenesis. Molecules such as vascular endothelial growth 
factors (VEGF) or TIMP-2 have been identified as a culprit that supports angiogenesis in 
the tumor microenvironment. These molecules are excellent candidates for cancer gene 
therapy because the inhibition of their activity can lead to significant tumor growth 
suppression and result in bystander effects. Angiogenesis can also be inhibited by a 
constitutive expression of anti-angiogeneic molecules such as angiostatin or endostatin. 
Adenovirus vector expressing a soluble form of VEGF receptor were recently shown to 
inhibit tumor growth in mouse models (Ogawa et al., 2002). An adenovirus expressing 
secretable endostatin was able to inhibit tumor growth in vivo (Li et al., 2006). Vectors 
have been designed to express siRNA to target VEGF and VEGF receptors. But these 
approaches so far are not very successful in the clinic because a relatively long-term
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expression of the therapeutic gene, at least until regression or apoptosis of tumor cells are 
deprived of their nutrition.
1.1.6.1.4 Immunomodulatory approaches
Recent research has identified numerous mechanisms used by cancer cells to escape 
host immune surveillance. These include expressing high amounts of immunosuppressive 
cytokines like interleukin (IL)-IO or TGF-p, lowering the expression of MHC class I and II 
protein, impairing growth and differentiation of effectors immune cells that down regulate 
expression of different costimulatory molecules (Rosenberg, 1992). Thus, using viral 
vectors to express some of these immunostimualtory genes to activate the host immune 
system is an attractive strategy. The types of immunostimulatory genes used in the clinical 
and pre-clinical settings in cancer gene therapy are IL-2. IL-4, IL-12, IL-6 and tumor 
necrosis factor, interferon-y and T-cell costimulatory molecules such as B7.1 and B7.2. 
The viral vectors carrying these molecules are also being used ex-vivo to develop cell- 
based vaccines, in which case the patient can be vaccinated with autologous tumor cells 
infected with gene therapy vector. If successful, immunomodulation approaches have the 
potential to develop as systemic cancer therapies.
1.1.6.1.5 Fusogenic membrane glycoprotein
Fusogenic membrane glycoprotein (FMG) is derived from viral genes, which mediate 
viral binding and subsequent internalization via viral envelope fused with cell membrane. 
In vitro, when FMG is expressed in cell monolayer containing the appropriate receptor, 
massive cell-cell fusion occurs and multi-nuclei syncitia are formed. All enveloped viruses 
enter cells by protein mediated membrane fusion. These include viruses from diverse 
groups such as retroviruses, paramyxoviruses and orthomyxoviruses. These viruses enter
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cells primarily by one of two pathways: entry following direct fusion between the viral and 
cell membranes at the cell surface or entry by endocytosis and fusion between the viral and 
endosomal membrane. The first mechanisms is pH independent and unlike the second one. 
But both routs of entry require initial binding via the receptor-binding domain to a cellular 
receptor. The N-terminus of each fusion contains a hydrophobic region, the ‘fusion 
peptide’, which in the stable conformation inserts into the target membrane during 
membrane fusion.
The idea of using FMG as a therapeutic gene against cancer relies on the induction of 
extensive cell-cell fusion of tumor cells to generate nonviable syncitia, resulting in a desire 
cytoreductive effect (Bateman et al., 2002). For this to occur, it is more likely to be 
effective using FMG that undergo pH independent fusion. The FMG used in the future 
studies in this thesis is the envelope of a C-type retrovirus, Gibbon ape leukemia virus 
(GALV), which will be discussed in detail (Hanger et al., 2000).
The GALV envelope shows very close homology to other C- type retrovirus envelopes 
such as Murine leukaemia virus and Feline leukemia virus. This envelope is composed of 
two polypeptides formed following the cleavage of the 85 kDa precursor protein. The large 
70 kDa surface polypeptides are completely extracellular and correspond to the N-terminal 
region of the precursor. The smaller 15 kDa transmembrane polypeptide corresponds to the 
C- terminal region of the precursor. The receptor for GALV is a sodium-dependent 
phosphate symporter, PiT 1 (Takeuchi et al., 1992) and is widely expressed in many 
tissues.
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1.1.7 Oncolytic virus
The therapeutic efficacy of most of the cancer gene therapy approaches is significantly 
compromised by the inability of the current viral vectors to deliver gene efficiently in vivo. 
To overcome this problem, people have used the viruses’ ability to spread from their site of 
infection and infect the neighboring cells. As a consequence of virus infection, infected 
cells are killed as they become the factories for producing the new infectious viral particles 
(Figure 1.5). This approach not only amplifies the application therapeutic genes in a tumor 
selective manner, but also uses its ability to lyses and kills the infected cell and eliminates 
the tumor cells selectively. The success of this approach depends on our ability to engineer 
or select viruses that replicate specifically in tumor cells, but not in the normal cells.
Replication incompetent vector
Viral spread & 
oncolysis
Replication competent vector
Figure 1.5 Replication-defective verses replication-competent vector for cancer gene 
therapy. Replication-defective vectors are limited transduction efficiency, oncolytic viruses 
are capable of progressive replicative spread, resulting in an amplification of the initial 
input dose and more effective in eliminating tumor. Adapted from Yoon (2001).
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These viruses, termed oncolytic viruses, are essentially tumor-specific, self-replicating, 
lysis-inducing cancer killers. In this part of the chapter, we will summarize what is 
currently known about many of these oncolytic viruses and discuss some of the obstacles of 
this approach of cancer gene therapy. Many oncolytic viruses belonging to several viral 
families have been identified or engineered. They include herpes simplex viruses, 
adenovirus, retroviruses paramyxoviruses and poxviruses. These viruses can be categorized 
into four major groups on the basis of their oncolytic restriction: I) mutation/deletion 
derived viruses, II) transcriptional targeted oncolytic viruses, III) transductional targeted 
oncolytic viruses and IV) ‘naturally smart’ viruses.
1.1.7.1 Mutation/deletion derived oncolytic viruses
One of the earliest approaches takes advantage of tumor specific changes that allow 
preferential replication of the virus only in target cancer cells by introducing strategic 
mutation or deletion in the viral genome, thus inhibiting natural viral replication in the 
nontargeted normal cells.
The tumor suppressor gene p53, so-called guardian of the genome, is responsible for 
inducing cell-growth arrest and apoptosis in response to cellular stress, DNA damage or 
viral infection. The wild-type adenovirus naturally suppresses p53 activity by expressing 
E1B, which prevents apoptosis and allows the virus replication to occur (Yew & Berk, 
1992). Since almost 50% of all tumors have deletion or mutations in the p53 gene, E1B is 
not necessary for the virus to replicate in these cells and the virus should replicate 
efficiently. However, in normal, quiescent cells, E1B deleted viruses are unable to replicate
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A. Tumor targeting strategies
Transcriptional 
targeting
Transductional 
targeting
Inherent or 
targeted deletion 
of viral genes
Normal cell Cancer cell
Viral spread & 
oncolysis
Figure 1.6 Retargeting of adenoviral vector for cancer gene therapy. Targeting can be 
achieve at three levels: (1) expression of adenoviral genes can be limited to target tissue by 
the introduction of tumor/tissue specific promoters (transcriptional); (2) adenovirus can be 
conjugated with retargeting moieties to avoid binding to its native receptor CAR and 
introducing binding to new receptors present on target cells (transductional); (3) replicative 
essential viral gene can be deleted selectively so the vector can not replicate in any cells 
except the target cells (targeted deletion).
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because of their inability to inhibit wt p53 activity and prevent apoptosis in the infected 
cells -  at least in theory (Figure 1.7). A virus -  known as ONYX -015 or d ll520 (Bischoff 
et a l, 1996) deleted for E1B gene is one of the first engineered oncolytic virus used in 
clinical trials. The ONYX-015 has been used successfully to treat different tumor models in 
animals, but it has been less successful in treating cancer in humans (Ries & Korn, 2002). 
ONYX-015 showed some therapeutic benefits when used in combination with standard 
chemotherapies (Heise et al., 1997). But several reports are showing that ONYX-015 can 
replicate in some tumor cell lines that retain wild-type p53 (Goodrum & Ornelles, 1998) 
(Turned et al., 1999). These findings have raised concerns about safety and replication 
selectivity of ONYX-015 and the specificity of ONYX-015 for p53-deficient cells remains 
controversial (Dix et al., 2001). Many different gene deletion strategies have been used to 
develop the gene deleted viruses show, which some promising selectivity and killing 
activity in vitro culture systems, even against the tumor in animal models.
A. ONYX replication in normal cell
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ONYX replication in cancer cell
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Figure 1.7 Interaction between adenovirus-encoded proteins and cellular factor that 
facilitate ONYX-015 replication and host cell disruption. A. Early gene El A expression 
induces forced entry into S phase, resulting in activation of the p53 pathway leading to cell 
death. Adenovirus counteracts p53 by ElB-55kD and E4orf6 that bind to, and inactivate 
p53. ONYX-015 is ElB-55kD deleted, which cannot replicate in normal cells with wild 
type p53. But tumor cell with dysfunction p53 pathway able to support ONYX-105 
replication because they cannot activate p53 dependent apoptotic pathway.
However, none of them stand out when they are used in clinical trials. Additional genetic 
modifications need to be developed for increasing the effectiveness of the 
mutation/deletion derived oncolytic viruses.
1.1.7.2 Transcriptionally targeted oncolytic viruses
Another approach to achieve tumor-selective replication involves expressing viral genes 
under promoters that are only functional in tumor cells. This strategy has been used 
primarily with the adenovirus and herpes simplex virus (HSV). Researchers have employed 
various tumor-specific promoters (hTERT, Try, CEA) or tissue-specific promoters (MUC1, 
PSA, AFP) to drive the replication-essential viral gene such as the adenoviral El A in order
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to achieve tumor selective replication. One such tumor-specific promoters, which shows a 
lot of promise in vitro and animal models is the promoter that derived the gene that encodes 
the telomerase reverse transcriptase (hTERT). The hTERT protein is necessary for the 
extension telomeres, and expresses at high levels in cells that are rapidly dividing. Over 
85% of human tumors overexpress the hTERT gene (Irving et al., 2004). A number of 
studies have demonstrated that the oncolytic selectivity can be achieved by using the 
hTERT promoter to derive the expression of early gene, such as adenoviral El gene. 
Another tissue specific promoter MUC1 has been used to express El A, supporting virus 
replication selectively in breast cancer cells in which MUC1 is aberrantly expressed (Chen 
et al., 2005). Using these tumor selective promoters to develop conditionally replicating 
viral vectors shows success in both the preclinical and the clinical settings, but the 
commercial and clinical development and use of these viral vectors for cancer gene therapy 
might be complicated by a dominating patent on the use of tissue-specific promoters for 
gene therapy (Novartis US patent 5,998,205, Hallenbeck, Chang and Chiang 1999).
1.1.7.3 Transductional targeted oncolytic viruses
Different viruses use different cellular receptors and distinct sequential steps to infect 
target cells. For examples, two different cellular receptors are responsible for adenovirus 
entry. First, the knob domain of the adenovirus fiber capsid protein binds to the cellular 
receptor CAR on the cell membrane of the target cells and then the RGD peptide sequences 
in the penton base interacts with the cellular integrin receptors to initiate internalization of 
the virion (Wickham et al., 1993). During tumorigenesis, various genetic and epigenetic 
events cause overexpression of so-called ‘tumor antigens’ on the surface of tumor cells. As 
recognition of specific cell surface receptors is the key initial step for virus entry and
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productive infection, researchers are able to engineer viruses that only recognize and use 
the antigen present on the tumor cell surface to enter the target cells, which then restrict 
replication of an oncolytic virus to malignant cells. The first step of this targeting strategy 
requires creating a blind virus that no longer recognizes its normal cellular receptors for 
entry. This receptor blind virus then can be retargeted to tumor cells by using bifunctional 
crosslinkers or structural modification to recognize the antigens that are predominantly 
expressed on the tumor cell surface. The oncolytic measles virus has been successfully 
modified by this strategy. During normal infection, measles virus binds by its 
hameagglutinin (H) attachment protein to one of two cellular receptors: CD46 and SLAM 
(Dorig et al., 1993) (Tatsuo et al. 2000). By introducing mutations in SLAM and CD46 
binding domains of the measles virus H-protein, Vongpunsawad et al created a blind virus, 
which was then subsequently engineered to express H-protein fused with growth factors 
such as EGF and IGF, as well as single-chain antibodies against tumor antigens such as 
CEA, CD20 or CD38 ( Vongpunsawad et at., 2004, Nakamura et al., 2005).
1.1.7.4 ‘Naturally smart’ viruses
Many viruses have a natural tropism for tumor cells for different reasons. For example, 
RNA viruses such as vesicular stomatitis virus (VSV) (Lichty et al., 2004), reovirus 
(Coffey et al., 1998) or Newcastle diseases virus (Cassel & Garrett, 1965) replicate 
selectively in tumor cells because these cells fail to mount a protective interferon response 
against the viral infection. These viruses demonstrated oncolytic potency in studies from 
tissue culture up to human clinical trials, but difficulties in engineering and uncleared 
restriction mechanisms somewhat hampered the progress to take these viruses into the 
clinic (Russell, 2002).
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1.1.7.5 Conclusion and future direction
As vectors of cancer gene therapy, oncolytic viruses face similar challenges as any 
nonreplicating virus would. The major problem is that the host immune responses to 
circulating viral particles prevent vectors from having any prolonged persistence. To 
replicate, oncolytic viruses must produce viral protein intracellularly. These protein can 
also be presented on major histocompatibility complex class I (MHC I) protein as viral 
antigen, attract cytotoxic T lymphocytes (CTLs), which are responsible for clearing 
intracellular pathogens and will arbitrarily destroy infected cells that are attempting to 
produce therapeutic oncolytic viruses. Conversely, attracting CTLs at the site of infection 
in the tumor could be therapeutically beneficial to patients. The viral infection could 
produce wide variety of chemo- and cytokines, which can create a suitable environment for 
CTLs to eliminate cancer cells more efficiently and also help antigen-presenting cells to 
recognize tumor associated antigens that lead to generate immune response against the 
tumor and break the immune tolerance for tumor. Thus, the advantages and disadvantages 
of immune responses against the vectors in oncolytic virotherapy must be further examined 
for each vector used. Also, the preexisting humoral immunity against the viral vectors such 
as adenoviral vector is a major hurdle for systemic delivery of these vectors. To evade 
these antibodies against the therapeutic vectors, formulations based on cationic liposomes 
have been produced to encapsulate in a lipid bilayer and protecting the vector from initial 
detection and agglutination (Yotnda et al., 2002). Formulating adenovirus in collagen- 
based matrices (Siemens et al., 2001) and polyethylene glycol (PEG) has been shown to 
protect the viral vector from the host immune system (Croyle et al., 2002). In addition, 
different immunosuppressive drugs have been used to inhibit B-cell maturation and mast
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cell activation (Bouvet et al., 1998). Viral immunomodulatory gene, such as adenoviral E3 
gene that has been deleted from most of the adenoviral vectors, could be useful for 
controlling the host immune response against the therapeutic vectors (Wang et al., 2003b).
In the future, it is likely that a successful oncolytic virus will use a combination of 
different methods of selectivity to ensure the maximum safety and therapeutic efficacy. The 
oncolytic activity itself may not be sufficient enough to eradicate the tumor burden. To 
enhance the therapeutic potency at the level where clinically relevant therapeutic efficacy 
can be achieved by an oncolytic virus, the therapeutic vector may need to carry an 
additional therapeutic genes such as suicide gene HSV-TK or immunostimulatory gene 
such as TNF-a, IL-24/mda-7 (Lambright et al., 2001). Also, multiple genetic restriction 
points for enhanced tumor specificity and vector-specific immune suppressant to overcome 
the host immune response is the key to create a vector that will be safe and effective for 
cancer gene therapy in the clinic.
1.2 mRNA degradation and stability in regulation of gene expression.
1.2.1 Introduction
It is becoming increasingly clear that controlling the rates of mRNA decay is a key factor in 
the regulation of gene expression (Shim & Karin, 2002) (Wilusz & Wilusz, 2004). Controlling 
gene expression at mRNA level is faster and more economic than other regulatory mechanisms 
such as selective protein degradation in the proteasoms. The rate of mRNA decay varies 
considerably from one mRNA species to another and can be altered by many extracellular 
stimuli ranging from development, hormonal and nutritional, to environmental stresses
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(Guhaniyogi & Brewer, 2001). Genes like most cytokines and many proto-oncogenes produce 
mRNAs that are unstable in quiescent environments, but are considerably stabilized upon 
appropriate stimulation. In this part of the chapter, I will provide a brief overview of all the 
important components involving the process of mRNA decay and stability.
1.2.2 mRNA decay pathway in mammalian cells
The regulation of mRNA decay in mammalian cells is a tightly controlled process, which is 
orchestrated by the interaction between the mRNA’s structural components and the frans-acting 
factors. The mRNA components include the 5’ untranslated region (UTR), the 5’-cap structure, 
the protein-coding region, 3’UTR and the 3’ polyadenylation [poly(A)] tail. Experiments from 
both yeast and mammalian systems reveal that the majority of the physiological mRNA decay is 
initiated by a deadenylation-dependent pathway, which starts with the selective removal of the 
3’ poly (A) tail followed by the 3’—>5’ decay by the poly(A) specific exonucleases. The length 
of the poly(A) tail is very important for deciding the stability of any mRNA (Komer & Wahle,
1997). In the stable transcripts, the 3’ poly(A) tails form a complex with a highly conserved 70- 
kDa poly(A)-binding protein (PABP) that stabilizes the mRNA by protecting 3’ poly(A) tail 
from deadenylation (Bernstein et al., 1989). The exosome, a complex of 10 or more 3’—>5’ 
exonucleases plays a key role in the mRNA turnover. Also the PABP bound to poly(A) tail 
interacts with the translation initiation factor eIF4 family proteins, which are bound at the 5’- 
cap region of the mRNA (Wells et al., 1998) and circularize the mRNA molecule, thereby 
initiating the assembly of the translation initiation complex at the 5’ cap and increase the 
translation rate. The 5’-cap structure can also be the target for an exonucclease-dependent 
decapping activity, which then initiates the 5’—>3’ decay of the mRNA. The cap-binding eIF4 
family protein can inhibit the 5’ decapping activity and the presence of the adenylate-uridylate
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rich (AU-rich) elements (ARE) in the 3’UTR of the mRNA can stimulate the decapping activity 
(Gao et al., 2001). In mammalian cells, the exosome mediated 3’—>5’ mRNA decay is more 
active than the 5’—>3’ decapping pathway (Mukherjee et al., 2002).
1.2.3 Control of mRNA decay by cA-acting elements (ARE)
Many cytokines and proto-oncogenes respond to the extracellular stimuli by transiently 
stabilizing their transcripts and inducing protein expression. But in the resting environment, the 
rapid disappearance of these mRNA is mediated by specific ds-acting elements found either in 
the coding region or, more frequently, within the 3’ UTR region of the RNA. The most well 
studied cis-acting element involved in controlling the half-life of many mRNAs is AU-rich 
element (ARE) found in the 3’UTRs of these unstable mRNA. The first ARE was identify from 
the human granulocyte/macrophage colony stimulating factor mRNA, which was 51-nucleotide 
long and able to destabilize a very stable p-globin mRNA by its incorporation into the 3’ UTR 
region (Shaw & Kamen, 1986). Since then, many different AREs have been discovered and 
extensively examined. These AREs can be quite variable in length and sequence, but a common 
feature of carrying multiple copies of AU-rich elements characterizes most of them. These 
AREs are divided into three major subclasses: (i) Class I AREs contains 1-3 copies of AUUUA 
repeats within the AU-rich region and are present in the proto-oncogene (c-fos, c-myc) and 
cytokines coding genes (IL-4, IL-6), (ii) Class II AREs contain 5-8 copies of AUUUA repeats 
and are only found in the cytokines mRNAs (GM-CSF, TNF-a), (iii) Class III AREs lack 
AUUUA repeats, but contain a long U-rich region- such elements are found in the c-jun proto­
oncogene mRNA (Peng et al., 1996). The AREs in mammalian cells are more conserved than 
the sequences in the open reading frames of the mRNAs: for examples, only 45% of sequence 
homology was found in the coding region between murine and human IL-3, but the AU-rich
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region in the 3’UTR were highly conserved with 93% sequence homology (Dorssers et al., 
1987). The ARE-directed mRNA turnover is extremely heterogeneous in the rate of decay as 
well as in the decay mechanisms (Wilusz et al., 2001). This heterogeneity presumably arises 
from the diverse RNA-protein and protein-protein interactions that regulate this process. 
Specific protein binding to ARE-elements in the 3’UTR may be either sequence specific or 
dependent on the secondary structure of the ARE-elements formed in the mRNA. The 
mammalian 70-kDa heat shock protein (Hsp) has been identified in a cellular complex 
containing an ARE-binding protein as well as being detected in direct contact with ARE 
sequences (Laroia et al., 1999). It has been hypothesized that Hsp 70 and other chaperones may 
be recruited for unwinding the complex secondary structure of AREs to expose critical ex­
acting sequences, which may then facilitate binding of all the necessary trans-acting factors 
involved in the mRNA turnover. The AREs activity can also be differentially regulated in 
response to specific extracellular stimuli and is cell lines dependent (Nair et al., 1994). In vitro, 
the ARE sequences are able to stimulate decapping {Gao, 2001 #131}, exosome recruitment 
{Mukherjee, 2002 #132} and poly(A) shortening. The ARE mediated mRNA destabilization 
involves AU-binding proteins (AUBPs) that physically recruit the exosome on the RNA to be 
degraded - as opposed to AUBPs involving in stabilizing ARE containing mRNAs are not able 
to interact with the exosome complex, thus protecting the transcript degradation (van Hoof & 
Parker, 2002). The ability of specific AREs to stabilize or destabilize a target mRNA is 
governed by the synchronized interaction between the trans-acting RNA-binding proteins, 
extracellular stimuli and intercellular signaling pathways.
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1.2.4 Trans-acting factors regulating mRNA stability
Several AU-binding proteins have been identified, characterized and cloned over the past 
decade (Wilson et al., 1999). The binding of these proteins to mRNA containing an ARE can 
have either negative or positive effects on the turnover, translation and localization of the 
mRNA. Here we discuss a few well-characterized AUBPs known to play a significant role in 
influencing the stability of the ARE bearing mRNA.
1.2.4.1 Tristetraprolin
Tristetraprolin (TTP) belongs to a group of zinc finger proteins that is characterized by two 
copies of CCCH zinc finger motif (Thompson et al., 1996). TTP inhibits the TNF-a production 
from macrophages by directly binding to the ARE and destabilizing the TNF-a mRNA 
(Carballo et al., 1998) (Lai & Blackshear, 2001). The macrophages from the TTP deficient mice 
are inefficient in regulating the TNF-a mRNA stability, which leads to aberrant expression of 
TNF-a and develop a complex phenotype consisting of dermatitis, cachexia, myeloid 
hyperplasia and autoimmunity (Taylor et al., 1996). TTP serves as an adaptor protein that 
bridges the ARE-mRNA to exosome and initiates the mRNA degradation (Chen et al., 2001). 
This protein can exist in numerous phosphorylated forms and be affected by the signaling 
pathways such as mitogen-activated protein kinase (MAPK) or the p38 MAPK (Mahtani et al., 
2001). The phosphorylation statuses of TTP also determine its ability to decay the ARE-mRNA.
1.2.4.2 AUF1
AUF1 is the most extensively characterized AUBP. It was first identified from an enriched 
cytosolic protein fraction, which is able to accelerate ARE-dependent c-myc mRNA decay in 
vitro (Zhang et al., 1993). AUF1 is expressed as four related isoforms (p37, p40, p42 and p45) 
generated by alternative splicing (Wagner et al., 1998). Different isoforms appear to display
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different effects on mRNA turnover. AUF1 induced mRNA-decay is initiated by AUF1 forming 
multi-subunit complexes on ARE with itself as homodimers or heterodimers and with additional 
cellular factors such as eIF4G, PABP and the hsp70 (Laroia et al., 1999). Although the 
destabilizing function of AUF1 is well-documented, recent reports suggest that AUF1 may also 
be involved in the interaction with mRNA stabilizing factors, such as embryonic lethal 
abnormal vision (ELAV) (Levine et al., 1993) and HuR (Ma et al., 1996) and initiate 
stabilization of ARE bearing mRNAs (Myer et al., 1997). In vitro, the stabilizing effect of 
AUF1 is thought to be highly selective for class II AREs. The AUF1 expression is increased 
during T-cell activation where AUF1 selectively stabilizes the class II ARE containing 
cytokines mRNAs (Ming et al., 2001).
1.2.4.3 HuR
HuR belongs to the ELAV family protein that is known to bind the ARE motifs with 
three RNA recognition motif (RRM)-type RNA-binding domains; also it stabilizes and/or 
activates the translation of the target mRNA. This protein is ubiquitously expressed in all 
cell types (Antic & Keene, 1997) and has a high binding affinity for several AREs (Levy et 
al., 1998). By using the immunoprecipitation of the HuR containing RNA/protein complex 
to identify the global target mRNA for HuR, Gorospe’s lab was able to show that 15% of 
9600 analyzed genes are able to form a complex with HuR (Lopez de Silanes et al., 2004). 
The overexpression of HuR protein leads to the accumulation of ARE bearing target 
mRNAs. Although predominately nuclear (>90%), it shuttles between nucleus and 
cytoplasm, influencing mRNA translation and stability (Fan & Steitz, 1998); so moreover 
the subcellular localization is closely linked to its functions. The nucleocytoplasmic 
trafficking of HuR is modulated by HuR-binding proteins that interact with the nuclear
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export factor CRM1 and initiates shuttling to cytoplasm (Gallouzi et al., 2001). The 
cytoplasmic localization of HuR is also known to be influenced by the activity of AMP- 
activated kinase (AMPK), an enzyme that has a key physiological role in the cellular 
response to stress (Hardie & Hawley, 2001). HuR is shown to interact with the 
endonucleolytic site in the target mRNA and to protect this site from endonuclease 
cleavage (Zhao et al., 2000).
1.2.4.4 Hsp70
During different cellular stress, mammalian cells respond by elevating the synthesis of a 
highly conserved set of proteins, known as heat shock proteins (Hsp). The primary function 
of the four major groups of Hsps (Hsp27, Hsp60, Hap70 and Hsp90) is to help proper 
protein folding in vivo. But recently, this family of proteins and more specially Hsp70, is 
implicated in playing an important role in the cytoplamic metabolism of lymphokine and 
other short-lived mRNAs by physiologically regulating the interaction between the AU- 
binding protein, AUF1 and the ARE-mRNAs. It also directly competes with other AUBPs 
during the heat shock, thus influencing the ability of these factors to stabilize or destabilize 
the ARE-mRNAs. It is thought that the competitive equilibrium between AUF1 and Hsp70 
for ARE substrates is rapidly shifting in favor of Hsp70 under heat shock conditions, which 
contributes to the stabilization of these mRNAs at the elevated temperatures. Alternatively, 
the chaperone activity of Hsp70 alters the local RNA structures and influences the binding 
of the AUBPs to the ARE bearing mRNAs (Wilson et al., 2001).
1.2.5 Signal transduction pathways in regulation of mRNA stability
The ARE-mediated RNA decay is highly dependent on the stimuli induced signal 
transduction pathways. The ability of these signaling pathways to post-translationally modify
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AUBPs by phosphorylation and alter the binding affinity towards ARE-mRNAs has a 
profound effect on the stability of many ARE-bearing mRNAs. Early reports describing the 
signaling pathway altering ARE-mRNAs included phorbol ester, antibodies induced T cell 
activation and TNF-a. In this section I will describe some examples of this regulation.
One of the most well studied signaling pathways that alter the stability of many ARE-bearing 
mRNAs is the p38-signaling cascade. p38 belongs to the large family of Mitogen-Activated 
Protein Kinases (MAPK). Different stresses, such as heat shock or UV rays activate this 
signaling cascade by dual tyrosine/threonine phosphorylation of p38, which then activates the 
downstream effectors and alter the interaction between AU-binding proteins and ARE- 
mRNAs. As described before, TTP directly interacts with the ARE of the TNF-a mRNA and 
induces decay. During arsenite stress, p38-MAPK mediates TTP phosphorylation, which 
leads to its association with 14-3-3 proteins and result in exclusion from stress granules 
(Stoecklin et al., 2004). Under these conditions, another AUBP HuR binds to the ARE of the 
TNF-a mRNAs in the stress granules and stabilizes the transcripts. But under mitochondrial 
stress, TTP remains unphosphorylated and can be localized to the stress granules where it 
binds to AREs and acts as a potent destabilizing factor (Stoecklin et al., 2004).
The AREs of other cytokines such as GM-CSF or IL-3 are able to regulate mRNA stability in 
response to calcium signaling {Bickel, 1992 #159}. During the T-cell activation, the 
stabilization of the IL-2 mRNA is mediated via two different cis-acting elements and 
signaling pathways (Chen et al., 2000). One of the pathways involves JNK signaling cascade 
activation and binding of two proteins, YB-1 and nucleolin to the 5’UTR of the IL-2 mRNA. 
The second pathway requires activation of protein kinase C (PKC) and/or calcineurin
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signaling pathway and also binding an AUBP known as NF90 to the ARE at the 3’UTR to 
stabilize the IL-2 mRNA.
Many different environmental stresses induce signaling pathways also known to alter the rate 
of ARE-mRNAs decay. Among them, hypoxia is one of the well-characterized stresses that 
is known to induce VEGF through mRNA stabilization. A recent study demonstrated that the 
hypoxia-induced activation of stress signaling pathways like JNK and p38 is required for the 
selective VEGF mRNA stabilization (Pages et al., 2000). When exposed to UV light (UVC), 
the AU-binding protein HuR-dependent p21 mRNA stability was shown to be associated 
with the elevated retention of the HuR protein in the cytoplasms (Wang et al., 2000b).
The stimuli induce a signaling pathway and also change the ARE-mRNA turnover by post- 
translational modulating the activity of specific endonucleases. One such example is 
endonuclease G3BP, which interacts with the oncogene RAS. G3BP is a 52kDa 
endoribinuclease known to require site-specific phosphorylation for its catalytic activity 
(Gallouzi et al., 1998). The c-myc mRNA, which contains a high-affinity G3BP binding site 
at the 3’UTR region, can be cleaved by G3BP in a phosphorylation-dependent manner. In the 
serum stimulated cells, the G3BP gets phosphorylated by RAS and localizes to the nucleolus 
where G3BP cleaves the 3’UTR and destabilizes the c-myc mRNA (Touniere et al., 2001).
1.2.6 Physiological significance
The ARE-dependent mRNA degradation functions as a sensor for regulating the adaptive 
cellular response to different physiological stimuli. Many biological processes such as 
development, aging, host defense, cell cycle regulation, apoptosis and angiogenesis require 
transient response in the gene expression; moreover the ARE-mediated control of mRNA 
stability is proven to be one of the most economic and efficient way of regulating gene
49
expression. The following are few examples of physiological conditions where ARE-mediated 
mRNA stability is proven to be extremely important.
1.2.6.1 Regulated mRNA stability
Throughout the development specific and timely gene expression is very critical. This 
regulation of gene expression is coordinated at multiple levels including transcriptional, post- 
transcriptional, mRNA and protein turnover. The aim of this section is to introduce few 
examples that illustrate the developmental role of mRNA turnover in the gene regulation.
1.2.6.1.1 £-to-a Hemoglobin gene switching
Hemoglobin exists as a tetramer, which is composed of two a  chains and two (3 chains, 
encoded by a-globin and p-globin gene clusters. In humans, the a-chains consist of a  and £ 
forms, which express simultaneously during the embryonic yolk sac development. But a switch 
to exclusive production of a-chains occurs in enucleated erythroid cells of the fetal liver at 6-7 
weeks of gestation (Russell et al., 1997). The exclusive production of the a-chains then persists 
throughout adulthood in the bone marrow. The total shutdown of the ^-globin gene and 
exclusive synthesis of the a-globin gene requires the 3’UTR sequence of these genes to 
destabilize the ^-globin mRNA and stabilize the a-globin mRNA selectively in concert with the 
transcriptional silencing of the £-globin gene. Both the 3’UTR sequence of £-globin and a- 
globin mRNA contain a polypyrimidine-rich element (PRE), but they differ in sequence and 
binding affinity to different RNA-binding proteins. The disassociation constant for a-PRE and 
£-PRE is about 0.5 nM and3.0 nM respectively, a difference of six-fold (Russell et al., 1998). 
The reduced affinity of RNA-binding protein complex for the £-PRE allows rapid degradation 
of ^-globin mRNA via deadenylation. It is also observed that the poly(A) tails of the ^-globin 
mRNA are shorter than those of a-globin mRNA, which may also contribute to the rapid decay
of the ^-globin mRNA (Russell et al., 1998). This is one of the elegant examples of how 
differences in RNA-protein binding affinity control an important physiological process during 
development.
1.2.6.1.2 Cytokines expression profile in newborns versus adults
GM-CSF plays a very important role in generation of immune responses against infection 
by modulating myeloid activation, proliferation and differentiation of neutrophils, monocytes 
and platelets. The expression of GM-CSF mRNA and protein in activated neonatal mononuclear 
cells (MNCs) from umbilical cord blood are about seven and four fold less compared to adult 
peripheral blood MNCs (Buzby et al., 1999). The expression of GM-CSF is partly controlled by 
the rate of the mRNA decay, which is regulated by the ARE sequence within the 3’UTR region 
of the GM-CSF mRNA (Shaw et al., 1986). The transcription rate of GM-CSF is very similar in 
the MNC to the two groups, but the half-life of the GM-CSF mRNA is three-time shorter in the 
neonatal MNC (19 min as oppose to 79 min in the adults MNC) (Buzby et al., 1999). The rapid 
decay in vitro is both ARE and RNA-binding protein AUF1 dependent. Wagner et al were able 
to show that the p37 isoform of AUF1 is predominately expressed in neonatal MNC, whereas 
the p45 AUF1 is exclusive to adults MNC (Wagner et al., 1998). They were also able to show 
that p37 possesses a higher ARE-binding affinity than p45 isoform, which promote rapid ARE- 
bearing mRNA degradation in the neonatal MNC (Wagner et al., 1998). The half-life of other 
cytokines such as MIPla, IL-3 IL-8 and IL-12 are shorter in neonatal MNC as well. Thus, 
mRNA stability can play a major role in age dependent immune functions.
1.2.6.1.3 Control of c-myc proto-oncogene during differentiation
As mentioned before, the embryonic development and cellular differentiation are totally 
regulated by the coordinated control of gene expression and cellular proliferation. One of the
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most intensely studied master regulators of gene that has a significant influence on cellular 
proliferation and differentiation is the c-myc transcription factor. Experiments in the human 
K562 cell line are able to show elegantly how the c-myc silencing controls the fate of 
differentiating into the erythroid or the platelet precursors during development. The activation 
of protein kinase C (PKC) signaling pathway in the K562 cells reduces the half-life of the c-myc 
mRNA by four fold, resulting in 90% decline of c-myc mRNA, which leads to loss of erythroid 
properties and differentiation into megakaryoblast (Brewer, 1998). The PKC induced 
destabilization of c-myc mRNA is mediated by a deadenylation-independent pathway.
1.2.6.1.4 Iron-responsive element (IRE) and iron-regulatory protein (IRP)
The 3’UTR of the transferring receptor (TfR) contains five iron response elements (IRE), 
three of which are reported to regulate the mRNA half-life, another one is located in the 5’UTR 
and is known to affect translation. These IREs interact with two specific iron-regulatory 
proteins known as IRE-binding proteins (IRP1 and IRP-2) and modulate the intercellular iron 
concentration by assembling an iron-sulfur cluster in IRP1 and stabilizing the IRP2 protein. The 
IRP responds to low intercellular iron concentration in two different ways, (i) it interacts with 
the three IREs located at the 3’UTR of the TfR mRNA, thereby stabilizing it and allow the iron 
uptake, (ii) it also can bind to the IRE in the 5’-UTR of the ferritin mRNA, an iron sequestration 
protein, thereby blocking the translation initiation and preventing iron sequestration. On the 
other hand, when the iron concentration is very high, the iron-sulfur cluster in the IRP1 is 
disassembled and the IRP2 is a target for ubiquitin-directed proteolysis. This inhibits the 
interaction between IRPs and TfR mRNA, which then becomes more accessible for 
endonucleolytic cleavage, thus limiting iron uptake (reviewed in Hardie et al., 1998).
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1.2.6.1.5 mRNA stability during replicative-senescence
The AMP-activated protein kinase (AMPK), is an enzyme that works as a metabolic sensor 
for low fuel status in the cell (Hardie et al., 1998). The AMPK is activated by the high 
concentration of AMP and is inhibited by the elevated levels of ATP. The AMP:ATP ratios are 
2-3 fold higher in the high-passage senescent old fibroblasts compared to young fibroblast, 
which leads to the activation of the AMPK pathway. By using the in vitro human IDH4 
fibroblast model system, Wang and his colleagues were able to show that AMPK influences the 
ARE-containing mRNA turnover by inhibiting the cytoplasmic export of the RNA-binding 
protein HuR (Wang et al., 2002). As mentioned previously, the HuR is predominantly a nuclear 
protein (>90%) in the unstimulated cells and cytoplasomic translocation is necessary for the 
HuR to stabilize ARE-mRNAs. The AMPK-induced inhibition of the HuR migration and 
decreased cytoplasomic mRNA turnover of many different prolifirative genes including cyclins 
A, and Bl, c-Fos and DP-1 have been observed (Jain et al., 1997). They were also able to show 
that aged or high passage cells express less total HuR (both cytoplasmic and nuclear). The 
combined effects of both decreased expression and cytoplasmic localization of HuR allow faster 
decay of these mRNAs (Wang et al., 2003a). The aged cells contain decreased levels of HuR 
dependent ARE-RNA-binding and stabilizing activity compared to young cells. Interestingly, 
the level of another AUBP AUF1 also decreases with age, which is shown to increase the 
stability of cyclin-dependent kinase inhibitors p21WAF1 and pl6INK4a, which may contribute to a 
cell-cycle arrest and induce replicative senescence (Wang et al., 2005).
1.2.6.2 Deregulated mRNA stability: A diseases mechanism?
As repeatedly mentioned throughout this review, many of the early and transient response 
genes are regulated at the level of mRNA stability by the ARE located in the 3’UTR of their
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mRNA, which is critical for controlling important biological responses such as cell growth, cell 
cycle regulation and apoptosis, host defense, angiogenesis, ionic homeostasis and responses to 
exogenous agents like radiation, virus and inflammatory stimuli. A recent report showed that 
ARE-mRNA represents 8% of all the mRNAs transcribed from functional human genes 
(Khabar, 2005). So the deregulation in the ARE-mediated control of gene expression could have 
a dire consequence in maintaining a normal physiology that lead to undesirable pathologic 
states. Following are few examples of human disease conditions resulting from unwanted 
changes in ARE-mediated events.
1.2.6.2.1 a-Thalassemia
a-Thalassemia is a disease that arises from decreased stability of the normally very stable a- 
globin mRNA by the presence of an anti-termination sequence. The expression of goblin genes 
is regulated both transcriptionally and post-transcriptionally. The diseased alleles of the a- 
globin gene contain termination mutation of UAA to CAA that allows translating ribosomes to 
proceed into the 3’UTR, which mask the binding sites for stabilizing protein at the C-rich 
regions of the 3’UTR. By preventing the interaction between the RNA-binding proteins and the 
a-globin mRNA, the poly(A) undergoes rapid shortening and premature degradation of mRNA, 
which leads to a-thalassemia (Forget, 1979).
1.2.6.2.2 Myotonic Dystrophy
Myotonic dystrophy (DM) is a dominant inherited multi-system disorder, which is caused 
by an expanded number of trinucleotide (CTG) repeats in the 3’UTR of a cAMP-dependent 
protein kinase gene (DMPK). Most of the normal alleles of the DMPK gene contain 5-30 
repeats, but with the most severe forms of disease, characterized by respiratory distress, 
endocrine dysfunction and mental retardation, the number of repeats reaches 1000 or more (Lu
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et al., 1999). The mutated mRNA is thought to bind to an ELAV-like ribonucleoprotein and is 
retained within the DM myoblast nuclei, which leads to impaired kinase synthesis and reduces 
its function in ion channel phosphorylation (Davis et al., 1997) that is thought to be cause of 
change in the muscle excitability.
1.2.6.2.3 Alzheimer’s Diseases (AD)
In the brain of Alzheimer’s patients, iron cannot be properly sequestered by ferritin, which 
leads to an excessive iron accumulation, cells therefore become vulnerable to oxidative stress 
(Percy et al., 1998). The iron homeostasis in normal physiological conditions is achieved by the 
simultaneous regulation of ferritin, an iron sequestration protein, and the transferrin receptor 
(TfR), which is the iron uptake protein. These two proteins allow the cell to obtain iron when 
needed and sequester it when in excess. It has been hypothesized that a more stable form of 
iron-responsive element/ iron-regulatory protein complex in the Alzheimer’s patient brains 
could stabilize the TfR mRNA while inhibiting ferritin synthesis (Guhaniyogi & Brewer, 2001). 
Such alteration would result in an increased iron uptake without appropriate sequestration of 
iron by ferritin.
Another AD related gene that has received much attention is the amyloid precursor protein 
(APP) (Rajagopalan et al., 1998). APP synthesis is deregulated in the AD patient brains and 
APP deposits of extracellular a-amyloid within the central nervous system in the AD patients 
were observed. The transgenic mice that overexpress APP has accelerated deposition of a- 
amyloid. Elevated levels of APP mRNA was detected in the brain tissue of AD patients. A 
29-nt, C+U-rich sequence located approximately 200-nt downstream of the stop codon in the 
3’UTR of the APP mRNA is required and sufficient to control the stability of the APP 
mRNA (Zaidi & Malter, 1994). It has been reported that the stabilization of APP mRNA in
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the AD patients is regulated by heterogeneous ribonucleoprotein C (hnRNP C) and its 
interaction with the U-rich sequences in the 3’UTR of the APP mRNA may contribute to 
elevated APP levels in the AD (Rajagopalan et al., 1998).
1.2.7 mRNA stability in cancer
The fundamental abnormality resulting in the development of cancer is the continual 
unregulated gene expression that leads to an uncontrolled proliferation of cancer cells. The 
genes required for the maintenance of the abnormal cell growth are known as oncogenes. 
Oncogene overexpression is one of the hallmarks of cancer; cancer cells utilize variety of 
different molecular pathways to achieve that. A most efficient and economic way of 
regulating gene expression is controlling the stability of the transcribed mRNAs, which has 
been exploited by the cancer cell very efficiently. The stability of the many different ARE 
bearing mRNAs including poto-oncogenes and growth factors are significantly altered by the 
presence of the unregulated trans-acting factors in the cancer cell, leading to the cancer 
causing protein overexpression and cellular transformation.
Figure 1.8 Mechanisms of post-transcriptional
regulation and their alteration in cancer
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The regulation of mRNA stability is controlled by a complex network of RNA/RNA-binding 
protein interactions, which are influenced by the signal transduction pathway that can post- 
translationally modify RNA-BPs and the interaction with the target mRNA. The mechanisms 
of altering the mRNA stability and gene regulation in cancer cells can be divided into three 
major groups: (i) altering mRNA stability by point mutation or deletions in the regulatory 
element of the mRNA, (ii) modification of the RNA/RNA-BPs interaction by mutations in the 
RNA-BPs which change the affinity of the RNA-BP for its target mRNA or by 
over/underexpressing the RNA-BPs, and (iii) alteration of signaling pathways that affect the 
RNA/RNA-BPs interaction (Audic & Hartley, 2004). In this part of the chapter I will briefly 
review the mechanisms of altering the mRNA stability as a means to up or downregulate gene 
expression in cancer.
1.2.7.1 Alteration of regulatory elements in the 3’UTRs:
Although the regulatory sequence that influences the mRNA stability can be found in the 
all-different parts of the mRNA, the elements located in the 3’ untranslated region are 
considered to be the most important mRNA stability determinants. From a mechanistic point 
of view, any RNA/protein interaction that takes place at the 3’UTR, which determines the 
stability of the mRNA, can persist throughout the translation, because it is very unlikely that 
ribosomes scan the 3’UTR region (Poyry et al., 2004). So the regulatory elements in the 
3’UTR can influence the mRNA stability at any time. We will discuss few examples of how 
alterations in regulatory sequence can promote tumorigenesis.
1.2.7.1.1 Cyclins D
A fundamental aspect of cancer is the impaired cell cycle checkpoint. Unlike normal 
cells that only proliferate in the presence of mitogenic signals in response to the
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extracellular stimuli or during development. The proliferation of cancer cell is uncontrolled 
due to the alteration in the many aspects of the cell cycle. The endpoint of these alterations 
is the inappropriate proliferation commonly associated with carcinogenesis. Cyclin and 
cyclin-dependant kinases (cdks) complexes are central for the progression and control of 
the mammalian cell cycle (Malumbres & Barbacid, 2001). The activation of each cdk is 
controlled by the availability of a cyclin partner and a complex network of post- 
translational modification of these proteins, which then control the progress from one cell 
cycle phase to other. The expression of different cyclins is regulated by the phase of the 
cell cycle; cell cycle dependent mRNA stability plays an important role in controlling the 
cyclin expression. D-type cyclin (Dl, D2 and D3) expression is highest in the early G1 
phase where they interact and activate cdk4 and cdk6. The complexes then phosphorylate 
the Rb tumor suppressor and release E2F transcription factors to initiate the S-phase of cell 
cycle.
The 3’UTR elements of the cyclin Dl and D3 mRNA can regulate the mRNA turnover and 
gene expression in response to different extracellular stimuli (Langenfeld et al., 1997). 
Several human cancers are known to overexpress the cyclin Dl gene (Donnellan & Chetty,
1998). Rearrangement in the 3’UTR of the cyclin Dl gene have been reported in patients 
with mantle cell lymphomas and t(llql3)-associated leukemia, ((Tsujimoto et al., 1985) 
(Nakagawa et al., 2006). In both cases, deletion of the AU-rich region of the 3’UTR is 
responsible for stabilizing the cyclin Dl mRNA, which leads to an overexpression of cyclin 
Dl protein. The half-life of the rearranged cyclin Dl mRNA is greater than 3 hours 
compared to 0.5 hour for cyclin Dl mRNA from normal tissue (Rimokh et al., 1994). A 
similar rearrangement is also reported in the 3’UTR region of the cyclin Dl in
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neuroblastoma (Molenaar et al., 2003). MDA MB-453 a human breast cancer cell line, 
contained cyclin Dl mRNA where the AU-rich region is deleted. This truncated cyclin Dl 
mRNA is more stable than the full length mRNA and is considered to be the cause of the 
cyclin Dl overexpression in the MDA MB-453 cell line (Lebwohl et al., 1994). 
Prostaglandin A2 (PGA2) is an experimental chemotherapy that causes cell cycle arrest in 
several human tumor cell line by decreasing the cyclin Dl expression (Gorospe et al., 
1996). Cells treated with PGA2 are shown to upregulate ARE-binding protein AUF1, which 
leads to a decrease in stability of the cyclin Dl mRNA through a specific 390 bp region in 
the 3’ UTR (Lin et al., 2000). Glucocorticoids is another chemotherapeutic agent that is 
know to inhibit cyclin D3 expression and induces a G0/G1 cell cycle arrest in the T 
lymphoma cells by destabilizing its mRNA (Reisman & Thompson, 1995). These examples 
highlight the potential importance of mRNA stability in cancer development and also in 
cancer therapy.
1.2.7.1.2 C-myc
C-myc is a master transcription factor known to dimerize with its cellular partner, binds to 
E-box DNA and transactivate many different genes in different stages of the development 
(Levens, 2002). In normal cells c-myc mRNA is extremely labile. The stability of c-myc 
mRNA is controlled by three different elements, which include AREs in the 3’UTR that 
control instability (Herrick & Ross, 1994) a coding region elements (Wisdom & Lee, 1991) 
and a 5’UTR internal ribosomal entry site (Nanbru et al., 1997), which controls translation. 
Deregulated c-myc expression is associated with cancer, which supports many aspects of 
tumorogenesis including proliferation, growth, metabolisms and differentiation. Both 
deletion (Aghib et al., 1990) and translocation in the 3’UTR region of the c-myc gene
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(Hollis et al., 1988) have been reported in human T-cell leukemia and human myeloma cell 
line respectively. These observations suggest that the deletion in the 3’UTR region may be 
playing a role in the cancer cell selective c-myc mRNA stabilization and overexpression of 
c-myc proteins. But, transgenic mice carrying a similar deletion in the c-myc gene show no 
phenotype and the half-life of the c-myc mRNA was normal (Langa et al., 2001). It has 
been speculated that beside mRNA stability, another mechanisms may be involved in 
deregulating the c-myc expression in cancer cells.
1.2.7.2 Alteration in the RNA binding factors
AREs facilitate the binding of cellular RNA-binding proteins that recruit other proteins at 
the site and guide degradation or stabilization of the target mRNA. The overall protein 
production from a specific mRNA is ultimately determined by the competition between the 
stabilization and degradation factors binding at the site of the ARE of this mRNA. In the 
human genomes about 500 proteins have been identified to contain RNA-binding domain 
(Anantharaman et al., 2002). At least 14 of these proteins known to alter their activity in 
cancer in various ways, which than affect the stability of different ARE-containing 
mRNAs. We will discuss a few well characterize RNA-binding proteins that known to play 
a significant role in cancer development.
1.2.7.2.1 HuR
Human-antigen R (HuR), is one of the best characterized RNA-binding proteins. It was 
first isolated as a tumor antigen in lung carcinoma of individuals with paraneoplastic 
neurological disorder (Szabo et al., 1991). HuR is predominately a nuclear protein and
60
thought to bind to ARE containing mRNAs in the nucleus and export through the nuclear 
pores to the cytoplasm and induced mRNA stabilization (Fan & Steitz, 1998).
Increased expression of cyclooxygenase-2 (COX-2) has been observed in several human 
tumors (Thun et al., 2002). COX-2 affects many aspects of carcinogenesis including 
angiogenesis, apoptosis, immune escape and tumor invasiveness (Gupta & Dubois, 2001). 
Different oncogenes, cytokines, growth factors and tumor-associated genes known to 
induce COX-2 expression by activating transcription and also by enhancing mRNA 
stability transiently (Ristimaki et al., 2002). In human colon cancer, Increased HuR 
expression is directly correlated with the COX-2 expression (Dixon et al., 2000). Increased 
binding of HuR to a conserved AU-rich element in the 3’UTR region within the COX-2 
mRNA decreased COX-2 mRNA decay and increased COX-2 protein levels. Other ARE- 
containing, tumor promoting factors such as angiogenic factor VEGF and proliferative 
factors IL-8 also upregulated in colon and brain tumor cells presumably due to mRNA 
stabilization by the overexpressed HuR protein (Dixon et al., 2000). Cyclin A and B1 play 
a central role in controlling the cell cycle progression from the S to the G2 phase and their 
expression are tightly regulated during the cell division. The post-transcriptional regulation 
by mRNA stability is very important for the regulated expression of these proteins (Maity 
et al., 1995). During the S phase, the HuR protein localizes from nuclear to cytoplasm and 
selectively stabilizes the cyclin A and B1 mRNA (Maity et al., 1997). In the RKO 
colorectal cancer cell, the antisense mRNA mediated inhibition of the HuR expression 
leads to a reduced half-life of the cyclin A and B 1 mRNA and an inhibition of cell growth 
and proliferation (Wang et al., 2000a). These results illustrate the importance of HuR in the 
cell cycle regulation by post-transcriptional mechanisms.
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1.2.7.2.2 Tristetraprolin (TTP)
It has been reported that the defects in the ARE-mediated mRNA stabilization result in 
an increased expression of the autocrine hematopoietic growth factors GM-CSF, which is 
known to contribute to the pathogenesis of leukemia (Hoyle et al., 1997). The ARE-binding 
protein tristetraprolin has been shown to regulate the GM-CSF mRNA stability by 
interacting with the AU-rich region of the ARE and induce deadenylation mediated mRNA 
decay (Schuler & Cole, 1988). The GM-CSF mRNA is markedly stabilized in the TTP 
knockout transgenic animals (Carballo et al., 2000), which establishes a clear role of TTP 
in regulating GM-CSF expression via mRNA stabilization.
In a human colorectal cell line HCA-7, two different COX-2 mRNA with different lengths 
of 3’UTR have been identified. One of the mRNA with a longer 3’UTR contains the 
binding site for the TTP and is subject to TTP mediated mRNA degradation. The COX-2 
mRNA with the shorter version of 3’UTR without the TTP binding site cannot be targeted 
by the TTP for degradation and is responsible for a sustaining elevated level of COX-2 
expression in the cancer cells (Boutaud et al., 2003).
1.2.7.2.3 AUF1
AUF1 is an ARE-binding protein that is shown to cause mRNA destabilization. The 
target mRNAs for AUF1 encode many important proteins that are involved in mitogenic 
signaling, immune response, cancer-associated and cell-cycle regulation. As mentioned 
before, this protein is expressed in four isoforms (p37, p40, p42 and p45) arising from the 
same mRNA by alternative splicing (Wilson et al., 1999). In vitro, the p37 isoform has the 
highest affinity for the AREs and is most efficient in destabilizing the ARE-mRNA (Loflin 
et al., 1999). The p37 AUF1 overexpressing transgenic mice develop sarcomas by
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upregulating the cyclin Dl expression (Gouble et al., 2002). Elevated levels of interleukin- 
10 (IL-10) production were observed in the malignant melanoma cells, which is responsible 
for inhibiting immune surveillance and tumor rejection (Steinbrink et al., 2002). The IL-10 
mRNA half-life of the melanoma cells increases dramatically compared to normal 
melanocytes (75 min. vs 7 min.). This abnormal stabilitization of IL-10 mRNA in the 
melanoma cell appears to be due to the very low cytoplasmic levels of AUF1 (Brewer et 
al., 2003).
1.2.7.3 Alteration in the signaling pathways and mRNA stability
The third most important component of the ARE-mediated regulation of mRNA 
turnover is comprised of the intracellular cell signaling pathways. Compared to our current 
understanding of how intracellular signaling regulates cellular processes such as 
transcription, very little is known about the signaling events regulating mRNA stability. 
However, several reports have provided increasing support for signal transduction 
pathways as being possibly involved in regulating the mRNA stability. The following are 
the few examples of the best characterize signaling pathways that are involved in regulating 
stability of the different ARE-mRNAs.
1.2.7.3.1 p38 MAPK signaling
The p38 MAPK pathway has been shown to regulate the half-life of a number of ARE- 
bearing mRNAs including COX-2, IL-3, IL-6, IL8, TNF-oc, VEGF, GM-CSF, c-fos and 
uPA (Dean et al., 2004). Extracellular ligands such as different pro-inflammatory stimuli 
can bind to the target receptor and activate upstream MAP kinases such as MKK6 and 
MKK3, which then activate the p38 MAPK and regulate the stability of the p38 responsive
63
mRNAs. More than 40 ARE-mRNAs have been recently reported as potential targets for 
the p38 MAPK pathway (Frevel et al., 2003). The ARE-mediated deadenylation directly 
correlates with the p38 MAPK activity. The inhibition of p38 MAPK pathways leads to a 
reduction of mRNA decay and an increase in translation efficiency (Dean et al., 2003). 
Several studies identify the MK2 as the key downstream effectors molecule in the p38 
mediated mRNA stabilization. Both the endotoxin-induced COX-2 mRNA stabilization 
and the COX-2 expression can be abolished by expressing dominant-negative MK2 or 
inhibition of the p38 pathway using pharmacological inhibitor SB203580 (Dean et al.,
1999). The COX-2 expression is linked to poor prognosis of many human cancers. Also 
treatment with the selective COX-2 inhibitor celecoxib reduces the number of colorectal 
polyps in patients with familial adenomatous polyosis (Phillips et al., 2002). The p38 
MAPK pathway has been reported to play an important role in the cancer cell selective 
COX-2 mRNA stabilization and COX-2 induction. In HeLa cell, IL-1 induced COX-2 
expression can be reduced by an inhibition of p38 signaling by destabilizing the COX-2 
mRNA (Ridley et al., 1998). In Barrett’s esophagus, acid-activated p38 MAPK stabilized 
COX-2 mRNA and increases the COX-2 expression, suggesting potential mechanisms 
whereby acid reflux might promote carcinogenesis (Souza et al., 2004).
The transforming growth factor-pl (TGF-pl) is a member of a large family of 
multifunctional polypeptides that promotes tumor growth, immune suppression, 
angiogenesis and metastasis (Steams et al., 1999). Both the intercellular and serum levels 
of TGF-pl are elevated in prostate cancer patients and even more so in patients with 
metastasis (Eastham et al., 1995). In the prostate cancer, TGF-pl can elevate the expression 
of ARE-binding protein HuR (Park et al., 2003), which binds to ARE elements within the
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3’ untranslated region of the tumor-promoting cytokine IL-6 mRNA and stabilize the 
mRNA. The inhibition of the p38 signaling pathway abrogate TGF-pl-induced IL-6 
mRNA expression (Park et al., 2003). Matrix metalloproteinase protein-9 is involved in 
disrupting the basement membrane during angiogenesis and tumor invasion. The TGF-pl 
induces MMP-9 mRNA stabilization and elevated MMP-9 expression is reported in 
different malignancies (Sehgal & Thompson, 1999).
The urokinase-type plasminogen activator (uPA) interacts with its receptor (uPAR) to 
promote cell migration as well as proliferation and contributes to the pathogenesis of 
neoplastic growth and invasiveness. The expression of both uPA and its receptor at the 
tumor sites correlates with poor prognosis of cancer. In the invasive breast cancer cells, 
constitutive p38 MAPK activity is essential for uPA expression by promoting stability of 
the ARE-containing uPA mRNA (Han et al., 2002). The expression of the dominant 
negative MK2 inhibits uPA expression as it destabilizes the uPA mRNA.
The precise mechanism of how the p38 pathway regulates the ARE-containing mRNA 
turnover remains unknown. Hypothetically, RNA-binding proteins could be an ideal target 
for the post-translational modification by the p38 pathway, which eventually leads to 
alteration in their ability to stabilize or destabilize ARE-mRNAs. In recent years, there has 
been much progress in identifying RNA-binding proteins that are affected by the 
intercellular signaling. One such example is the p38-mediated modification of the mRNA 
binding protein tristetraprolin (TTP). TTP exists in numerous phosphorylated forms and 
known to be targeted by several signaling pathways including p38. The 
hypophosphorylated form of TTP binds to ARE sequences more efficiently than the
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hyperphosphorylated form (Carballo et al., 2000), which alters its ability to destabilize 
ARE-mRNAs.
1.2.7.3.2 Wnt/p-catenin pathway
The wnt/p-catenin pathway has been extensively linked to cancer (Kikuchi et al., 2006). 
This pathway rapidly induces expression of cell type specific transcription factor Pitx2, 
cyclins Dl and D2 by stabilizing the mRNA of these genes. Wnt activation induces the 
cytoplasmic localization of the ARE-binding protein. Wnt-induced Pitx2 mRNA 
stabilization is due to a decreased interaction of its ARE with the destabilizing ARE-BPs 
like TTP and an increased interaction with the stabilizing ARE-BPs HuR (Briata et al., 
2003).
1.2.8 MicroRNA and the 3’UTR mediated mRNA stability:
MicroRNAs (miRNAs) represent a new class of highly conserved, about 22-nucleotide 
non-coding RNAs that are thought to negatively regulate the expression of protein-coding 
genes by targeting mRNAs for cleavage or translation repression (Bartel, 2004). By using 
bioinformatics prediction and molecular cloning strategies, hundreds of miRNAs have been 
identified in worms, flies, fish, plants and mammals (Ambros et al., 2003). The primary 
miRNAs (pre-miRNAs) are first transcribed in the nucleus to produce stem-loop structure 
of about 80nt (Bartel, 2004) and immediately processed by the RNase III enzyme Drosha, 
which excises the stem-loop from pre-miRNA (Bartel, 2004). This pre-miRNA is then 
exported from the nucleus to cytoplasm by export receptor Exportin-5 (Bartel, 2004) and 
are further processed by another RNase III endonuclease, Dicer, to generate the mature 
miRNAs as part of a short RNA duplex. The mature miRNA is then subsequently unwound 
by a helicase-like enzyme and is incorporated into a RNA-induced silencing complex
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(RISC), where they can direct RISC to downregulate target gene expression by either 
mRNA cleavage or inhibition of effective mRNA translation (Bartel, 2004). The 
mammalian miRNAs are thought to inhibit gene expression by repressing productive 
translation through imperfect complementary sequences with the 3’-UTR of the target 
mRNAs (Doench et al., 2003). Hundreds of miRNAs have been identified, but their targets 
are yet to be determined. But theoretically based on bioinformatics approach to predict 
miRNA targets, a given miRNA can target one to hundreds of different genes. About 1-5% 
of all animal genes are comprised of miRNA, making it one of the most abundant classes of 
regulators (Bartel, 2004).
In a recent study, Jiahuai Han and colleagues observed that miR16, a human miRNA 
containing an UAAAUAUU complementary sequence to the ARE sequence of the TNF-a 
mRNA, is required for ARE-mediated mRNA turnover (Jing et al., 2005). An 
overexpression or inhibition of miR16 expression decreases or increases, respectively, the 
stability of a reporter RNA containing AREs (class II ARE containing multiple AUUUA 
repeats) of both TNF and COX-2, but has no effect on the reporter RNA containing uPA 
ARE (class III ARE with no AUUUA repeats). The miR16-mediated ARE-mRNA decay is 
sequence-specific and the ARE-binding protein tristetraprolin (TTP) plays an essential role 
in the process ARE-mRNA degradation. By using very elegant knockdown experiments in 
both Drosophila and mammalian systems with the siRNA, they were also able to show that 
many cellular components involved in the miRNA-mediated regulation gene expression are 
required or even essential for ARE-mediated RNA degradation, suggesting these two 
mechanisms of gene regulation are somehow interconnected. Comprehending the 
relationship between these two pathways of gene regulation will not only be important for
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improving our knowledge of regulation of gene expression globally, but also it will give us 
new insights about their involvement in human diseases. For example, it has been reported 
that a cluster of two miRNAs, miR-15 and miR16-l located on chromosome 13ql4.3, is 
most frequently deleted genomic region in human chronic lymphocytic leukemia (CLL), 
which leads to a downregulation of both genes in the majority of CLL cases (approximately 
68%) (Calin et al., 2005). The antiapoptotic protein bcl-2 expression in CLL is inversely 
correlated with the miR15-a and miR16-l expression and both of the miRNAs negatively 
regulate bcl-2 at a posttranscriptional level. Many other genes (e.g. MRP, COX-2) have 
been reported to overexpress in CLL by increasing the stability of their mRNA and are 
important for the tumorogenesis (Ryan et al., 2006). Based on these reports, it might not be 
premature to speculate that miRNAs like miR16, may be an important component of the 
ARE-mediated mRNA decay.
1.2.9 Conclusion and future direction
The mechanism of mRNA stability as a means to regulate gene expression is found in 
all living organisms. The kinetics of mRNA accumulation following transcription is 
determined by the stability of the mRNA, which is one of the key factors that control the 
quantity of protein produced from that mRNA. A given mRNA may also be controlled by 
several post-transcriptional mechanisms, such as microRNA or mRNA stability, in order to 
achieve the appropriate expression in both time and space. The ARE-mediated mRNA 
turnover is an important component of the post-transcriptional process of gene regulation, 
which is control by a dynamic equilibrium among cis-acting elements in the mRNA, RNA- 
binding proteins and the signaling pathways that are capable of modifying the interaction 
between mRNA and RNA-BPs in a particular cellular environment.
68
Compared with the amount of knowledge we have in regards to the regulation of gene 
expression by transcription, our understanding on the post-transcriptional regulation of 
gene expression is still in its infancy. Many questions remain to be answered. There is very 
little information about the secondary structure of the ARE and how that may play a role in 
the mRNA turnover. Increasing knowledge on the structure of ARE will be very important 
for better understanding of the interaction with the RNA-binding proteins and the ARE 
within the 3’UTR of the target mRNA. Many RNA-BPs seem to shuttle between the 
nucleus and cytoplasm; different cellular signaling pathways have been shown to modulate 
this process. It has become clear that some signaling events modify specific RNA-BPs by 
phosphorylation, which controls their interaction with the AREs. But the relationship 
between intracellular signaling and the compartmentalization of the RNA-BPs is not well 
understood. We also need to address the role of microRNAs in the process of ARE- 
mediated mRNA decay. Recent reports have identified cellular factors that are involved in 
both of these regulatory processes. It is yet to be determined how these two post- 
transcriptional pathways of gene regulation are interconnected. And finally, as pointed out 
in this review, several human diseases are caused by the defects in the process of mRNA 
turnover. In-depth knowledge about the post-transcriptional regulation of gene expression 
will provide a solid ground for designing effective therapy for these diseases.
1.3 Cyclooxygenase-2
1.3.1 Introduction:
Aspirin has been used as an analgesic and anti-pyretic medicine for over a century with 
very little knowledge about its mechanisms of action. In the late sixty’s, Samuelsson and
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Bergstrom discovered the prostaglandin (PG) synthesis pathways (Nugteren et al., 1966) 
and few years later JR Vane and his colleagues identified cyclooxygenase (COX) as the 
molecular target for Aspirin, the rate-limiting enzyme for prostaglandin biosynthesis 
(Ferreira et al., 1971). In 1982 the Noble committee acknowledged the importance of this 
discovery by awarding Drs. Vane, Samuelsson and Bergstrom the Noble Prize for 
Physiology and Medicine. Now a family of drug exists with the similar properties, 
collectively known as non-steroidal anti-inflammatory drugs (NSAIDs).
The enzyme COX exists as two distinct isoforms, COX-1 and COX-2. COX-1 is 
constitutively expressed as a housekeeping enzyme in most of the tissues and controls 
normal physiological functions such as platelet aggregation, and regulation of renal blood 
flow (Smith et al., 2000). By contrast, COX-2 is expressed by cells that are involved in 
inflammation and responsible for the synthesis of the PGs associated with pain and fever. 
The suppression of COX-2 activity is thought to be the main therapeutic action of NSAIDs, 
on the other hand the inhibition COX-1 results in unwanted side effects such as ulceration, 
bleeding, and obstruction at the gastrointestinal tract (Smith et al., 2000). The expression of 
COX-2 has been reported to be elevated in many different human cancers including 
colorectal, breast, cervical, prostate and lung (Zha et al., 2004). Multiple lines of 
epidemiological evidence indicated that the use of COX-2 inhibitor NSAIDs is associated 
with a reduced risk of several malignancies (Zha et al., 2004). Also, transgenic animals 
with knockout COX-2 or animals treated with selective COX-2 inhibitor, tumor formation 
and growth are significantly reduced, indicating a clear association between COX-2 
expression and carcinogenesis (Oshima et al., 1996). Here we review the fundamental
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properties of COX enzyme, especially COX-2 as related to tumorogenesis and discuss the 
proposed mechanisms behind their roles in cancer.
1.3.2 Gene, enzyme and structure:
The human gene encoding COX-1 is located on chromosome 9 (9q32-9q33.3), which 
contains 11 exones spreads across 40 kb and its mRNA is approximately 2.8 kb (Smith et 
al., 2000). The gene encoding COX-2 is located on chromosome 1 (lq25.2-25.3) and 
contains 10 exones with a 4.5 kb transcript (Smith et al., 2000). Although the two members 
of COX family enzymes are very different in their genomics structure and transcript size, 
the proteins for both enzymes are about 600 amino acids with the calculated molecular 
weight of about 6 8  kDa. But after the post-translational modifications by glycosylation, the 
molecular weight becomes 75-80 kDa (Smith et al., 2000).
Both of the COX isoforms catalyze the same reaction by using the same substrate and 
generate the same products. The X-ray crystal structures of both of the isoforms are near 
superimposible with few profound differences. First of all, the isoleucine 590 in the 
substrate channel of COX-1 is replaced by a smaller amino acid valine in COX-2 
(Kurumbail et al., 1996), which gives COX-2 larger substrate binding pocket and ability to 
use a broader spectrum of substrate. The isolucine/valine substitution is also thought to be 
the structural basis for the COX-2 selective inhibitors. Another important structural 
difference between these two enzymes is that COX-2 contains an additional 18 amino acids 
towards its C-terminus end, while COX-1 enzyme contains an insertion of extra 17 amino 
acids towards its N-terminus end (Smith et al., 2000). COX-2 can be found in both the 
endoplasmic reticulum (ER) and the nuclear envelope, but COX-1 is only localized to the
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ER. It has been hypothized that the C-terminal insertion might carry a nuclear localization 
signal that initiate the COX-2 nuclear membrane localization (Smith et al., 2000).
As mentioned above, COX-1 is constitutively expressed with constant levels in many 
tissues, whereas COX-2 is an inducible enzyme, which is only expressed in response to 
different cellular stimuli. But the high amount of constitutive expression of COX-2 is also 
documented in the central nervous system, the kidney and in the seminal vesicles. The 
substrate for COX-2 enzyme is present in the ER and the nuclear membrane where COX-2 
catalyzes the rate-limiting step for prostaglandin synthesis.
1.3.3 Prostaglandin biosynthesis:
Both COX isoforms catalyze the synthesis of prostaglandins (PGs) from arachidonic 
acid, which is a 2 0 -carbon polyunsaturated fatty acid released by phospholipase A2 from 
the cell membrane (Figure 1.9). COX catalyzes the oxidative cyclization of arachidonic 
acid to form the unstable intermediate PGG2 , which is then rapidly reduced to a more stable 
PGH2 by the peroxidase activity of COX. Under different physiological conditions, 
different cell types metabolize PGH2 differently to produce dramatically different products. 
For examples, PGD is usually found in the mast cells and in the brain; PGF is produced in 
the uterus; PGI is found in the endothelial cells; thromboxane is commonly produced by 
platelets and macrophages (Smith et al., 2000).
Membrane phospholipids
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Figure 1.9 Prostaglandin biosynthesis pathway.
1.3.4 Regulation of COX-2 expression:
1.3.4.1 Transcriptional regulation
The expression of COX-2 is regulated by a broad-spectrum stimulus associated with 
the inflammation. The most well studied COX-2 inducers are bacterial lipopolysaccharide 
(LPS), pro-inflammatory cytokines such as IL-lp, TNF-a, IL-2, growth factors (e.g. 
epidermal growth factor, platelet derived growth factor), and some tumor promoting agents 
such as PM A. On the other hand, anti-inflammatory cytokines like IL-10 have been 
reported to inhibit COX-2 expression (Zha et al., 2004). The promoter of the COX-2 gene 
contains a TATA box and binding sites for several transcription factors including activator 
protein l(AP-l), nuclear factor kB, nuclear factor for activated T cells (NFAT), which can 
modulate the transcription of COX-2 (Smith et al., 2000). As a negative regulator wild 
type, but not mutant, p53 markedly suppresses COX-2 transcription by competing with the 
TATA-binding protein for binding to the TATA-box (Smith et al., 2000). Several reports 
highlight the importance of the p53 status in human tumors as one of the determinant factor 
of COX-2 overexpression (Erkinheimo et al., 2004).
1.3.4.2 Post-transcriptional regulation
When Needleman and his colleagues first discovered the inducible isoform of the 
cyclooxygenase gene COX-2, they also recognized that the COX-2 expression was 
temporally regulated at both transcriptional and post-transcriptional levels (Raz et al.,
1989). Then the identification of multiple regulatory elements within the 3’UTR of the 
COX-2 mRNA solidified the notion that COX-2 might be regulated at the post- 
transcriptional levels. The 3’UTR of the human COX-2 gene is located in the exon 10,
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which contains 22 copies of the AUUUA Shaw-Kamen sequences (Gou et al., 1998). The 
post-transcriptional regulation of the COX-2 mRNA is dependent on these elements since 
its presence induces rapid decay of a naturally stable reporter mRNA (Dixon et al., 2000). 
This AU-rich region (ARE) is highly conserved among human, mouse, rat chicken, pig and 
sheep COX-2 transcript, implying that the function of these regulatory elements has been 
conserved throughout the evolution. I will discuss later in this chapter how all the trans­
acting regulatory elements and the signal transduction pathways interact with the 3’UTR 
and initiate post-transcriptional regulation of the COX-2 expression.
1.3.5 Physiological and pathophysiological functions of COX-2
1.3.5.1 COX-2 in pain management
COX-2 is constitutively expressed in the dorsal horn of the spinal cord and becomes 
upregulated briefly after trauma and during inflammation. This causes an increased 
synthesis of the COX-2-dependent PGs, which sensitize peripheral nociceptor terminals 
and produces localized pain. Experimental evidences suggesting that the increased COX-2 
expression in the spinal cord may facilitate transmission of the nociceptive input. The 
specific COX-2 inhibitor celecoxib inhibits the inflammation-induced PGs synthesis in the 
cerebrospinal fluid and suppresses pain sensation (Smith et al., 1998).
1.3.5.2 COX-2 in kidney function
The kidney is one of the organs that have been reported to express COX-2 
constitutively. In the human kidney, the COX-2 expression is observed in the renal 
vasculature, medullary interstitial cells and in the macular dense by immunohistochemistry. 
The limited evidence in humans indicated that the COX-2 is involved in the sodium 
regulation and the kidney perfusion under stress, but do not contribute in maintaining the
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basal renal blood flow (Khan et al., 2001b). Various clinical studies clarify the involvement 
of COX-2 in human renal function and show that specific inhibitors cause peripheral 
edema, hypertension, and worsen a pre-existing hypertension by inhibition water and salt 
excretion by the kidney.
1.3.5.3 COX-2 and the cardiovascular system
It has been suggested that the COX-2 expressed by the endothelium to plays a 
vasoprotective and anti-atherogenic role by catalyzing the production of PGI2 , which is a 
potent inhibitor of platelet aggregation, activation and adhesion of leukocytes, and 
accumulation of cholesterol in vascular cells. In the clinical studies, specific COX-2 
inhibitors have been shown to decrease systemic PGI2 (McAdam et al., 1999).
1.3.5.4 COX-2 and the Alzheimer’s diseases
The involvement of COX-2 with Alzheimer’s diseases has been mostly based on 
epidemiological studies. A study conducted with 1686 participants showed that the risk of 
developing Alzheimer’s disease was significantly reduced in the group of NSAIDs user. 
Also, COX-2 is upregulated in brain areas like the hippocampus and the cortex, which are 
related to memory. COX-2 expression is also correlated with the deposition of (3-Amyloid 
protein in the Alzheimer’s plaques (Xiang et al., 2002). However, the precise role of COX- 
2 in Alzheimer’s disease is not yet known.
1.3.6 COX-2 and cancer
The idea that the COX-2 may play a role in carcinogenesis was first suggested by the 
epidemiological studies demonstrating the effectiveness of different NSAIDs in reducing 
the relative risk of clone cancer (Gupta & Dubois, 2001). Now, compelling evidence is
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indicating that COX-2 is an important contributor to the process of carcinogenesis. In this 
part of the chapter, I will focus on two sources of evidence: epidemiological studies and 
results from transgenic animal models, which indicate that the COX-2 could be one of the 
rate-limiting factor and also will discuss proposed mechanisms for the role of COX-2 in 
cancer development.
1.3.6.1 Epidemiological evidence for an association between COX-2 and 
carcinogenesis
One of the earliest epidemiological study that evaluated the anti-cancer properties of a 
selective COX-2 inhibitor sulindac was reported by Dr. Willlliam Waddell and his 
colleagues, where they were able to show the regression of rectal polyps in a small number 
of familial adenomatous polyposis patients (FAP) in response to sulindac (Waddell & 
Loughry, 1983). This work initiated a number of additional epidemiological studies as well 
as clinical trials. The results from one of the randomized double-blind placebo controlled 
trials on FAP patients suggested that treatment with celecoxib 400 mg twice daily for 6  
months reduced the number of colorectal polyps by 28% (Steinbach et al., 2000). Similar 
studies on other high-risk populations have shown some beneficial reduction of the number 
and the size of adenoma, but the effects were inconsistent (Baron et al., 2003). A number of 
epidemiological studies on colorectal cancer patients also showed about 30-50% reduction 
in risk of colorectal cancer or adenomatous polyps or death from colorectal cancer. Based 
on these results, the FDA approved celecoxib as an adjunctive therapy for FAP patients. 
These beneficial effects of NSAIDs as anti-cancer agents directly correlate with escalating 
doses and duration of the treatment (Giovannucci et al., 1995). Although the early results
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look very promising, currently there is not enough evidence out there to draw any 
conclusion on the chemo-preventative value of NSAIDs.
The COX-2 overexpression in human colon cancer was first reported by the Eberhart’s 
group in 1994. Among all the clinical colon cancer samples tested in different studies, the 
percentage of COX-2 positive cells varied from 40-100%. There was a great deal of 
variability among these studies, even though most cases are from the FAP patient group. In 
these patients, increased COX-2 expression correlated with larger polyp size and also the 
invasiveness of the polyp (Khan et al., 2001a). But it is still unclear which cell-type 
actually expresses COX-2 in the tumor microenvironment or when COX-2 expression is 
required during the tumor progression.
1.3.6.2 Genetic evidence for an association between COX-2 and carcinogenesis
The first genetic evidence of the involvement of COX-2 in the process of 
carcinogenesis came from a transgenic murine model of FAP (mice carrying inactive tumor 
suppressor gene APCA716). When these APCA716 mice were crossed with another transgenic 
model carrying an inactivated COX-2 gene, the number and the size of the intestinal polyps 
were reduced in a dose-dependent manner (Oshima et al., 1996). In the transgenic mice 
model, where COX-2 is placed downstream of the murine mammary tumor virus promoter 
and a high level of COX-2 expression is induced in the mammary gland only during 
pregnancy, development of mammary gland hyperplasia, dysplasia and metastatic tumors 
were observed. The overexpression of anti-apoptotic protein Bcl-2 is seen in only in the 
tumor of these mice. In addition to these genetic evidences, it was found that treatment with 
the selective COX-2 inhibitor suppressed the growth of the different tumors in the animal 
model, which supports the role of COX-2 in tumorigenesis.
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1.3.6.3 Proposed mechanisms for the role of COX-2 in cancer
1.3.6.3.1 Support angiogenesis
Tumor angiogenesis not only supports tumor growth by supplying all the necessary 
nutrients, but also provides an important path for tumor metastasis. The first evidence that 
COX-2 is involved in tumor angiogenesis came from a study where the growth of the 
COX-2 positive tumor cells was suppressed in the nude mice by COX inhibitor diclofenac 
through blocking angiogenesis. Subsequently, numerous reports showed by 
immunohistochemistry that COX-2 is co-localized with angiogenic factor like VEGF, 
PDGF or bFGF in different cancer cells. The COX-2 up-regulation leads to prostaglandins 
synthesis, which has been shown to play an important role in ocVp3 integrin-induced 
endothelial cell migration, a necessary step for tumor angiogenesis (Dormond et al., 2001). 
The overexpression of COX-2 also leads to the production of matrix metalloproteinase, 
which is known to initiate the ECM invasion. Moreover, tumor angiogenesis is thought to 
be a major target in the clinical trials for different COX-2 inhibitors in many cancers 
(Masferrer et al., 2000).
1.3.6.3.2 Anti-apoptotic
The COX-2 overexpression in the tumor microenvironment makes the tumor cells 
resistant to apoptosis via altering the membrane death receptor pathway and shifting the 
balance of the pro-apoptotic to the anti-apoptotic protein expression. Treatment of human 
colon cancer cells with the PGE2 leads to increased expression of the anti-apoptotic protein 
Bcl-2 and reduction in the basal apoptotic rate (Sheng et al., 1998b). Also in the transgenic 
mice, where selective COX-2 overexpression in the mammary gland leads to mammary 
gland hyperplasia and metastatic tumors, reduced expression of pro-apoptotic genes Bcl-
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x(L), Bax and increased levels of anti-apoptotic protein Bcl-2 were observed only in the 
COX-2-induced tumor tissue.
1.3.6.4 Conclusion:
In the last 15 years, our understanding of the biology of the COX-2 enzyme has begun 
to shed some light on the mechanisms of the pro-cancerous roles of this enzyme. But it is 
still not clear at what stage of carcinogenesis the COX-2 is required or expressed. 
Inhibiting COX-2 by NSAIDs blocked or slowed down the development of different stages 
of cancer, but more clinical trials are required to draw a conclusion. All these findings 
highlight the importance of the chronic inflammation in cancer development and that 
NSAIDs may become an important part of preventative care for cancer.
1.3.7 Deregulated mRNA stability and expression of COX-2 gene in cancer
Collective evidence from epidemiological studies, transgenic animal models and cell 
culture studies repeatedly indicates that the overexpression of COX-2 is an important step 
in tumorigenesis. The regulation of COX-2 expression is maintained both at the 
transcriptional and post-transcriptional levels and requires contribution from the multiple 
signaling pathways. Recent findings indicate that the increased expression of COX-2 in 
cancer is a combined effect of the loss of both the transcriptional and post-transcriptional 
regulation. This part of the chapter is intended to summarize the recent finding of 
deregulated COX-2 expression in cancer at the post-transcriptional levels.
1.3.7.1 3’UTR-mediated post-transcriptional regulation of COX-2 expression in 
cancer
The loss of AU-rich element (ARE)-mediated post-transcriptional regulation is one of 
the major causes of aberrant expression of different growth-associated genes in cancer
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(Khabar, 2005). In the human T-cell leukemia, the deletion of the 3’UTR of c-myc proto- 
oncogene leads to an increase in mRNA stability and enhances oncogenecity (Aghib et al.,
1990). With regard to aberrant expression of COX-2 in human colon carcinoma cells, 
similar findings have also been observed. Due to the alternative polyadenylation sites 
usage, the human COX-2 gene is able to produce two different primary transcripts (4.6kb 
and 2.6 kb). The 2.6 kb COX-2 mRNA is missing the distal part of the of the 3’UTR, 
which leads to the stabilization of its message and an increase in expression of COX-2 in 
the colon cancer (Sawaoka et al., 2003). This is one of the rare examples of naturally 
occurring alteration in the ARE region of the COX-2 mRNA resulting in deregulated 
protein expression in cancer. Most of the reported mechanisms of loss of COX-2 ARE 
function in tumor cells are primarily due to the alteration in cellular signaling or the trans­
acting regulator factors that influence the post-transcriptional regulation.
1.3.7.2 Altered interaction between the COX-2 AREs and ARE-binding protein:
The post-transcriptional regulation of any ARE-containing mRNA is a dynamic 
process, which is maintained by the cellular signaling pathway and the interaction between 
various ARE-binding proteins with the AREs-mRNA. So far, eight cellular factors have 
been identified that bind to ARE of the COX-2 3’UTR and influence the function of the 
3’UTR to promote rapid mRNA decay, increased mRNA stability or regulate translation 
efficiency. The role of these factors in deregulating COX-2 expression, and their 
importance in carcinogenesis are discussed below.
1.3.7.2.1 HuR
Both in vitro and in vivo study showed that HuR binds to COX-2 ARE and stabilizes the 
COX-2 transcript (Dixon et al., 2000). Elevated levels of HuR expression is the main cause
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of enhanced stabilization of the COX-2 mRNA, which leads to the overexpression of COX- 
2 protein in colon cancer cells. Inhibiting CRM 1-mediated nuclear export of the HuR 
protein with the anti-tumor agent leptomycin B significantly impaired the COX-2 
expression (Sengupta et al., 2003). And recentstudies have shown that, an increase in 
cytoplasmic localization of HuR protein is shown to be associated with COX-2 
overexpression and poor clinical outcome in different cancers (Denkert et al., 2004). 
Several recent reports indicated that an increased cytoplasmic expression of HuR is 
associated with a poor histological differentiation, large tumor size, and a decreased overall 
survival in ductal breast and ovarian carcinomas (Heinonen et al., 2005). In a study with 
the 83 primary ovarian carcinomas and the 9 ovarian carcinoma cell lines, a significant 
correlation between cytoplasmic HuR expression and the increased COX-2 expression 
(P=0.002) as well as histological grade (P=0.008) and mitotic activity (P=0.002) was 
observed (Denkert et al., 2004). Thus, HuR is the first mRNA stability protein, of which 
the expression in the different subcellular compartments is associated with a poor prognosis 
in cancer.
1.3.8.2.2 Tristetraprolin (TTP)
TTP is a zinc finger containing protein, which was originally identified as an 
immediate-early response gene. Extracellular stimuli induced activated ERK, p38 MAPK 
signaling pathway rapidly phosphorylated TTP and altered its function by reducing the 
affinity for the ARE-containing mRNA. In the human colorectal cancer cell line, HCA-7, 
TTP is shown to bind in a distal region of the COX-2 3’UTR and promote rapid 
degradation of full-length (4.6 kb) COX-2 transcript, whereas a 3’UTR-truncted (2.6 kb) 
mRNA escapes TTP-induced decay and maintains elevated COX-2 level in the tumor cells.
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Although, TTP expression is downregulated in many colon cancer cells and tumor samples 
(Zhang et al., 1997), the exact role of TTP in deregulated expression of COX-2 in cancer is 
still unclear.
AUF1 is another ARE-binding protein that is known to bind the COX-2 ARE (Sully et 
al., 2004). A recent report demonstrated that the overexpression of AUF-1 in transgenic 
mice promotes sarcoma development (Gouble et al., 2002) by increasing the cyclin D1 
mRNA and protein expression. Other noticeable RNA-binding proteins, known to interact 
with the ARE within the COX-2 3’UTR are CArG box-binding factor-A (CBF-A) (Sully et 
al., 2004), CUGBP2 (Mukhopadhyay et al., 2003) and T-cell intracellular antigen-1 (TIA- 
1). Most of the studies describing the interaction between these RNA-binding proteins and 
COX-2 ARE are under normal physiological condition and the mechanisms of deregulating 
COX-2 expression by these proteins in the tumor microenvironment are currently 
unknown.
1.3.7.3 Signaling pathways effecting the post-transcriptional regulation of COX-2
The majority of human tumors support their aberrant cell growth by strategically 
introducing genetic mutations that results in an altered signal transduction. The signaling 
pathways involved in maintaining the post-transcriptional regulation of genes is also 
targeted by the tumor cells to increase the expression of the growth-promoting genes such 
as COX-2. Here we discuss the signal transduction pathways that are involved in regulating 
the COX-2 expression in human cancers at the post-transcriptional levels.
1.3.7.3.1 Wnt/APC
Mutation in the tumor suppressor gene adenomatous polyposis coli (APC) is a 
common phenomenon in both sporadic and familial colorectal cancers (Cottrell et al.,
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1992). The upstream of the APC gene is the Wnt mammary oncogene, secretes the 
signaling factor and promotes mammary cell carcinoma. The alteration in both molecules is 
reported in many different cancers, which then leads to a nuclear accumulation of the 
transcriptional activator (3-catenin and the expression of a number of cancer-associated 
genes (Polakis, 2000).
COX-2 seems likely to be a common downstream target for the altered Wnt/APC 
pathways in cancer. An elevated COX-2 expression due to increased transcriptional 
activation was observed in Wnt transformed murine epithelial cells (Howe et al., 1999). 
The nuclear localization of (3-catenin due to APC mutation is directly correlated with the 
increased COX-2 expression in the human colon cancer cells (Dimberg et al., 2001). 
Recent reports demonstrate that mutated (3-catenin cooperates with K-RAS and 
synergistically stabilizes the COX-2 mRNA to promote COX-2 overexpression (Araki et 
al., 2003).
1.3.8. Ras signaling
Ras proteins are approximately 21-kDa membrane associated proteins, which act as a 
molecular switch that converts extracellular stimuli to intracellular signaling responses and 
modulate many important aspects of cell functions including cell proliferation, 
differentiation, survival and apoptosis. The membrane bound Ras proteins cycle between a 
GDP-bound inactive to a GTP-bound active state. The GDP/GTP cycling is regulated by a 
wide range of cell surface receptors those belong to receptor tyrosine kinases, G protein 
coupled receptor, cytokines receptors and integrins. Activated Ras interacts with more than 
2 0  downstream effectors proteins including mitogen-activated protein kinase
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(MAPK)/extracellular signal-regulated kinase (ERK1), PI3-kinase, Raf-1 serine/threonin 
kinase and Ral GDS.
Three different Ras genes encode three classical Ras proteins: Harvey (H)-Ras, 
Neuroblastoma (N)-Ras and Kirstan (K)-Ras. In humans, these genes are located on 
chromosome 11 (H-Ras), chromosome 1 (N-Ras) and chromosome 12 (K-Ras). These 
proteins display approximately 85% sequence homology and most of the differences are 
clustered in the C-terminal hypervariable regions. The sequence differences also correlate 
with functional differences of each Ras isoform. Inactivation of K-Ras is embryonically 
lethal, whereas both H-Ras and N-Ras knockout mice are viable (Koera et al., 1997) 
(Esteban et al., 2001). After the Ras proteins synthesize, they undergo posttranslational 
modification by prenylation and famesylation. The appropriate posttranscriptional 
modification is essential for the intercellular transport of Ras proteins to the plasma 
membrane (Winter-Vann & Casey, 2005). H-Ras and N-Ras are targeted to plasma 
membrane via exocytotic pathway through the golgi apparatus; K-Ras reaches the plasma 
membrane by microtubule-dependent mechanisms. The femesyl moieties of the proteins 
serve as a membrane anchor inside the plasma membrane where proteins become 
functionally active. Once activated, H-Ras and K-Ras need to translocate into the 
endosomal or other intracellular compartments to complete their signaling functions by 
activating the downstream effector molecules.
Mutated forms of Ras proteins are found in 30% of all cancers. About 90% of 
pancreatic cancers, 50% of colon cancers and 25% of adenomas carry K-Ras mutations. 
Most of these mutations are in codon 12, 13 and 61, which abolish GAPs mediated GTP- 
hydrolysis and cause the mutated Ras proteins to stay constantly in their active GTP-bound
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state, independently of extracellular stimuli. This leads to an inappropriate signal 
transduction and a constitutive activation of multiple downstream MAPK signaling 
cascades, which initiate cellular transformation. It is becoming clear that oncogenic Ras 
requires cooperation from other poto-oncogene and signaling pathways such as c-myc, p53 
or transforming growth factor-p (TGF-P) to promote all phases of the carcinogenesis, 
including the transformation of primary cells, migration, invasion and metastasis. For 
example, in an animal model the coexpression of c-myc with mutated Ras synergistically 
enhances the tumor formation (Sinn et al., 1987). The epithelial-to-mesenchymal transition 
is a necessary step for tumor invasion and metastasis requires cooperation between the 
active-Ras and the TGF-p-mediated signaling (Janda et al., 2002).
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Figure 1.10 Ras signaling in human cancer.
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The two downstream pathways targeted by the activated Ras that have been extensively 
linked to tumorigenesis are: (i) the Raf/MEK/ERK pathway and (ii) the PI3-kinase 
pathway. Mutation in Ras or aberrant signal transduction from the overexpressed receptor 
tyrosine kinases or G protein-coupled receptors in the surface of the tumor cells are the 
primary source for the oncogenic activation of Ras proteins. Once activated, Ras targets 
Raf in the plasma membrane, where Raf is activated and than phosphorylates the duel- 
specific kinases MEK 1 and 2. MEK then activates ERK 1 and 2 by phosphorylation. The 
activated ERK translocates into the nucleus and it interacts with different transcription 
factors and induces gene expression that subsequently promotes cell growth, differentiation 
and apoptosis. Uncontrolled Raf/MEK/ERK signaling has been observed in several tumors. 
The second downstream signaling cascade of Ras is PI3-K, which is extremely important 
for translating signals from a variety of extracellular stimuli into different cellular 
responses. PI3-K controls the phosphoinositide lipid metabolism and production of PIP3 at 
the plasma membrane, which is involved in the recruitment and activation of a wide variety 
of downstream targets, including serine/threonine kinase Akt/PKB. The main effects of 
aberrant activation of the PI3-K/Akt pathway in the process of transformation are the 
support of cell survival and cell proliferation.
1.3.9 Ras signaling and COX-2 expressing in the tumor
Both the transcriptional and post-transcriptional mechanisms are involved in Ras- 
mediated COX-2 induction during carcinogenesis. The transcription of COX-2 gene has 
been reported to be induced by the activation of ERK, p38 MAPK, Rho and JNK pathways, 
whereas the mRNA stability of COX-2 is increased through the activation of ERK, p38 
MAPK and Akt/PKB signaling pathways, which known to contribute in the aberrant
86
induction of COX-2 synergesticelly in cancer. The post-trancriptional mechanisms that 
mainly located downstream of the Ras also maintain a cross talk with the Ras signaling 
cascade. Recent work in the Ras-transformed intestinal epithelial cells has demonstrated 
that TGF-P, a signaling pathway required for Ras-mediated invasion and metastasis, also 
synergistically enhances the COX-2 mRNA stabilization and COX-2 expression (Sheng et 
al., 2000). In the colorectal cancer cells, the constitutive activation of ERK pathway results 
in an elevated expression of COX-2. The inhibition of the ERK pathway reduces the COX- 
2 mRNA stability and the COX-2 induction in these cell lines (Dixon et al., 2000; Sheng et 
al., 2000). In the Ras-transformed intestinal epithelial cells, the induction of both the COX- 
2 promoter and COX-2 mRNA stabilization is depended on the ERK activation (Sheng et 
al., 1998b). The Ras induced sequential activation of the PI3-K/PDK/AKT/PKB by various 
growth factor receptors or mutated Ras signaling facilitates a number of cellular events 
associated with the cellular transformation. Constitutive activation of the Akt/PKB pathway
Figure 1.11 Mechanisms of COX-1 upregulation by Ras mutation in human cancer.
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has been reported in colon cancer cells, which is associated with the COX-2 overexpression 
by modulating COX-2 mRNA stability (Sheng et al., 2000). The activation of this pathway 
is also required for the Ras-mediated stabilization of the COX-2 mRNA in the intestinal 
epithelial cells (Sheng et al., 2000).Activation of p38 MAPK works as a sensor for different 
cellular stresses and inflammations. Many inflammatory genes have been found to be 
regulated by p38 MAPK both transcriptionally and post-trancriptionally. A number of 
reports demonstrated the
ability of pro-inflammatory signals such as p38 MAPK to induce different pro- 
inflammatory genes expression by promoting a stabilization of different ARE-containing 
mRNAs including COX-2 mRNA. In the LPS-treated human monocytes, the p38 MAPK 
activation is required for selective COX-2 mRNA stabilization (Dean et al., 1999 #281). 
The association between chronic inflammations with cancer development is well 
documented. Constitutive activation of pro-inflammatory signaling cascades such as p38 
MAPK has been observed in neoplastic tissues (Hardwick et al., 2001). In both intestinal 
and breast cancer cells, the aberrant activity of p38 MAPK promotes a COX-2 stabilization 
(Sheng et al., 2000). The anti-inflammatory drug dexamethasone abolishes p38 MAPK 
activity by inducing the expression of mitogen-activated protein kinase phosphatase 1 
(MKP-1), which inhibits the mRNA stabilizing functions of p38 MAPK and decreases 
COX-2 expression (Lasa et al., 2001).
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1.4 Hypothesis
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Over-expression of various proteins associated with rapid responses to inflammation and/or 
proliferation can be controlled at the level of mRNA stability. Since tumor cells 
continually recapitulate intracellular programmed of proliferation, we propose that tumor 
cell selective stabilization of mRNA can be used as a novel mean to control therapeutic 
gene expression in cancer gene therapy.
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Chapter 2
MATERIALS AND METHODS
90
2.1 CELL BIOLOGY
2.1.1 Eukaryotic cell culture -  General procedures
All manipulations involving cell culture were carried out in a sterile environment provided 
by a laminar flow hood. All tissue culture reagents were filter sterilized by passage 
through a 0 . 2 2  pm filter and stored in sterile autoclaved containers.
The cell lines used in this work were:
293 (Graham et al., 1977)
293A (Quantum Biotechnologies, qbiogene)
293T (Klages et al., 2000)
Human melanoma cell lines, a kind gift from Professor Hart, London)
Mel 624 
Mel 8 8 8  
A378M
RIE-iRas cell line with an inducible activated Ha-RasVa112 cDNA was generated by using 
the LacSwitch eukaryotic expression system (Stratagene, La Jolla, CA) and was maintained 
in DMEM containing 400 pg/ml G418 (Life Technologies,Inc), 150 pg/ml hygromycin B 
(Invitrogen, Carlsbad, CA) and 10% FBS. A kind gift from Professor Beauchamp from 
Vandarbil Medical school.
The following human tumor cell lines were obtained from the American Type Culture 
Collection (ATCC; Manassas, VA) and were maintained as a monolayer in Dulbecco's 
modified Eagle's medium (DMEM, Life Technologies, Inc.) containing 10% fetal bovine 
serum:
HT1080 human osteosarcoma cell line
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HCT116 colorectal cancer cell line 
LnCap, PC-3 prostate cancer cell line
BEAS-2B is an immortalized normal human bronchial epithelial cell line.
U118,U87,U251 gliomas
hTER: Primary human retina pigment epithelial cell hTER were purchased from Clonetech. 
Adherent cell lines were grown as monolayers in plastic tissue culture flasks or dishes 
(Nunc, Nalge Nunc, Napeville, IL) in DMEM supplemented with 10% v/v heat-inactivated 
fetal calf serum (Gibco BRL, Life Technologies, Grand Island, NY) and incubated at 37 °C 
in 5 or 10% CO2 . Cells were grown until just subconfluent (approximately 2 to 4 days) and 
were subcultured 1:10, using trypsin (0.05% W/v)/5mM EDTA to detach the cells. Cell 
counts were performed using an Improved Neubauer haemocytometer and an inverted 
microscope (Olympus 1X70).
2.1.2 Storage and recovery of cells stored in liquid nitrogen
Cells were trypsinised, pelleted and resuspended at approximately 106 cells/ml in medium 
containing 10% v/v dimenthylsulphoxide (DMSO). 1 ml aliquots were transferred to 1.5ml 
Nunc cryotubes, which were then placed within a 1 °C Freezing Container (Nalgene) and 
stored in a 70°C freezer. Using this apparatus, the cells cooled at approximately 1 °C per 
minute. Frozen cells were then transferred to liquid nitrogen tanks (-196 °C) the following 
day.
Rapid thawing in a 37 0 C water bath performed recovery of cells from liquid nitrogen 
storage. Thawed cells were washed in 10ml of medium, harvested by centrifugation (llOg 
for 5 minutes) and were then transferred to 25 cm flasks containing fresh culture medium.
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2.1.3 Gene transfer into eukaryotic cells
2.1.3.1 Growth selection system
I. Geneticin (G418 sulphate)
Geneticin is an aminoglycosied antibiotic related to Gentamicin and is toxic to both 
prokaryotic and eukaryotic cells. Introduction of the neomycin phosphotransferase gene 
into eukaryotic cells can confer resistance to Geneticin added to normal medium 
(Southern and Bert, 1982). Geneticin (Gibco, Life Technologies, Scotland) was added 
to DMEM to a concentration of 5 mg/ml for selective growth of B16 cells and to 1 
mg/ml for other cell lines, these being the concentrations previously determined to be 
optimal for selective growth of these cells.
II. Puromycin
Purmycin inhibits protein synthesis in eukarotic cells by acting as an analogue of 
amunoacyl-tRNA thus causing premature chain termination. The purmycin-N-acetyl- 
transferase gene from Streptomyces alboniger may be expressed in mammalian cells 
and used as a selectable marker for purmycin resistance (Vara et al., 1986). For
2.1.3.2 Transfection protocols
2.1.3.2.1 Calcium phosphate/DNA co-precipitation (ProFection)
This method involves mixing DNA with CaCL and a phosphate buffer to form a fine 
precipitate, which is deposited, onto the cultured cells. Reagents provided in a ProFection 
kit (promega) were used. Twenty-four hours prior to transfection, 5X105 cells were plated 
out in a 25cm2 flask. 10 pg of the plasmid DNA to be transfected were made up to 263 pi 
using sterile distilled water followed by the addition of 37 pi of 2M CaCL. 300 pi of 2 x
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HEPES (N-(2-hydroxyethyl)piperazine- N’- (2-ethanesulphonic acid)) buffered saline 
(supplied in the kit) was then added drop wise to the mixture, during which time a fine 
precipitate became visible. The sample was incubated at room temperature for 30 minutes 
and then added drop wise to the medium in the cell culture flask. On the following day the 
medium was removed and replaced with fresh medium.
2.1.3.2.2 Effectine Transfection
This method involves complexing DNA with a non-liposomal lipid and was performed as 
recommended by the manufacturer’s guidelines (Qiagen). Briefly cells were prepared as for 
the calcium phosphate protocol. For the transfection of a 25cm2 flask 1 pg of DNA is first 
mixed with buffer EC to a total volume of 150 1. Next 8  pi of Enhancer was added to 
condense the DNA before mixing with 10 pi of Effectene. After standing for 5 minutes at 
room temperature 800 pi of media was added and the mixture added to the cells.
If the aim was to obtain stable transfectants, the cells were split into selection medium after 
another 48 hrs. One method was to serially dilute the cells in selection medium and plate 
them in 96 well plates. After about 10-14 days wells containing a single colony were 
identified and transferred to a 24 well then 25cm2 flask. The other method used was to plate 
cells in selection medium into 6 cm dishes. After about 10-14 days resistant colonies were 
either pooled or individually lifted using trypsin-soaked filter paper microsquares and 
transferred to individual wells of 24-well plate, followed by expansion into larger cell 
culture flasks.
Transfections and Luciferase Reporter assays: Plasmids used in DNA transfections were 
purified by DNA maxi kit (QIAGEN, Valencia, CA). DNA concentrations were 
determined by UV spectrophotometers and confirmed by analytical agarose gel
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electrophoresis. For transient transfection, cells were seeded and grown to 50-80% 
confluent for 24 h prior to transfection. For 6  well plates, cells were transfected with 1 pg 
of DNA per well with Lipofectin (QIAGEN, Valencia, CA) at a 2:1 to 4:1 Lipofectin:DNA 
mass ratio (depending on the cell type). Twenty-four hours after transfection, cells were 
washed with PBS and lysed in the lysis buffer provided with the luciferase kit (Promega, 
Madison, WI). The luciferase activity of pGL3-control plasmid in each cell line was 
considered as 1 0 0 %.
2.1.4 ASSAYS
2.1.4.1 Cell survival assay
293 cells were plated at a density of 5X104 cell/well of a 5 well plate. After overnight 
incubation they were transiently transfected using the ProFection protocol detailed above. 
After 24 hours the cells were washed. Those wells containing cells tranfected with suicide 
genes were then incubated in media containing the appropriate prodrug: for HSVtk this was 
5 pg/ml ganciclovir, for CD this was 3 pmM 5-fluorocytosine. All other cells were 
incubated in normal media. 5 days after transfection-surviving cells were determined using 
trypan blue exclusion: cells were washed, trypsinised and collected in 1ml of media. 15 pi 
was then mixed with ~ 1  pi of trypan blue and the number of viable cells counted using an 
Improved Neubauer haemocytometer and an inverted microscope (Olympus 1X70). Counts 
were performed 2  times per sample.
2.1.4.2 MTT assay
To evaluate the selectivity of the cytophatic effect of the conditionally replicating 
adenovirus, 500-1000 cells were seeded in 96-well plates. On the next day cells were 
infected with AdDNMT or WT Ad5 at 1.0 MOI. At indicated times post infection, 200 pi
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of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT, Roche, 
Indianapolis, IN) in cell culture media (2mg/ml) was added to each well. After 4 h 
incubation at 37°C, the precipitate was dissolved with 200 pi of dissolving solution 
provided by the manufacture (Roche, Indianapolis, IN). Plates were than read on a 
microplate reader at 540 nm, All assay were performed triplicate and plotted as percent of 
non-infected cells treated with MTT in the same condition.
2.1.4.3 GM-CSF ELISA
ELISA plates (Rainin) were first prepared with the addition of 100 pi capture antibody/well 
(R&D Systems anti-human GM-CSF antibody MAB615) at 2 pg/ml in PBS. The plate was 
then sealed and incubated overnight at RT. The plate was then aspired and washed three 
times with wash buffer(0.05% Tween 20 in PBS) using a MultiWash Plus microplate 
washer. The plate was then blocked with 300 pi of PBS containing 1% BSA, 5% sucrose 
and incubated at RT for 60 mins. The aspiration / wash procedure was repeated as 
described above and 1 0 0  pl/well of test sample and standards were added in triplicate and 
incubated for 2 hours at RT. Standards were made up from a stock of 118 ng/ml 
recombinant human CM-CSF (R&D Systems): 20 pi of stock was added to 2.36mls of 
diluent (0.1% BSA, 0.05% Tween 20 in PBS) giving an upper standard value of lng/ml. 
serial dilutions of 1 : 2  were then performed down to 15.625pg/ml.
The aspiration / wash procedure was repeated as described. The ‘detection’ Biotinylated 
anti-human GM-CFS antibody (R&D Systems antibody BAM215) was then added as 
lOOpl to each well from a working stock of 1 pg/ml in diluent (0.1% BSA, 0.05% Tween 
20 PBS). This was sealed and incubated for 2 hours at RT.
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The aspiration / wash procedure was repeated as described. Streptaviding-Horseradish 
peroxidase (Zymed laboratories Inc., San Francisco, CA) was then added as 100 pi to each 
well: 1:5000 in diluent (0.05% Tween at 20 in PBS) of a 1.25mg/ml stock. This was sealed 
and incubated for 20 minutes at RT.
The aspiration / wash procedure was repeated as described. 100 pi of ‘substrate’ solution 
(1:1 mixture of H2O2 and Tetramethylbensidine (BD PHamingen, San Diego, CA)) was 
then added.
2.1.5 Flow cytometry for cell cycle analysis
For cell cycle analysis, cell were collected by trypsinizing, washed twice with PBS, fixed 
with 95% ethanol and stored at 4°C for 24 h. These cells were treated with Rnase A 
(Roche, Indianapolis, IN), and were stained with propidium iodide (PI) (Sigma) at the final 
concentration of 25 pg/ml. The PI fluorescence of nuclei was measured using FACScane 
with FL2.
2.1.6 Quantitative analysis of mRNA by Northern blot
Total cellular mRNA was extracted by using an Rneasy kit (QIAGEN, Valencia, CA), 
according to the manufacture's protocol. The mRNA samples (5-10 pg/lane) were separated 
on formaldehyde-agarose gels and blotted onto nitrocellulose membranes. Next the RNA 
concentration was estimated by absorbance at 260 nm as previously described. 1 0  pg of 
total RNA was made up to 20 pi with diethyl pyrocarbonate (DEPC) treated distilled water 
for each sample. 2.5 pi of 5x RNA loading buffer (64 pi 5% bromophenol blue, 80 pi 0.5 
M EDTA, 720 pi 37% formaldehyde, 2 ml glycerol, 3.084 ml fromamide, 4ml lOx MOPS, 
made up to 10ml with DEPC dFbO) was added. (lOx MOPS is 200mM 3-[N-morhilino] 
propanesulfonic acid (MOPS), 50mM sodium acetate, lOmM EDTA). The samples were
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then heated to 65 °C for 4 minutes and kept on ice before loading on to a 1.2% agarose gel 
(1.6g agarose, 15ml lOx MOPS, made up to 150 ml with DEPC dFLO was heated to fully 
dissolve the agarose. After cooling to ~ 65 °C 2.7 ml formaldehyde and 5 pi ethidium 
bromide was added and the gel poured). The gel was then equilibrated by running for 30 
minutes at 80V in lx running buffer (100ml lOx MOPS, 20 ml 37% formaldehyde, 880 mo 
DEPC dH^O). after equilibration the samples were loaded on to the gel and run at ~80V for 
~ 2  hours.
Northern blot of luciferase mRNA: The blots were hybridized with the 1.7-kb HindHI/XhoI 
fragment from pGL3 control containing the full length luciferase ORF cDNA probes 
labeled with [a-32P] dCTP by random primer extension (Stratagene, La Jolla, CA) (Mawji 
et al). After hybridization and wash, the blot was subjected to autoradiograph. 18S rRNA 
signals were used to determine integrity of RNA and equality of the loading. For 
determination of mRNA stability, cells were transfected with thelpg of pGL3 control or 
pGL3 DNMT 3’UTR plasmids. 12-16 h post transfection the transcription was stopped by 
the addition of 10 pg/ml Act D (Sigma). The RNA samples were isolated at 0, 3, 6 , 9 and 
12 hour following the Act D treatment and analyzed for mRNA levels by Northern blotting. 
Northern blot of El A mRNA: For determination of mRNA stability, infected (10 moi of 
Ad-ElA-COX) and transfected (lpg of CMV-E1A or CMV-E1A-COX plasmids) RIE- 
iRas cells were treated with or without IPTG for 24h, then the transcription was stopped by 
the addition of lOOpM DRB (5,6-dichlorobenzimidazole riboside; Sigma). The RNA 
samples were isolated at 0,1, 2, 3,4, and 5 hour following the DRB treatment and analyzed 
for mRNA levels by Northern blotting.
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2.1.6 Quantitative analysis of protein by western blot
Protein extracts were prepared at 11-14 h postinfection by lysis of infected cells with 
radioimmunoprecipitation assay buffer (lOmM Tris buffer [pH7.4], 425mM NaCl, 1% NP- 
40, 1% deoxycholate, 0.1% SDS, lOOpl of protease inhibitor cocktail [Roche, Indianapolis, 
IN], 5 mM EGTA, 100 pM Na3V0 4 , 50 mM NaPyrophosphate, 50 mM NaF) and protein 
expression was determined by Western Blot after separation of lOpg of cell lysate on 10% 
SDS-PAGE and transferred to a PVDF membrane (Millipore, Bedford, MA). The protein 
concentration was determined using a BCA protein assay with bovine serum albumin as a 
standard (Pierce, Rockford, IL).
The detection of adenovirus E1A and H-RAS proteins were accomplished using rabbit 
polyclonal antibody (Santa Cruz Biotech., Santa Cruz, CA) against the target proteins. 
Immunoreactive bands were visualized by enhanced chemiluminescence (Pierce, Rockford, 
IL). The detection of adenovirus fiber protein, a monoclonal antibody from NeoMarker was 
used. For the detection of Phospho-MAP kinase a monoclonal antibody from New England 
Biolabs Inc. was used. The MAP kinase specific inhibitor PD98059 was also purchased 
from New England Biolabs Inc.
2.1.7 Preparation of complementary DNA for analysis with PCR
The RNA sample was first incubated with 1 pi DNAse (RNAse Free) (Boerhinger 
Mannheim) and incubated at 37 °C for one hour. Next the RNA concentration was 
estimated by absorbance at 260 mm as previously described. A First strand cDNA was 
generated from an RNA template using a First Strand cDNA Synthesis Kit supplied by 
Boerhinger Mannheim Roche (Indianapolis, IN). For each RNA sample two aqueous 
solutions containing 1 pg of total RNA were made up to 10 pi with sterile water. To one
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sample 10 pi of the ‘Reaction Mixture’ containing RNAase inhibitor, magnesium chloride, 
DNTPs, aqueous buffer and 2 pi Oligo-p(dT) 15 primer was added; this was the rt negative 
control. To the other sample was added the same reaction mixture plus 1 pi AMV reverse 
transcriptase; this was the rt positive sample. All samples were then incubated at 25 °C for 
10 minutes and then at 42 °C for 60 min. For analysis with polymerase chain reaction 
(rtPCR) 2 pi of the reaction mixture was used in each PCR sample. Both rt positive and 
negative samples were first analyzed for glyceraldehydes phosphate dehydrogenace 
(GAPDH) to confirm a lack of DNA contamination of the mRNA and identify equal 
quantities of input RNA to the rtPCR procedure. The GAPDH primers used were from the 
human GAPGH PCR primer pair (R&D system, Minneapolis, MN) with the following 
sequence:
Forward: AAAGGGTCATCATCTCTGCC 
Reverse: TGACAAAGTGGTCGTTGAGG
PCR was performed in a 50pl reaction mixture with 250pM of each dNTP, lOOnM of 
primers, 5pl of lOx buffer (HT Biotechnology Ltd, Cambridge, U.K.) and 1 unit of super
Taq DNA polymerase (HT Biotechnology Ltd, Cambridge, U.K.) using 30 cycles (94°C, 1
minute denaturation; 58°C, 1.5 minute annealing; and 72°C 2 minutes extension). For 
GAPDH positive PCR is identified by a band at 576 base pairs. Subsequent analysis by 
PRC of the rt samples was performed using primers of interest with the appropriate PCR 
conditions.
The reaction mix (25pi samples) was analyzed by agarose gel electrophoresis (1%) in TAE 
buffer containing 0.2pg/ml ethidium bromide. In all experiments, a mock PCR (without 
added DNA) was performed to exclude contamination. To exclude carry over of genomic
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DNA during the RNA preparation step, controls were also carried out in which the reverse 
transcriptase enzyme was omitted.
2.2 MOLECULAR BIOLOGY 
2.2.1 General Procedures
Distilled water was used to prepare all the solutions utilized to prepare and manipulate 
nucleic acids. The solutions were stored in a sterile container after being either autoclaved 
before use or filter sterilized when thermolabile. Sigma (St.Louis, MO) supplied all 
chemical reagents and New England BioLabs (Beverly, MA) supplied all the enzymes, 
unless differently stated.
2.2.2 Determination of nucleic acid concentration
When measuring the absorbance of an aqueous solution of the nucleic acid at 260nm, it 
was determined that a double standard DNA concentration of 50 pg/ml is equivalent to an 
absorbance on one unit while 40 pg/ml represented an RNA concentration.
2.2.3 Amplification of DNA sequences by the polymerase chain reaction
Two types of Thermus aquaticus (Taq) DNA polymerase (AmpliTaq for diagnostic 
purpose or AmpligTaq for cloning purposes) were used to perform polymerase chain 
reactions (PCR) when samples containing template DNA mixed with sequence-specific 
oligonucleotide primers were cycled through three temperature incubations: 1 .
Denaturation of double stranded DNA; 2. Annealing of primers to DNA 3. Extension of 
target sequences by Taq DNA polymerase.
The PCR was carried out in a Biometra TRIO-thermoblock (Biometra, Gottingen, ERG)
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The optimal cycle number and exact annealing and extensions were as described for each 
individual reaction (see Results). Primers were synthesized by the Molecular biology Core 
Facility, Mayo Foundation , on an Applied Biosystems 380B Synthesizer.
The reaction mixtures were prepared in a laminar flow hood isolated from normal areas of 
DNA handling. Each reaction sample consisted of template DN (1 jLig of genomic DNA or 
0.1-0.5pg of plasmid DNA; for semi-quantitative rtPCR the cDNA equivalent of 0.1 pg 
RNA was used), 8  |il dNTPs (40 mM), 5 pi of lOx PCR buffer, 0.2 pg 5’ primer, 0.2pg 
3’promer, 0.5 pi Taq DNA polymerase (5 units/pl) and distilled water added to a total 
volume of 50 pi. The reaction was then heated to 94°C for 10 minutes and then allowed to 
proceed through 20 to 30 cycles of denaturation, annealing and extension to produce the 
required degree of amplification. If the PCR product was required for cloning experiment a 
final 10-minute extension cycle at 72°C was added. The amplified PCR products were 
evaluated by mixing 1 2  pi of the reaction mixture with 2  pi of the reaction mixture with 2  
pi of 6 x loading buffer stock solution and run on an agarose gel.
2.2.4 Ligation of PCR products
PCR products were ligated into the pCR3.1 vector using a TA Cloning Kit (invitrogen, 
Carlsbad, CA). This system takes advantage of the nontemplate-dependent activity of Taq 
polymerase that adds a single deoxyadenoisine to the 3’ termini of the double stranded 
molecules. The linearised vectors that are supplied possess single overhanging 
deoxythimidine residues at the 3’ termini, thus allowing the PCR product to ligate 
efficiently with the vector. The ligation reactions were performed according to the 
manufacturer’s instructions in 1 0  pi volumes consisting o f : 1 pi of lOx ligation buffer, lpl 
T4 DNA ligase, 2 pi linearised vector (60 ng pCR3.1), 1 pi PCR reaction mixture and 5 pi
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distilled water. The reaction mixture was incubated overnight at 14°C and was then 
transformed into competent e.coli (TOPIOF’ strain for pCR3.1) and plated onto L-agar 
containing kanamycin.
2.2.5 Agarose gel electropheresis of DNA
Gels were prepared by adding agarose (0.7 to 1.8% w/v) to 150ml x TAE (Tris-acetate- 
EDTA) buffer (diluted from 50X TAE stock solution: 2M Tris base, 2M glacial acetic acid, 
50 mM EDTA) and boiled in microwave cooker for r5 minutes. On cooling to below 50°C, 
2 pi of ethidium bromide stock solution (10 mg/ml) was added. Gels were poured into a gel 
former with a well-comb in place. After setting, the gel was submerged in an 
electropheresis tank containing 1 x TAE buffer. Loading buffer (1/6 volume of 6 x stock 
solution: 0.25% bromophenol blue, 40% w/v sucrose in water) was added to the DNA 
solutions, which were then transferred into the wells, and electropheresis was performed 
using a voltage between 70 and 110 volts. Geh gel was transilluminted with short wave 
ultraviolet lights and the DNA was visualized by 2uv transilluminator (UVP, Upland, CA) 
and Alpha Ease 5.04 Software (Alpha Innotech Corporation, San Leandro, CA), DNA 
fragment were sized by reference to a ‘DNA ladder’.
2.2.6 Transformation of bacteria
The plasmid DNA was added to 100 pi of competent E.coli. The suspension was cooled on 
ice for 45 minutes, warmed at 42 °C for 1 minute and then returned to ice for 2 minutes. 
400 pi of L-broth was then added to the samples followed by incubation in a shaking 
incubator at 37 °C for 1 h to permit expression of the antibiotic resistance gene on the 
plasmid. The bacteria were then plated out onto 90mm Petri dishes (Becton Dickenson 
Lab ware, NJ) containing L-agar (L-broth with 1.5% w/v agar) with ampicillin (final
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concentration of 100 pl/ml) or Kanamycin (final concentration of 25 pl/ml). The plates 
were incubated overnight at 37°C.
2.2.7 Small scale preparation of plasmid DNA (“miniprep”)
Plasmid DNA was prepared from small cultures of bacteria using a QIAprep 8  plasmid 
minipreparation kit and QIAvac Manifold 6 S (Qiagen, Valencia, CA), following the 
protocol supplied by the manufacturer. This procedure was based on the alkaline lysis 
method for rapid extraction of plasmid DNA from bacterial cells followed by the 
absorption of DNA onto silica in the presence of high salt.
Single bacterial colonies were inoculated into 5ml of L-broth containing ampicillin and 
incubated overnight in a shaking incubator at 37 °C. 1.4ml of the overnight cultures were 
centrifuged at 10,000g for 5 minutes and bacteria were then resuspended in 250 pi of 
resuspension buffer PI (50mM Tris-HCl pH 8.0, lOmM EDTA, 100 pg/ml RNAse). 250 pi 
of lysis buffer P2 (200mM NaOH, 1% SDS) was then added and mixed, followed by 
adding 500 pi of neutralization buffer N3 which adjusts the sample to high salt binding 
conditions and causes precipitation of denatured proteins, SDS, cellular debris and 
chromosomal DNA. The samples were then centrifuged at 10,000g for 10 minutes and the 
supernatants were then transferred to individual wells of a QIAprep 8  strip placed in a 
QIAvac Manifold 6 S. Vacuum suction was applied to cause flow through the silica 
membrane, which forms the floor of the wells. After washing with 2 ml of buffer PE to 
remove salts, the DNA was eluted by applying 100 pi of distilled water to the silica 
membrane.
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2.2.8 Large scale preparation of plasmid DNA (“maxiprep”)
Qiagen Plasmid Maxi kit was used which is based on the modified alkaline procedure 
followed by binding of plasmid DNA to an anion-exchange resin. A single bacterial colony 
was used to inoculate a 2 ml volume of L-broth containing ampicillin which was incubated 
for 8 h in a shaking incubator at 37°C. 1ml of this culture was used to inoculate 100 ml of L- 
broth containing ampicillin which was then incubated overnight. The bacteria was pelleted 
by centrifugation at 6,000g for 20 minutes (J2-HS centrifuge, Beckman)and resuspended in 
10 ml of resuspension buffer PI. 10ml of lysis buffer P2 was then added and left at room 
temperature for 5 minutes. 10 ml of neutralization buffer P3 (3M potassium acetate pH 5.5) 
(pre-chilled to 4°C) was added and the lysate poured into a QIAfilter Maxi cartridge and 
incubated at room temperature for 10 minutes. The cell lysate was then filtered onto a 
QIAGEN-tip which had been pre-equilibrated with 10ml buffer QBT (750ml NaCl, 50mM 
MOPS pH 7.0, 15% ethanol, 0.15% Triton X-100) and allowed to enter the anion-exchange 
resin by gravity flow. Under these conditions, the plasmid DNA binds to the anion- 
exchange resin. The resin was then washed with 0 ml of medium salt buffer QC (1M NaCl, 
50mM MOPS pH 7.0, 15% ethanol) to remove RNA, proteins and low molecular weight 
impurities. The DNA was eluted with 15ml of high salt buffer QF (1.25M NaCl, 50mM 
Tris-HCl pH 8.5, 15% ethanol), and was then desalted by precipitation with 10.5ml 
isopropanol. The DNA was pelleted by centrifugation at 15,000g for 30 minutes at 4°C, 
washed with 70% v/v ethanol, air dried and then dissolved in TE buffer.
2.2.9 Digestion of DNA with restriction enzymes
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Plasmid DNA was digested in volumes of 30 pi using 1-2 units of enzymes per pg of 
DNA, buffers supplied by the manufacturer and incubated for 60 minutes at the appreciate 
temperature; BSA was added when indicated.
2.2.10 Removal of 5’ terminal phosphate groups
To reduce re-ligation of the vector DNA in cases where cohesive ends were present, 
treatment with calf intestinal alkaline phophatase (CLAP) to remove the 5’ phosphate 
groups of linear double stranded DNA was performed. At the end of restriction enzyme 
digestion, 1 unit of CLAP (Promega, Madison, WI) was added to the reaction sample with 
5pl of lOx reaction buffer (50mM Tris-HCl pH 9.3, ImM MgCl2 and ImM spermidine) and 
the reaction mixture made up to 50 pi with DH2O. This was then incubated for a further 60 
minutes at 37°C. the sample was then run on an agarose gel and the appropriate fragment 
was purified as described above.
2.2.11 Purification of DNA restriction fragments
Agarose gels were visualized by UV transillumination and the bands of interest excised 
using a scalper blade. The DNA was purified from the gel using the QIAquick gel 
extraction kit (Qiagen, Valencia, CA) following the instructions provided by the 
manufacturer. The method is based on the binding of DNA to silica under high salt 
conditions. The excised portion of gel was dissolved in 3 volumes of buffer QG and 
incubated at 50 °C for 10 minutes. Once the gel had completely dissolved 1 volume of 
isopoppanol was added if the DNA fragment was between 500-4000 base pairs. The 
sample was then added to the QLAquick column and centrifuged at >10,000g for 1 minute. 
The column was then washed with 500 pi of buffer QG and centrifuged as before. 750 pi 
of buffer PE was then added and centrifuged as before. The DNA was elute form the
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column by the addition of 30 jil TE, waiting 1 minute before recentrifugation, 1 pi of the 
elute was run on an agarose gel to confirm successful purification of the DNA fragment.
2.2.12 Ligation of DNA fragments into vectors
Ligations were performed overnight at 14 °C in volumes of 15 pi using 1 unit of T4 
DNAligase and ligase buffer (50mM Tris-HCl pH 7.8, 10 mM MgCL lOmM DTT, lmM 
ATP, 25pg/ml BSA). Reaction samples were such that the concentration of the 5’ temrinin 
was 0.1-1.0 pm. The molar ration of vector to insert was in the range of 1:3 to 1:10.
2.2.13 Plasmid construction
The 469bp human COX-2 3'UTR cDNA clone was isolated by reverse transcription- 
polymerase chain reaction (PCR) amplification using human COX-2 sequence-specific 
primers. PCR products were legated into the TOPO TA-cloning vector (Invitrogen, 
Carlsbad, CA) and subsequently excised with Xhol. The DNA fragments were purified by 
agarose gel electrophoresis and extracted using Gene clean Kit (QIAGEN, Valencia, CA). 
DNA inserts were ligated into the unique Xhol site of the pElA-K2 vector (pElA-K2- 
COX), located in the 3'-end of the adenovirus type 5 El A gene.
The pCR3.1-GALV expression plasmid consists of the human CMV promoter driving 
expression of the hyperfusogenic Gibbon Ape Leukemia Virus (GALV) envelope cDNA as 
described in {Fielding, 2000 #2372} and {Bateman, 2000 #2629}. The 469bp human 
COX-2 3'UTR cDNA clone was isolated by reverse transcription-polymerase chain 
reaction (PCR) amplification using human COX-2 sequence-specific primers.
The plasmid pGL3-control was purchased from Promaga. For the construction of pGL-3 
DNMT 3’UTR, human DNMT-3’ UTR (5090-5408) was amplified by reverse transcription 
(RT) -PCR from ljixg of total RNA prepared from human melanoma Mel624 cell line. Reverse
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transcription was carried out with random primers (Roche Molecular Biochemicals), AMV 
Reverse transcriptase (Roche Molecular Biochemicals) and 1.0 pg of total RNA as 
recommended by the manufacturer in a total volume of 20 pi. Two micro liter of reverse 
transcribed cDNA was used for subsequent PCR amplification of the 3’UTR with Taq 
polymerase (Roche), 50 ng of the sense primer (5’-CTCGAGTCTGC CCTCCCGTCACCC- 
3’) and antisense primer (5’-CTCGAGGGTTT ATAGGAGAGATTT-3’), 1 mM dNTPs, and 
the manufacturer’s amplification buffer. Cycling conditions were as followed: 95°C for 1 min, 
53.9°C for 1.5 min, and 72°C for 1.5 min for 30 cycles. The amplified fragment was subcloned 
into pCR2.1 TOPO using the TA cloning kit (Invitrogen, Carlsbad, CA) as recommended by 
the manufacturer. To generate pGL3 DNMT1 3’UTR, the 318 bp 3’UTR was excised from 
pCR2.1 TOPO DNMT 3’UTR with Xbal and Spel and legated into the Xbal digested pGL3- 
control (Promega, Madison, WI) vector.
2.3 Construction and production of recombinant adenovirus
2.3.1 Ad-ElA-COX virus
The 469bp human COX-2 3'UTR was cloned as described in the previous chapter. The Ad- 
E1A-COX is an E1/E3 deleted, serotype 5 vector that contains the cytomegalovirus (CMV) 
immediate-early gene promoter-enhancer driving the adenovirus El A cDNA (llOObp) which 
is fused with COX-2 3' UTR (469bp). This vector was constructed by using an AdEasy kit, 
according to the manufacturer's protocol (Qbiogene,CA). Briefly, E1A-COX-2 gene was PCR 
cloned from plasmid pElA-K2-COX and inserted into the transfer plasmid, pShuttle (AdEasy 
kit, Qbiogene,CA) by using the unique HindUI-EcoKV sites. The resulting plasmid (pShuttle- 
E1A-COX) was than linearized with Pme 1 and co-transfected into E.coli strain BJ5183 
together with pAdEasy-1 (Qbiogene,CA), the viral DNA plasmid. The recombinant adenoviral
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construct was then cleaved with Pacl to expose its Inverted Terminal Repeats and transfected 
into 293A cells to produce viral particles. The viral clones were screened by PCR diagnosis of 
Hirt extracts. The selective vector clone was then plaque purified at least three times before it 
was used in experiments. For in vivo experiments, the virus was purified on cesium chloride 
gradient columns.
2.3.2 AdDNMT virus
The novel conditionally replicating adenovirus was constructed using the Microbix 
(Hamilton, Canada) system, according to the manufacture's protocol (Qbiogene,CA). 
Briefly, the 1498bp adenovirus-5 E1A transcriptional unit with the El A promoter was PCR 
amplified from the Adenovirus-5 genomic DNA (Sigma) using 50 ng of sense primer (5’- 
CATC ATAATATACCTTATTTTGG-3 ’) and antisense primer (5’- 
GCTAGCCCATGAGGTCAG ATGTAACCAAGA-3’). The PCR product than gene 
cleaned (QIAGEN, Valencia, CA) and subcloned into pCR2.1 TOPO vector. After the 
sequence was verified, the El A transcriptional unit was excised as a Notl/EcoRV fragment 
and legated into the shuttle vector pDC512, which also contain an Xbal/Hindlll fragment 
of DNMT1 3’-UTR upstream of the SV40 polyA (p512-ElA-DMNT3’). The control 
shuttle vector do not contain any DNMT1 3’-UTR (p512-ElA). Recombinant viruses 
(AdDNMT and Ad El A) were generated by site directed homologous recombination in 
293 cells followed by calcium phosphate transfection of p512-El A or p512-ElA-DMNT3’ 
with the adenoviral genome contain in pBGHfrt (Microbix, Hamilton, Canada). Individual 
plaques were expended in 293 cells and purified using cesium chloride gradient 
ultracentrifugation (McGrory, 1988 #18). Viral titers were determined by the plaque-
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forming assay in 293 cells and expressed as pfu/volume. The viral titer range from 1010 to 
1011 pfu/ml. Wild type adenovirus was purchased from Microbix (Hamilton, Canada).
2.3.3 Wild type replication competent adenovirus
Wild type adenovirus serotype 5 was purchased from Qbiogene, CA. The virus was grown 
on 293 cells and purified on cesium chloride gradient columns for use in in vitro and in 
vivo experiments.
2.4 In vivo studies
To establish subcutaneous tumors, 4-5 week old athymic nu/nu female mice (Harlan 
Sprague Dawley, Inc., Indianapolis, IN) were injected with 2X106 tumor cells (U118, U87, 
U251). When the tumors measured 0.3 cm in diameter, lX108pfu of wild type Ad-5 or Ad- 
E1A-COX were injected intratumorally in a 0.05 ml volume. Control tumors were injected 
with equal volume of PBS only. Animals were examined every other day and euthanized if 
tumor size reached 1.OX 1.0 cm. An animal was scored as tumor-free when tumor size 
remained <0 . 2  cm.
For evaluation of the relative uptake of virus into liver after i.v. injection, athymic nu/nu 
female mice (Harlan Sprague Dawley, Inc., Indianapolis, IN) were given 1X108 pfu of wild 
type Ad-5 or Ad-ElA-COX in single tail vein injection and euthanized at 24 and 72 hours 
postinoculation. Liver, blood and spleens were excised, divided, and processed for viral 
titer, western blot or RT-PCR. To determine the virus titers, tissues were weighed, 
homogenate and freeze/thawed three times, centrifuged (3000Xg), and the virus titer in the 
supernatant was determined by a plaque assay using 293A cells.
To establish subcutaneous tumors, 4-5 week old athymic nu/nu female mice (Harlan 
Sprague Dawley, Inc., Indianapolis, IN) were injected with 2xl06 tumor cells (U118,
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U251). When the tumors measured the appropriate size (palpable (0.2cm)) or 0.5-0.6cm, 
plasmid DNA, wild type Ad-5 or a combination was injected intratumorally in 50pl or 
lOOpl volume. In order to administer the combination treatment intratumorally, the 
pGALV and Ad5-Wt components were mixed in a syringe and injected simultaneously. 
Animals were examined every other day and euthanized if tumor size reached 1.Ox 1.0 cm.
2.5 Biodistribution and liver toxicity studies
Several doses were evaluated to assess a maximum tolerated i.v. dose of Ad-ElA-COX in 
immunocompetent C57BL/6J (Jackson Laboratory, Bar Harbor, Maine) mice. Desired 
amount of virus was diluted in PBS and injected into the tail vain in a volume of 0.1 ml. 
Mice were weighed and observed daily for signs of acute toxicities (such as lethargy or 
anorexia). When signs of acute toxicity were observed, mice were euthanized. Surviving 
animals were euthanized 14 days after virus injection. Gross pathological changes were 
recorded at necropsy. Liver were collected from all the mice, half of the liver was 
preserved in formalin for histopathological analysis and the other half was weighted, flash- 
frozen in liquid nitrogen, and stored at -70°C. These liver samples were then weighed, 
homogenated and used for determining the virus titer and examined for the presence of the 
viral DNA by southern blot.
For the evaluation of the relative uptake of virus into all the major organs (liver, lung, heart 
and kidney) after i.v. injection, immunocompetent C57BL/6J (Jackson Laboratory, Bar 
Harbor, Maine) mice were given 5X109 pfu of Ad-ElA-COX and wt-Ad5 virus in a single 
tail vain injection and euthanized at 24, 48 and 72 hours post inoculation (n=3 per time 
point). Serum was collected by cardiac bleeds and was analyzed for selective clinical
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chemistry parameters including aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT). All the organs were excise, divided and processed as described 
above for viral titer and southern blot for viral DNA.
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Chapter 3
Cloning and in vitro characterization of the COX-2 
3’untranstated region
113
3.1 Introduction:
Uncontrolled gene expression is a hallmark of cancer cells. Acquiring a new profile of 
gene expression helps cancer cells to overcome different cellular checkpoints and give 
them a growth advantage over normal cells. An efficient and rapid way to alter gene 
expression is via altering the stability of transcribed mRNAs. Many proto-oncogenes and 
proinflammatory cytokines require rapid and transient induction in response to extracellular 
stimuli, which involves both transcriptional and post-transcriptional mechanisms of gene 
expression. The half-life of these labile mRNAs is partly dependent upon specific cis- 
acting elements found in the 3’ untranslated region (3’UTR). The cis-acting destabilizing 
elements can be variable in sequence and length, but are well characterized by AU-rich 
regions (ARE), which contain multiple copies of AUUUA repeats within the U-rich 
sequence (Shaw & Kamen, 1986). ARE-mediated mRNA stability and translation are 
controlled through a complex network of RNA/protein interactions involving recognition 
of ARE-containing specific target mRNAs by specific RNA-binding proteins (RNA-BPs) 
in the presence of the appropriate signals. Abnormal expression of RNA-BPs, mutation in 
the cis-acting regulatory sequence in the target mRNAs or modulation of signaling 
pathways are all known to alter mRNA stability and induce deregulated gene expression in 
cancer cells. These alterations occur in diverse cancer types, which result in a deregulation 
of many genes involved in cancer progression.
It has been reported that the ARE sequence from some cancer associated or 
proinflammatoty genes is sufficient to change a stable long-lived mRNA, such as p-globin 
mRNA to an unstable form (Shaw & Kamen, 1986; Sheng et al., 2001). But in the presence 
of appropriate stimuli such as oncogenic or proinflammatory signals, the same ARE is able
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to reverse the destabilizing effects and to increase the reporter mRNA half-life 
significantly. In this chapter, we hypothize that we may be able to use the ARE sequence 
within the 3’UTR region of a tumor associated gene to stabilize therapeutic/viral mRNA 
within the tumor and thus achieve tumor selective expression of therapeutic/viral genes. 
We used the ARE from a well documented cancer associated gene cyclooxygenase 2 
(COX-2) to show that an essential replicative viral gene can be expressed selectively in Ras 
activated transformed cells.
Many studies have linked elevated expression of COX-2, a key enzyme in 
prostaglandin synthesis, to the pathology of breast, colorectal, head and neck and other 
cancer types (reviewed in Turini & DuBois, 2002). Expression of COX-2 is normally 
induced in cells by cytokines, growth factors and tumor promoters (Turini & DuBois, 
2002). Up-regulation of COX-2 is a downstream effect of RAS-mediated transformation 
(Sheng et al., 2001; Sheng et al., 1997b; Sheng et al., 1998b). Although RAS-mediated 
overexpression of COX-2 is also associated with an increased transcription of the COX-2 
gene, a large component of its up-regulation is mediated by selective stabilization of the 
mRNA of the COX-2 gene in RAS-transformed cells (Sheng et al., 2000) (Dixon et al., 
2000; Sheng et al., 2001) mRNA stability has been mapped to the 3’Untranslated Region of 
the COX-mRNA (Dixon et al., 2000) This mRNA stabilization was mediated in part 
through the activation of the mitogen activated protein kinase P-MAPK pathway, which is 
a well characterized downstream effectors of both RAS-, and EGF-receptor mediated 
intracellular signaling (Sheng et al., 2001) (Montero & Nagamine, 1999). Finally, the P- 
MAPK signaling cascade has previously been shown to be involved in preferential
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stabilization of other growth promoting mRNAs (Brook et al., 2000) and proteins that link 
RAS-mediated oncogenesis.
In this chapter, we describe a novel mean to achieve tumor restricted gene expression 
by using COX-2 ARE-mediated tumor selective mRNA stabilization. We constructed the 
CMV promoter driven E1A-COX2 plasmid by inserting 469bp of the human COX-2 
3'UTR cDNA in the 3'-end of the adenovirus type 5 E1A gene (Figure 2). By using the 
RIE-iRAS model cell system, we demonstrated that the CMV-E1A-COX2 construct could 
complement, in trans, the mobilization of a replication incompetent Ad-GFP adenoviral 
vector by expressing appreciable functional levels of El A protein only in the presence of 
IPTG induced activated Ha-RasVa112 protein. Moreover, using inhibition studies, we 
confirmed that COX-2 3'UTR-mediated stabilization of E1A expression in this system 
requires the activated P-MAPK signaling pathway, which is up-regulated in the presence of 
an activated Ha-RasVall2oncogene. Our results support the use of tumor selective mRNA 
stabilization mechanisms as a targeting strategy in the context of cancer gene therapy.
3.2 Results:
3.2.1 H-Ras mediated Conditional Cellular Transformation and COX-2 induction
It was previously reported that the increased expression of COX-2 during cellular 
transformation is a downstream effect of the aberrant activity of the RAS oncogene and a 
conserved AU-rich region located in the COX-2 3’UTR is required for RAS mediated 
COX-2 mRNA stabilization and tumor selective COX-2 induction (Sheng et al., 1997a) 
(Dixon et al., 2000). Based on these observations, we hypothesized that a therapeutic, or 
viral gene can preferentially be expressed by ligation to the COX-2 3’UTR to exploit tumor
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cell selective mRNA stabilization. To test our hypothesis, we used an in vitro model system 
where rat intestinal epithelial cells (RIE-1) were stably transfected with an inducible Ha- 
RasVa1' 12 cDNA and are referred to as RIE-iRas cells (Sheng et al., 1997a). In normal 
culture condition the RIE-iRas cells behave similarly to the parental RIE-1 cells and show 
nontransformed phenotypes, which include intact cell-cell contact inhibition (Figure IB-1 
and (Sheng et al., 1997a). But in the presence of 5mM IPTG, an induction of the activated 
Ha-RasV aM 2 was observed by the western blot (Sheng et al., 1997a)(and Figure 1A). After 
24-48 hours of treatment with IPTG, RIE-iRas cells acquire morphologic changes, such as 
a spindly appearance, growth in overlapping clusters and loss of contact inhibition (Figure 
IB-2). The IPTG induced activated Ha-RasVa1' 12 also gave the RIE-iRas cells significant 
growth advantages over the noninduced RIE-iRas cells (Fig. 1C) and the transformation 
could be completely reversed upon withdrawal of IPTG from the media for 48-72 hours 
(Sheng et al., 1997a and data not shown). In the Ha-RasVa112 induced RIE-iRas cells, an 
elevation of COX-2 protein was detected by western blot 8-12 hours after the addition of 
IPTG and the half-life of the COX-mRNA was almost doubled (13 min. to 30 minute) 
(Sheng et al., 1997a). For all the future experiments, we used the RIE-iRas inducible 
system to evaluate our hypothesis.
3.2.2 E1A-COX complements adenoviral replication in trans only in the presence of 
activated RAS expression
To investigate effect of the COX-2 3’UTR on transgene expression, we inserted the 469 bp 
COX-2 3’UTR downstream of the adenoviral El A gene, which is expressed under the 
CMV promoter (Figure 2). This construct was used to do the following vector mobilization 
experiment in the RIE-iRAS cells. Although RIE-iRAS cells are of rodent origin, they are
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still able to support wild type adenoviral replication but at reduced levels compared to 
human cell lines (data not shown). RIE-iRAS cells transfected with CMV-E1A or CMV- 
E1A-COX were subsequently infected with an ElA-deleted replication incompetent 
adenoviral vector carrying a marker gene GFP. ElA-expressing cells would be converted 
into transient adenoviral producer cells if they subsequently become infected with the Ad- 
GFP construct and would, therefore, mobilize the GFP reporter gene through the cell 
monolayer. FACS analysis of transfected/infected RIE-iRAS cells demonstrated that 
CMV-E1A supported considerable mobilization of the incoming Ad-GFP vector 
irrespective of the presence of IPTG (Figure 3A-3). In contrast, CMV-E1A-COX was 
unable to mobilize the Ad-GFP vector to any significantly enhanced levels compared to 
mock transfected cells unless cells were previously induced with IPTG to express the Ha- 
RasVa1' 12 oncogene (Figure 3A-6 and 7). To confirm that the mobilization of the GFP 
reporter gene was due to complementation in trans by the El A proteins, supernatants were 
removed from the transfected/infected RIE-iRAS cultures and plated on HT1080 cells 
(Figure 3B). FACS analysis of the infected HT1080 cells indicated that similar titers of 
Ad-GFP were present in the supernatants removed from CMV-EIA/Ad-GFP treated RTH- 
iRAS cells irrespective of the induction of Ha-RasVa112; however, there was only a 
significant titer of Ad-GFP released from CMV-ElA-COX/Ad-GFP-transduced RIE-iRAS 
cells if these cells were treated with IPTG to induce expression of Ha-RasVa1' 12 (Figure 
3B). No cytopathic effect was observed in the infected HT1080 cells, indicating that the 
virus released from the RIE-iRAS cells was replication incompetent and derived from 
complementation of the Ad-GFP vector by the El A proteins.
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3.2.3 COX-2 3’UTR-mediated E l A stabilization in Ha-RASva1'12 transformed cells is 
dependent upon the MAP kinase pathway
Working downstream of RAS to mediate cellular transformation is the mitogen-activated 
protein kinase (MAPK) cascade. Activation of RAS by different growth factors and 
cytokines leads to phosphorylation and activation of the MAPK (P-MAPK) signaling 
cascade, which subsequently activate downstream different effectors molecules. Inhibition 
of the MAPK pathway had been reported to block RAS-mediated COX-2 mRNA 
stabilization and expression (Sheng et al., 2001; Sheng et al., 1998a). Therefore, we 
investigated whether the effects we observed with Ha-RasVal'12-mediated control of E1A- 
COX expression operate through the P-MAPK signaling pathway. RIE-iRAS cells express 
minimal levels of P-MAPK in the absence of Ha-RasVa1' 12 induction (Figure 4A). 
However, the expression of the activated oncogene, even at relatively low levels, induces 
high levels of P-MAPK protein (Figure 4A). PD98059, an inhibitor of P-MAPK activity 
effectively blocked MAPK phosphorylation and activation in RIE-iRAS cells (Sheng et al., 
1998a), even when the cells were induced to express high levels of Ha-RasVa1' 12 (Figure 
4A). Therefore, we used PD98059 inhibition to demonstrate that the E1A expression from 
CMV-E1A-COX is also dependent upon the P-MAPK pathway. Mobilization of the Ad- 
GFP adenoviral vector through RIE-iRAS cultures by the CMV-E1A construct was 
independent of IPTG induced Ras signaling (Figure 4B-1 & 2) and the MAPK inhibitor 
PD98059 did not have any effect on the mobilization (Figure 4B-3) (Figure 4B). As 
shown before, transfection of CMV-E1A-COX required IPTG induction of Ha-RasVa1' 12 to 
be effective in vector mobilization (Figure 4B-4). However, inhibition of P-MAPK 
activity by PD98059 greatly reduced the ability of CMV-E1A-COX to support Ad-GFP
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mobilization even in the presence of high levels of expression of Ha-RasVa1'12 induced by 
IPTG (Figure 4B-5). From the results of these experiments, we can conclude that RAS 
mediated MAPK activation is essential for the COX-2 3’UTR to stabilize the E1A gene 
and support viral replication.
3.2.4 COX-2 3’ UTR able to regulate gene expression in different human tumor cell 
lines with elevated level of activated Ras/MAPK oncogenic signal
In our previous study we show that in an inducible model cell line, COX-2 3’ UTR can 
stabilize a viral gene in the presence of activated RAS, MAPK signaling. To prove that we 
can achieve a similar degree of specificity by the COX-2 3’ UTR in human tumor cell lines 
and this specificity is not transgene specific, we tested the ability of COX-2 3’UTR to 
regulate cytokine gene expression in human primary and tumor cell lines. The COX-2 3’ 
UTR was inserted downstream of a human cytokine cDNA GM-CSF (GMCSF-COX2 
3’UTR). Two human tumor cell lines (LnCap and HCT116) with elevated level of 
activated MAPK and a human primary cell line (BEAS) with basal level of MAPK (Figure 
3B, chapter 4, page-152) activity were then transfected with the pCR3.1-hGMCSF vectors 
with and without the COX-3 3’ UTR, allowed to recover for 24 hours after transfection, 
and assayed for GM-CSF expression by ELISA. In the presence of the COX-2 3’ UTR, 
significant increase in GMC-SF production over time was detected only in the two tumor 
cell lines (Figure 5A). Although there was some GM-CSF expression detected in the 
primary cell line, the expression level did not increase over time. At 96 hours post 
transfection the tumor cell lines were able to produce about two fold more GM-CSF than 
the primary cells (Figure 5A).
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3.2.5 Effects of copy number of COX-2 3’UTRs on tumor cell selective gene 
expression
To test weather increasing the length or the number of repeated copies COX-2 3’UTR 
element will increase the tumor cell selectivity, we generated a series of reporter vectors 
carrying 1, 2 and 3 copies of COX-2 3’UTR ligated downstream of the GM-CSF transgene. 
We transfect an equal amount of these plasmids into the human colorectal cancer cell line 
HCT116 and their effects on the GM-CSF expression by ELISA over time. As shown in 
figure 5B, the insertion of multiple copies of the COX-2 3’UTR did not improve its ability 
to express the GM-CSF gene selectively in the tumor cells. There was an inverse 
correlation between the number of copies of the COX-2 3’UTR and the amount of GMC- 
SF expression overtime in the tumor cell.
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Figure 1. A. Growth of RIE-iRAS cells in 5mM IPTG in culture leads to induction of Ha- 
RasVa112 as assessed by Western Blot. B. Morphological transformation of RIE-iRas cells. 
The cells were treated with 5mM IPTG 0 and 48 h. the pictures were taken by using an 
inverted microscope (original magnification X200) C. Induction of the Ha-RasVa112 gene in 
RIE-iRAS cells by 5mM IPTG induces transformation as seen by increased growth rate in 
culture.
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Figure 2. Construction of plasmids CMV-E1A and CMV-E1 A-COX. The adenoviral 
El A cDNA was PCR cloned into the expression plasmid pCR3.1 to generate CMV-E1A. 
A 469bp fragment of the 3’UTR of the COX-2 gene was cloned from genomic DNA by 
PCR and ligated downstream of the El A gene to give CMV-E1 A-COX.
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Figure 3. Induction of the Ha-RasVa112 gene in RIE-iRAS cells stabilizes El A expression 
sufficiently to allow mobilization of a replication incompetent adenoviral vector. A. 
5X105 RIE-iRas cells were plated in the presence or absence of IPTG(5mM). 24 hours 
following transfection with 1.0 pg of CMV-E1A (3-5) or CMV-E1 A-COX (6-7) DNA the 
cells were infected with a replication-defective Ad-GFP (10 m.o.i.) vector (3-7). Spread of 
the GFP reporter gene through the culture was assayed with time using FACS analysis. 
Expression of GFP is shown at 72 hours following Ad-GFP infection. Control cells were 
transfected with an irrelevant plasmid and infected with Ad-GFP. Results shown are 
representative of four different experiments.
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Figure 3B. HT1080 cells were exposed to 72 hour supernatants following Ad-GFP
infection of the RIE-iRAS cells transfected with either CMV-E1A or CMV-E1 A-COX and 
treated +/- IPTG as shown. Infected HT1080 cells were analyzed by FACS to detect levels 
of Ad-GFP.
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Figure 4. A. Levels of Ha-RasVa112 and activated P-MAPK were determined by western 
blot in RIE-iRas cells treated with IPTG in the presence of DMSO or PD98059 (50pM) for 
48 h.
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Figure 4. Inhibition of Ha-RasVall2-induced P-MAPK activation by PD98059 blocks COX- 
2 3’UTR-mediated stabilization of E1A expression. B. Mobilization of an Ad-GFP 
replication-incompetent vector through RIE-iRAS cells treated as shown was measured 
using fluorescence and FACS analysis. RIE-iRAS cells were transfected with (1-3) CMV- 
E1A or (4-5) CMV-E1 A-COX (1.0 pg), infected with Ad-GFP at an m.o.i. of 10 and then 
treated with IPTG (2-5) or IPTG and PD98059 [50pM] (3 and 5). 72 hours later, the 
number of cells expressing GFP (a measure of the mobilization of the Ad-GFP by El A 
expression) was measured as shown. For represents uninfected cells and cells infected with 
8xl05 pfu Ad-GFP, see figure 3A (1 and 2).
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Figure 5. A. COX-2 3’ UTR able to regulate GM-CSF expression in different human 
tumor cell lines with elevated level of activated Ras/MAPK oncogenic signal. One
primary cell line BEAS with low level of activated Ras/MAPK and two tumor cell lines 
(HCT116 and LnCap) with elevated level of activated Ras/MAPK were transiently 
transfected with pCR3.1 plasmids containing GM-CSF cDNA alone or ligated to COX-2 
3’UTR. The supernatant was collected every 24 hours for 96 hours and assayed for the 
GM-CSF by ELISA at day 5. Results of different treatment groups were expressed as a 
percentage of the control plasmid (pCR3.1 GM-CSF)(**p<.025).
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Figure 5. B. Effect of COX-2 3’UTR dosage on the tumor cell selective transgene 
expression. HCT116 cells transfected with pCR3.1 plasmid carrying GM-CSF transgene, 
which was ligated to multimers of COX-2 3’UTR. The supernatant from the transfected 
cells were collected every 24 hours for 96 hours and assayed for the GM-CSF by EFISA at 
day 5. (**/?<• 012).
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3.4 Discussion
In this chapter, we showed that inserting 469 bp of the ARE-containing 3’untranslated 
region from a tumor associated gene COX-2 downstream of the adenoviral early gene El A, 
is sufficient enough to restrict E1A expression in COX-2 overexpressed transformed cells. 
This restricted expression of El A was able to support in-trans tumor cell selective 
replication of a replication defective adenoviral vector. Tumor specific Ras signaling is 
essential for the COX-2 3’UTR-mediated tumor cell selective expression of the El A gene 
and inhibition of MAP kinase, a downstream effectors molecule of Ras, which could 
abolish the El A-COX2 dependent restricted adenovirus replication in tumor cells.
The association between aberrant COX-2 expression and carcinogenesis is well 
documented. A significant amount of both experimental and epidemiological data 
identified COX-2 as an important player in cancer initiation and progression. Deregulated 
induction of COX-2 in the tumor microenvironment is initiated by both transcriptional and 
post-transcriptional mechanisms. The post-transcriptional mechanism of COX-2 induction 
is mainly mediated by the highly conserved AU-rich cw-acting sequence, which is located 
in the 3’UTR of the COX-2 mRNA. In cancer cells, the presence of constitutively active 
Ras-MAPK signaling selectively stabilized very unstable COX-2 mRNA and increased 
COX-2 expression through the ARE of the COX-2 3’UTR. The results presented in this 
chapter show some in vitro evidence for the use of tumor specific COX-2 ARE-activity to 
stabilize mRNA and thus achieve tumor targeted therapeutic gene expression.
It has been previously reported that the 3’ UTR of the COX-2 alone can destabilize 
reporter luciferase and a-globin mRNAs, but also can stabilize the same mRNA in the 
presence of activated Ras signaling (Zhang et al., 2000) (Sheng et al., 2000). The 3’UTR of
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the COX-2 mRNA is about 1455-nucleotide and containes 12 highly conserved AU-rich 
elements (AUUUA repeats) (Jones et al., 1993). Six of these AU-rich elements (ARE) are 
cluster in the 116-nucleotide sequence located close to the COX-2 termination codon and 
play an important role in regulation of COX-2 expression by altering the mRNA stability 
and protein translation (Dixon et al., 2000). Based on this information, we cloned 469- 
nucleotide COX-2 3’ UTR downstream of the adenovirus El A gene, which contains these 
six AREs. One of our specific aims of this project is to develop a conditionally replicating 
adenoviral vector by using the COX-2 3’UTR. The adenoviral El A gene has been 
extensively and successfully used for this purpose and we choose to use this transgene to 
test our hypothesis by using in vitro mobilization assay, which measures the ability to 
support the replication and mobilization of a El A deleted replication-incompetent 
adenovirus vector expressing marker gene GFP (AdGFP) in the RIE-iRas cells. The E1A 
protein expressed from the control plasmid CMV-E1A was able to supports considerable 
mobilization of the incoming Ad-GFP vector independent of the inducible Ha-RasVa112 
(Figure 3A- 4 & 5). But in the presence of COX-2 3’UTR, the ability of the E1A to 
support Ad-GFP mobilization was decreased about 100 fold (Figure 3A-6) and the 
mobilization of Ad-GFP was partially regained about 60 fold once the Ha-RasVa112 was 
induced by IPTG (Figure 3A-7). Thus, El A expression in the presence of COX-2 3’UTR 
was dependent on the IPTG induced Ha-RasVa112 expression and able to support in-trans the 
replication and mobilization of a replication defective AD-GFP vector.
To test our hypothesis, we selected a model cell system where the normal rat intestinal 
epithelial cell (RIE-1) can be transformed by inducible expression Ha-RasVa112 (Sheng et 
al., 1997a). The induction of H-Ras in the RIE-iRas by IPTG led to a COX-2 expression,
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which is a direct consequence of Ras-mediated COX-2 mRNA stabilization (Sheng et al.,
2000). Although, this model cell system is artificial and does not have all the characteristics 
of other human cancer cells, it was an ideal in vitro system to evaluate our hypothesis 
because of its ability to induced COX-2 expression via oncogenic Ras-dependent post- 
transcriptional mechanisms (Sheng et al., 1997a). Our results suggest that the suppression 
of Ad-GFP mobilization by the COX-2 3’UTR element in the absence of IPTG-induced 
Ha-RasVa112 is relatively stronger than the activation of Ad-GFP mobilization after the 
induction of Ha-RasVa112 (100 fold decrease vs. 60 fold increase). Also, we do not know 
what is the minimal level of Ras activity required for the adequate amount of El A 
expression to support Ad-GFP expression. A more sensitive system such as rapamycin 
inducible system could be used to express Ras more controlled manner and address this 
issue. This information will be important to identify what kind of cancer cells we will be 
able to target with the COX-2 3’UTR-mediated tumor selective mRNA stabilization.
PD98059, a highly specific chemical inhibitor for Ras/MAP kinase signaling cascade, 
can prevent activation of a downstream effectors MAP kinase kinase-1 by blocking access 
to activating enzymes (Alessi et al., 1995). It has been shown that in colorectal cancer cell 
lines, constitutive activation of MAP kinase pathway induces elevated levels of COX-2 
expression (Dixon et al., 2000) and blocking MAPK activation by PD98059 decrease the 
level of COX-2. In RIE-iRAS cells, expression of the activated Ras oncogene, even at 
relatively low levels, induces high levels of MAPK activation and PD98059 can effectively 
block the MAPK activation (Figure 4A). When we treat IPTG-induced RIE-iRAS cell with 
PD98059, the ability of the COX-2 3’UTR to mobilize Ad-GFP is significantly reduced 
even in the presence of the activated Ha-RasVa112 (Figure 4B- 3 & 5). The MAPK inhibitor
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does not have any effects on the controlled plasmid CMV-ElA-mediated Ad-GFP vector 
mobilization and replication (Figure 4B- 2 & 3), which rules out the possibility of any 
nonspecific effects of the PD98059. These experiments demonstrate the requirement of the 
activated Ras/MAPK signaling cascade for the COX-2 3’UTR-mediated selective El A 
expression and Ad-GFP vector mobilization in the IPTG induced Ras-transformed cells.
The next question we asked has to do with selectivity of the COX-2 3’ UTR to regulate 
gene expression in human tumor and primary cell lines. Also, to prove that the COX-2 
3’UTR can be used to regulate the selective expression of other therapeutic genes in tumor 
cells, we inserted the COX-2 3’UTR downstream of the human cytokine gene GM-CSF 
and tested the effects of the COX-2 3’UTR on GM-CSF expression. Compared to primary 
cells, the COX-2 3’UTR was more active in the two different human cancer cell lines we 
tested (Figure 5A). GM-CSF expression from CMVp-GMCSF-COX2 plasmid was 
increased over time and reached about 80% of the control CMVp-GM, in both of the tumor 
cell lines. In the primary cells BEAS-2B, in the presence of the COX-2 3’UTR, GM-CSF 
expression never reached over 40% of the controlled plasmid. From these results we can 
conclude that the COX2 3’UTR is more active in human tumor cells than in normal cell 
and can regulate another transgene in a tumor cell selective manner. Next, we tried to 
improve the ability of COX-2 3’UTR element to stabilize specific mRNA selectively in the 
tumor cells. It has been previously reported that a targeting element such as COX-2 3’UTR 
can be used in multiple copies in a row in order to improve their ability to regulate gene 
expression in specific environments. For examples, a hypoxia-responsive element (HRE) 
derived from the 5’UTR of the human vascular endothelial growth factor improved its 
induction ability as the number of copies of HRE increased at tumor hypoxia (Shibata et
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al., 2000). Based on these reports, we thought we might be able to improve the Ras 
responsiveness of the COX-2 3’UTR by increasing the number of copies of the ARE- 
element from one to three. We constructs and compared the Ras responsiveness of a series 
of constructs carrying 1, 2 and 3 copies of 469 bp COX-2 3’UTR downstream of GM-CSF 
gene expressed under CMV promoter and test these constructs in the HCT116 by transient 
transfection and monitored the GM-CSF expression by ELISA. By increasing the number 
of 3’UTR element, we saw the GM-CSF expression was significantly suppressed in the Ras 
activated HCT116 cancer cells. Compared to one copy of COX-2 3’UTR, there was about 
50% reduction of GM-CSF expression with three copies of COX-2 3’UTR at 96 hours post 
transfection (Figure 5B). So the increased copy number of COX-2 3’UTR has a negative 
effect on tumor selective transgene expression.
Data from Chapter 3 indicates that tumor selective mRNA stabilization can be used as 
a novel strategy in tumor-selective gene expression for cancer gene therapy. We believe 
that such construct can be used to drive therapeutic genes or replicative essential viral gene 
to generate conditionally replicating viral vectors. We propose to exploit the tumor 
selective mRNA stabilization via COX-2 3’ UTR by fusing it with the adenovirus early 
essential gene El A, thereby obtaining a conditionally replicating adenovirus vector, which 
will preferentially replicate in the RAS transformed cells. To that end, the priority is to 
develop a conditionally replicating adenoviral vector by using the COX-2 3’UTR and this 
will be the focus of the following chapter.
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The data presented in this chapter from parts of the following paper:
Ahmed A, Thompson J, Emiliusen L, Murphy S, Beauchamp DR, Suzuki K, Alemany R, 
Harrington K and Richard G. Vile. A Conditionally Replicating Adenovirus Targeted to 
Tumor Cells Through Activated RAS/P- MAPK-Selective mRNA Stabilization. Nature 
Biotech; 2003 Jul; 21(7): 771-7.
138
Chapter 4
A Conditionally Replicating Adenovirus Targeted to Tumor 
Cells Through Tumor Cell Selective mRNA Stabilization
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4.1 Introduction
As described in previous chapters, COX-2 3’UTR can be used in vitro to regulate gene 
expression by tumor cell selective mRNA stabilization mechanisms and to control 
replication of an adenoviral vector. In order to assess the utility of the COX-2 3’UTR as an 
element to control viral replication when it is inserted in to the viral genome, it was 
necessary to develop adenoviral vector with E1A-COX2 3’UTR. In this chapter, we focus 
on the development and the characterizations of adenoviral vector carrying the El A gene 
ligated to 469 bp COX-2 3’UTR element.
Gene therapy for cancer has emerged as a targeted approach that would significantly reduce 
undesired side effects. In this approach, it is essential to ensure that the vectors used for 
gene therapy be targeted very efficiently in order to reduce toxicity compared to 
conventional therapies (Verma & Somia, 1997). In general, tumor-selective gene 
expression from adenoviral vectors (replication competent or incompetent) has been 
achieved through transcriptional regulation using selective promoters driving either 
essential replicative (Sadeghi & Hitt, 2005) or therapeutic genes (Bilsland et al., 2003). 
The promoter/enhancer used for these vectors is derived from genes whose expression is 
selectively upregulated in tumor cells as opposed to normal counterparts (Matsubara et al.,
2001) (Wirth et al., 2003) However, it is also clear that tissue specific promoter/enhancer 
elements inserted into adenoviral genomes are affected by viral enhancers requiring the 
addition of other insulator elements, thereby complicating the efficacy of such approaches 
(Sadeghi & Hitt, 2005) (Wirth et al., 2003). In contrast, the control of mRNA stability of 
tumor-associated proteins has not yet been exploited for the design of tumor specific 
replicating viruses. In the previous chapter, we demonstrated that in vitro the adenoviral
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El A gene can be selectively expressed by the COX-2 3’UTR element in the tumor cells 
with an elevated level of Ras/MAPK signaling and this tumor specific El A expression can 
support replication and mobilization of a replication incompetent adenoviral vector. Based 
on this, we hypothesize that we might be able to use tumor cell selective stabilization of 
mRNA as a novel mean to control viral gene expression and to develop a conditionally 
replicating viral vector for cancer gene therapy. We describe here the construction of a 
conditionally replication competent adenoviral vector in which expression of the essential 
El A gene is regulated by ligation to the 3’UTR of the COX-2 gene, allowing RAS/P- 
MAPK-specific stabilization of the mRNA. This is the first description of a replicating 
(adeno)virus whose tumor selectivity is based upon control of gene expression at the level 
of mRNA stability. This strategy has great potential for expansion since there are many 
different genes whose 3’UTRs control selective mRNA stability under different 
physiological, pathological and tumor-associated conditions
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4.2 Results
4.2.1 Construction of recombinant adenoviral shuttle vector expressing E1A ligated to 
COX-2 3’UTR
The 469bp human COX-2 3'UTR was cloned as described in the previous chapter. The Ad- 
E1A-COX is an E1/E3 deleted, serotype 5 vector that contains the cytomegalovirus (CMV) 
immediate-early gene promoter-enhancer driving the adenovirus El A cDNA (llOObp) 
which is fused with COX-2 3' UTR (469bp). This vector was constructed by using an 
AdEasy kit, according to the manufacturer's protocol (Qbiogene,CA). Briefly, E1A-COX-2 
gene was PCR cloned from plasmid pEl A-K2-COX and inserted into the transfer plasmid, 
pShuttle (AdEasy kit, Qbiogene,CA) by using the unique Hindlll-EcoRV sites. The 
resulting plasmid (pShuttle-El A-COX) was then linearized with Pme 1 and co-transfected 
into E.coli strain BJ5183 together with pAdEasy-1 (Qbiogene,CA), the viral DNA plasmid. 
The recombinant adenoviral construct was then cleaved with Pacl to expose its Inverted 
Terminal Repeats and transfected into 293A cells to produce viral particles. The selective 
vector clone was then plaque purified at least three times before it was used in experiments. 
For in vivo experiments, the virus was purified on cesium chloride gradient columns.
4.2.2 Confirmation of recombinant adenovirus by Hirt extraction
Incorporation of the El A gene with or without COX-2 3’UTR within the recombinant 
adenovirus was confirmed by Hirt extraction. The recovered DNA was analyzed in a PCR: 
2 pi of sample DNA was added per PCR reaction mix. Specific primers that were design to 
anneal in the shuttle vector just outside the inserted transgene were used to test for 
incorporation of the El A gene. PCR were performed by using AmpliTaq with the 
following condition: 94° for 10 minutes, then 30 cycles of 94° for 1 minute, 55° for 1.5
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minutes, 72° for 2 minutes. Samples from the PCR were run on the gel (See Figure IB). 
The PCR detects the incorporation of 1.0 kb fragment corresponding to El A gene and 1.5 
kb fragment corresponding to El A-COX2 3’UTR in their designated adenovirus.
4.2.3 E1A expression can be destabilized within an adenoviral genome by the COX-2 
3’UTR and re-stabilized in the presence of activated RAS and high levels of P-MAPK 
Next, we incorporated these E1A and E1A-COX cassettes into ElA-deleted adenoviral 
genomes using a protocol to generate recombinant adenoviral vector as described in the 
method and materials section. Both the Ad-EIA and Ad-El A-COX viruses recovered from 
transfection of 293 cells were purified (Figure IB) and used to infect RIE-iRAS cells in the 
presence or absence of IPTG with 10 MOI (described in the previous chapter). 7 days post­
infection, the surviving cells from infected culture were counted. As shown in figure 2A, 
replication and oncolysis of Ad-El A-COX in RIE-iRAS cells was heavily dependent upon 
IPTG induction of Ha-RasVa1'12. In addition to the cytotoxicity assay described in Figure 
2A, we also assayed replication of the Ad-El A-COX virus directly in infected RIE-iRAS 
cells (+/-) IPTG by measuring the viral titer (Figure 2B). Ad-El A-cox-infected RIE-iRAS 
cells in the presence of IPTG consistently produced in excess of 3 logs more virus (105 
plaques per 105 lysed infected cells) per cell than the same cultures in the absence of IPTG 
induction (102 plaques per 105 lysed infected cells) (Figure 2B). We also wanted to 
confirm that the effects we observed in the model RIE-iRAS system were reproducible in 
human cell lines with different levels of RAS or P-MAPK activity. Therefore, the levels of 
P-MAPK in several different human cell lines were measured by Western blot analysis 
(Figure 3B). Of these lines, uninduced RIE-iRAS, U118 glioma and the normal epithelial 
BEAS cell lines expressed low or undetectable levels of P-MAPK. The remainder
expressed moderate (HT1080, U87, U251 and HCT116) or high (IPTG-induced REE-iRAS, 
LnCap and PC3) levels of P-MAPK (Figure 3B). These lines were infected with the Ad- 
E1A or Ad-ElA-COX viruses (at a lower m.o.i. than with the RIE-iRAS line because of 
the improved ability of human lines to support adenoviral replication). 7 days following 
infection with an m.o.i. of 0.1, surviving cells were counted (Figure 3A). The wild type 
El A gene supported ongoing viral replication that caused lysis and killing of every cell line 
although the efficacy of the wild type virus was reduced in the human prostatic line PC3 
(Figure 3A). In contrast, the replication of Ad-El A-COX was much more heavily 
dependent upon the cell line; in general, oncolysis correlated very closely with the line’s P- 
MAPK activity status. Thus, cultures of normal bronchial epithelial cells (BEAS) with no 
detectable activated P-MAPK were completely eradicated by Ad-El A virus infection 
(Figure 3A) but Ad-El A-COX was significantly less toxic to these cells (BEAS cells are 
very sensitive to adenoviral infection). Ad-El A-COX also replicated only very poorly 
relative to the wild type Ad-El A in the U118 (glioma) (Figure 3A) and uninduced RIE- 
iRAS cells lines (Figure 2 A&B). We did observe some killing of U118 cells by Ad-ElA- 
COX due to the fact that these cells express low, but still detectable, levels of P-MAPK 
(see, for example, Figure 5A & B below). Infection of the U87 glioma line (moderate P- 
MAPK activity) with Ad-El A-COX was effective at killing these cells although not as well 
as the wild type virus. In contrast, one other glioma cell lines U251, the fibrosarcoma 
HT1080 and colorectal HCT-116 cell lines and two prostate cell lines LnCap and PC3 were 
as good substrates for replication of Ad-El A-COX as for Ad-El A and all 5 lines express 
elevated levels of P-MAPK. As for the RIE-iRAS cells in Figure 2A above, viral burst 
assays from the infected human cell lines confirmed the cytotoxicity data in that P-MAPK
expressing cells produced in general 3-4 or 2 logs more virus per infected cell in a 
replication assay (Sheng et al., 2000) than the BEAS or U118 cell lines respectively. In 
addition, Northern blot analysis confirmed a direct correlation between the levels of 
oncolysis of different cell lines, the levels of P-MAPK activity and the expression of steady 
state levels of El A mRNA species at early time points following infection with Ad-El A or 
Ad-El A-COX (Figure 4A).
4.2.4 Ad-ElA-COX is oncolytic in vivo against human tumors expressing high levels of 
P-MAPK activity
Although the RIE-iRAS cell line grew in nude mice, we observed induction of Ha-RasVa1' 
12 within all of the tumors in vivo irrespective of whether IPTG was administered. 
Therefore, to test the selectivity of the Ad-El A-COX virus, we used tumor lines that are 
closely matched histologically, but which differ in levels of P-MAPK activity. The glioma 
cell lines U118 with low level of P-MAPK and U87 or U251 with high level of P-MAPK 
moderate/high) (Figure 5A) were used to test the in vivo efficacy and selectivity of the Ad- 
E1A-COX virus. Western Blotting confirmed in vitro that the level of E1A expression 
supported by Ad-El A and Ad-El A-COX infection (Figure 5B) reflects very closely the P- 
MAPK activity of these lines (U 118« U87<U251) (Figure 5A) data, which was 
confirmed at the RNA level by Northern Blotting (data not shown).
There was a significant difference in the growth rate of established U118 tumors following 
a single intratumoral injection (108 pfu) of wild type Ad-El A compared to tumors injected 
with PBS (p<0.001) (Figure 5 C & D). However, injection with Ad-ElA-COX virus gave 
no statistically significant difference compared to the PBS injected control (Figure 5 C & 
D) in U118 (low P-MAPK activity) tumors. In the U251 model, the oncolytic effects of a
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single intratumoral injection of wild type adenovirus were reduced compared to those in the 
U118 model (Figure 5 D&E), but, consistent with the high levels of P-MAPK activity in 
this tumor (Figure 5A), the Ad-ElA-COX virus either matched, the example shown in 
Figure 5 C with U87 model, or exceeded the efficacy of the wild type virus (Figure 5E 
with U251 model). These findings were also confirmed in the second P-MAPK high 
glioma model, U87. Thus, combining the results of several experiments, the injection of 
wild type Ad-El A virus was effective at reducing the size of U118 tumors (>75% 
reduction in final tumor size relative to PBS injected control tumors). This therapeutic 
effect was less pronounced in the U87 model (-30% reduction with respect to PBS injected 
tumors) (Figure 5C). Ad-ElA-COX was, however, as effective as wild type adenovirus 
when used to treat U87 tumors (moderate/high P-MAPK activity) but had no significant 
effect on the treatment of subcutaneous U118 tumors (Figure 5C) (low levels of P-MAPK 
activity and de-stabilized E1A expression as shown in Figure 5B). The fact that Ad-EIA- 
COX was even more effective than wild type virus in the U251 model (Figure 5E), but that 
Ad-El A-COX was only similar to wild type virus in efficacy in the U87 model (Figure 
5C) is consistent with the observation that U251 tumors express somewhat higher levels of 
P-MAPK than U87 tumors (Figures 3B and 5A) and accordingly support higher levels of 
adenoviral replication. Taken together, these in vivo results are consistent with the in vitro 
data demonstrating a strong correlation between the P-MAPK status of a tumor and its 
ability to support the replication of the Ad-El A-COX virus.
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4.2.5 AdElA-COX shows reduced E1A expression in normal tissues following 
systemic administration in nude mice.
Given the particular sensitivity of the liver as a potential site of toxicity following therapy 
with adenoviral vectors, we tested whether the selectivity of Ad-El A-COX for non­
transformed cells was also maintained in normal liver in vivo. Athymic nude mice were 
injected intravenously with either wild type Ad-EIA or Ad-ElA-COX virus (106 pfu per 
mouse) in order to infect normal hepatocytes and other tissues. Three days later, livers were 
removed from the animals and assayed for expression of El A mRNA by rtPCR. Hepatic 
expression of El A could be detected following infection with Ad-El A virus in both treated 
mice (Figure 6A). However, the presence of the COX-2 3’UTR was sufficient to lower 
levels of expression of E1A mRNA to below detectable levels in both mice injected with 
Ad-ElA-COX virus (Figure 6A). Serum was also collected from the treated mice and 
tested for the presence of replicating virus. Serial dilutions of samples plated onto 293 
cells indicated that mice treated with Ad-El A had very low, but detectable titers of 
circulating virus (Figure 6B), presumably as a result of low level replication in the liver or 
elsewhere. In contrast, no detectable virus could be recovered from either mouse treated 
i.v. with Ad-ElA-COX virus. Therefore, the presence of the COX-2 3’UTR reduces 
significantly levels of El A expression and viral replication in normal -  albeit murine - liver 
tissue.
4.2.6 Systemic administration of AdElA-COX in the immunocompetent murine 
model induced hepatotoxicity
One of the major problems of using any conditionally replicating adenovirus to treat 
patients with metastatic disease is the toxicity caused by the viral vector after systemic
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administration in the immunocompetent host. So the safety of every viral vector must be 
evaluated very carefully in the animal model before it is considered for use in humans. To 
establish the maximum tolerated dose of the AdElA-COX virus in a immunocompetent 
murine model, C57BL/6J mice were injected with escalating doses (1X109-5X109 
pfu/mice) of wild type Ad-5 or recombinant AdElA-COX virus into the tail vain. The
o
highest dose of Ad-ElA-COX virus evaluated that resulted in 100% survival was 5X10 
pfu. Mice receiving 5X109 pfu of Ad-EIA- COX virus as five daily injections of 109 pfu 
resulted in 70% lethality (Figure 7A). There was no difference in the overall survival and 
the lethal dose 50 (LD50) between the groups treated with retargeted Ad-ElA-COX or Wt 
Ad-5 virus. This was true for all the different doses tested. At the highest dose of 5X109 
pfu/mice, the percentage of overall survival from each treatment group was the same 
(Figure 7A), but mice from the group treated with AdElA-COX virus started to die 5 days 
earlier than the group with wild type Ad-5. Histophatological analysis of livers from mice 
that died acutely revealed that the AdElA-COX virus induced significantly more 
hepatotoxicity as shown by increased amount of immune infiltrate and severe, diffuse 
necrosis than the wild type Ad-5 or PBS treated control (Figure 7B). Mice that survived 
the treatment were sacrificed 2 weeks after virus injection and showed normal liver 
histology. The elevated level of serum liver enzyme ALT was also observed 3 days post i.v 
administration also confirmed the hepatotoxicity induced by AdElA-COX virus. But at a 
later time the ALT level was very similar or even lower (day 14) than the mice treated with 
wild type Ad-5 (Figure 7C). However, there was no statically significant difference in the 
amount of virus recovered from the liver tissue of the mice treated with either of the virus 
(Figure 7D). If anything, we recovered higher amounts of wt Ad-5 compared to
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recombinant AdElA-COX virus at 48 and 72 hours post administration. But because of the 
smaller sample size (n=3) and large standard deviation, the difference between these two 
groups was not statistically significant. When we looked at the viral DNA synthesis in the 
liver tissues of the same mice from these two groups, the AdElA-COX virus able to 
synthesize significantly more DNA than the wt Ad-5 virus at 24h post administration. But, 
in the later time point at 48 and 72h after the i.v. injection, the viral DNA load was much 
higher in mice treated with wt Ad-5 than the AdElA-COX virus. There was no difference 
in the recovered viral titer between the two virus groups in other major organs such as the 
heart, lung and kidney.
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Figure 1. A. Schematic diagram of in  vivo homologous recombination step between a 
linearized transfer vector carrying adenoviral El A gene ligated to 469 bp COX-2 3’UTR 
and an intact supercoiled Ad plasmid in bacteria. B. Diagnostic PCR performed on Hirt 
extracted DNA from HT1080 cells infected with recombinant adenovirus. Lane A: 1Kb 
ladder, lane B: lOObp ladder, lane C: 1 pg of wild type adenovirus DNA. lane D: Hirt DNA 
extracted from HT1080 cells infected with 10 MOI of wild type adenovirus, lane E-H: Hirt 
DNA extracted from HT1080 cells infected with 10 MOI of recombinant Ad-El A-COX 
virus.
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Figure 2. Replication of Ad-El A-COX correlates with the P-MAPK status of tumor cell 
lines. A. RIE-iRAS cells grown in the presence or absence of IPTG to induce expression 
of the Ha-RasVal12 oncogene were infected with Ad-El A or Ad-El A-COX viruses at an 
m.o.i. of 10. 7 days later, surviving cells were counted.
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Figure 2B. HT1080 cells were exposed to 72 hour supernatants following Ad-El A-COX 
infection of the RIE-iRAS cells transfected with either CMV-E1A or CMV-E1 A-COX and 
treated IPTG or IPTG and PD98059 as shown. Virus titer was measured by plaque assay 
by using 293A cells.
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Figure 3A. The range of tumor cell lines, characterized in B below were infected with Ad- 
E1A or Ad-ElA-COX viruses at an m.o.i. of 0.1. 7 days later, surviving cells were
counted. B. Levels of P-MAPK activity in the cell lines used to assess the in vitro 
cytotoxicity of the Ad-El A and Ad-El A-COX viruses were measured by Western blot 
analysis. Lanes 1-6, human lines: normal bronchial epithelial cells (BEAS); 2, 
fibrosarcoma, HT1080; 3, glioma U118; 4, glioma U87; 5 glioma U251; 6, colorectal 
HCT116. Lanes 7 and 8 rat intestinal epithelial RIE-iRAS cells grown in the absence (7) or 
presence (8) of IPTG to induce expression of Ha-RasVa112. Lane 9, 10 human prostatic 
LnCap and PC3 cell respectively.
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Figure 4. Northern blot analysis for expression of El A mRNA of representative low P- 
MAPK (BEAS) or high P-MAPK (HCT116 and LnCap) cell lines infected with Ad-El A 
(lanes 1, 3, 5) or Ad-El A-COX (lanes 2, 4, 6) viruses as described in Fig. 3.
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Figure 5. Ad-El A-COX is selectively oncolytic to tumors expressing high levels of P- 
MAPK. A. Levels of P-MAPK activity in the glioma cell lines Ul 18, U87 and U251 were 
measured by Western Blotting. B. Levels of El A expression in the glioma cell lines U87, 
Ul 18 and U251 were assayed by Western Blot 15 hours following infection with Ad-El A 
or Ad-El A-COX viruses at an m.o.i. of 10.
155
5C
120
C/5
O§ 100o
0
73<D
<D 
5-i
4 -1100 
0QOh
£
0>N
00 
Vh3O
£3
H
80
60
40
20
0
PBS
Ad-El A-COX
<
Si-a
<
PBS
<
Ei73<
Ul 18 U87
Tumor Type
156
A
d-
El
 A
-C
O
X
5C
CD
N
CO
O
§ 5D
60
U 1 1 8 PBS
50
40 Ad-E1 A-COX
30
(p<0.001)
20
10
Ad-E1A
o o 5 10 15 20 25 30 35 40 45
U 2 5 1
80 PBS
70
60 Ad-E1 A
50
Ad-E1 A-COX40
30
20
10
0 0 20 4010 30 50 60 70 80 90
DAYS
Figure 5C, 5D. U118 (C) or U251 (D) tumors were implanted subcutaneously in nude 
mice (10 mice per group) and allowed to develop to size between 0.2-.04 cm. These 
established tumors were injected directly with equal doses of Ad-EIA, Ad-ElA-COX 
(108pfu) or PBS, in a total volume oflOOpl and tumor growth was followed with time. E. 
The same experiments as described in C and D were carried out with the U 118 and U87 
tumor lines. Experiments were terminated 60 days following virus injection when mean 
tumor sizes in all groups were measured. Results of different treatment groups, over 
different experiments, were expressed as a percentage of the mean size of the PBS injected 
control groups.
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Figure 6. Replication of Ad-ElA-COX cannot be detected following systemic 
administration. A. Mice (2 per group) were injected i.v with Ad-EIA or Ad-ElA-COX 
virus(106 pfu/mouse). Serum from these mice was recovered and plated in serial dilutions 
onto 293 cells. Presence of virus in the blood was assessed as cytopathic effect on the 293 
cells and titer of circulating virus determined. B. 3 days later, livers were recovered and 
used for preparation of cDNA, which was subsequently screened by PCR for levels of 
mRNA of El A.
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Figure 7A. i.v dosing studies of Ad-ElA-COX and wt Ad-5 administered in C57BL/6J 
mice. Data points, percent of mice surviving following tail vain injection with Ad-EIA- 
COX or wt Ad-5, mice were euthanized immediately if they show signs of acute toxicides 
such as anorexia or lethargy. Surviving mice were euthanized 14 days after virus injection.
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Figure 7B. Liver histology in C57BL/6J mice following a single i.v. injection of Ad- 
E1A-COX virus. Mice were injected with 5X109 pfu of different viruses. Representative 
photomicrographs of H&E-stained liver sections from mice died acutely (3-6 days after 
injection). Arrow showing the immune infiltrates in the liver of the mice treated with Ad- 
E1 A-COX virus.
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Figure 1C. Animals were treated with PBS of 5X109pfu of the indicated virus. Serum was 
collected for every three days interval for 14 days. Each data point represented individual 
mice.
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Figure 7D. Virus titer in liver in C57BL/6J following a single i.v. injection of Ad-El A- 
COX (RV251) or wt Ad-5 virus. E. Southern blot analysis of mouse liver total DNA, 24, 
48 and 72 hours following the administration of 5X109pfu of Ad-ElA-COX or wt Ad-5 
virus in C57BL/6J mice. Probing for the 8-kb fragment of adenovirus DNA. Each lane 
represents individual mice.
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Discussion:
In this chapter, we show that tumor cell selective stabilization of mRNA can be used as a 
novel means to regulate viral gene expression and thus restricting viral replication in the 
tumor cells. Ligation of the E1A gene to a 469bp region of the 3’UTR of the COX-2 gene 
(Dixon et al., 2000) is sufficient enough to regulate adenoviral replication to tumor cells 
expressing activated RAS oncoprotein or, more generally, increased P-MAPK activity. 
Activated RAS and/or receptor tyrosin kinase signaling, resulting in elevated P-MAPK 
activity, is characteristic of a very wide variety of human tumor types. The up-regulation of 
COX-2 is a downstream effect of RAS-mediated transformation (Sheng et al., 2001; Sheng 
et al., 1998b). Although RAS-mediated overexpression of COX-2 is also associated with 
increased transcription of the COX-2 gene, a large component of its up-regulation is 
mediated by selective stabilization of the mRNA of the COX-2 gene in RAS-transformed 
cells (Dixon et al., 2000; Sheng et al., 2001). Given the clear association in the literature 
between the proliferative response of cancer cells, P-MAPK activation and regulation of 
gene expression through selective stabilization of mRNA, we hypothesized that we might 
be able to use tumor cell selective stabilization of mRNA as a novel means to control 
therapeutic gene expression in viral vectors for cancer gene therapy. We describe here the 
construction of a conditionally replication competent adenoviral vector, in which 
expression of the essential E1A gene is regulated by ligation to the 3’UTR of the COX-2 
gene, allowing RAS/P-MAPK-specific stabilization of the mRNA. This is the first 
description of a replicating adenovirus whose tumor selectivity is based upon control of 
gene expression at the level of mRNA stability. This strategy has great potential for
expansion since there are many different genes whose 3’UTRs control selective mRNA 
stability under different physiological, pathological and tumor-associated conditions.
The data presented in this chapter demonstrates that inserting the COX-2 3’UTR element 
downstream of the El A gene in the adenoviral genome can restrict viral replication 
selectively in the tumor cells. Using a panel of human tumor cell lines with different levels 
of MAPK signaling, we are able to show that the Ad-ElA-COX virus is preferentially 
oncolytic in vitro in human tumor cells with high levels of P-MAPK activity. In vivo, the 
Ad-El A-COX virus is at least as effective oncolytically as the wild type virus in high P- 
MAPK expressing tumors (U87 and U251), but generates no significant therapeutic effects 
in low P-MAPK expressing tumors (U118). It is not yet clear exactly what levels of P- 
MAPK activity are required for sufficient stabilization of the E1A-COX-2 mRNA to 
support viral replication in order to achieve therapeutic efficacy. Such information will be 
important in order to identify the types of cancer that can be targeted by the Ad-El A-COX 
oncolytic vectors.
Although adenoviral replication in murine cells is greatly reduced as compared to human 
cells, different murine models have been extensively used to evaluate the safety and 
biodistribution of recombinant adenoviral vectors after systemic administration. Previous in 
vivo toxicity studies have shown that the intravenous administration of adenoviral vectors 
results mostly in hepatocyte transduction (Fechner et al., 1999). We first used the 
immunocompromised nude murine model to study the toxicity and biodistribution of the 
Ad-ElA-COX virus after systemic administration. Following intravenous injection of 
adenovirus, virus could be detected in the blood of the animals receiving Ad-El A, but not 
Ad-El A-COX virus. Moreover, the livers of injected mice expressed appreciable levels of
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E1A from the Ad-EIA virus. In contrast, undetectable amount of E1A mRNA could be 
found in the livers of mice that received similar doses of Ad-El A-COX. Given the 
particular sensitivity of the liver as a potential site of toxicity following therapy with 
adenoviral vectors, this data shows that the presence of the COX-2 3’UTR is sufficient to 
reduce significantly the levels of El A expression in nude mice - liver tissue. This would be 
expected to translate into significantly reduced levels of toxicity should such vectors 
become disseminated through the circulation.
A majority of patients dying to cancer do so because of metastasis diseases. The treatment 
of patients with systemic metastasis remains a difficult challenge. One of the goals for any 
new cancer gene therapy strategy is to target systemic metastasis for more effective and 
selective treatment against cancer. In the clinical setting, patient’s immune system is a 
major obstacle for any systemic gene therapy. Host immune system eliminates most of the 
therapeutic viral vectors after systemic administrations, which not only reduces the 
therapeutic efficacy, but also is the main cause of systemic toxicity induced by the viral 
vector. Both the systemic metastasis and the host immune system have proven to be the 
major challenges for the development of successful gene therapy for cancer treatment. So, 
the safety and therapeutic activity after the systemic administration of any new viral vector 
for the cancer gene therapy needs to be tested very thoroughly. For this purpose, an 
evaluation of the toxicity and biodistribution of the Ad-El A-COX virus were carried out in 
the presence of the immune system by delivering the virus intravenously in the 
immunocompetent C57/B6 mice. In this murine model, the dosing regimen of 2.5X109 pfu 
resulted in 50% lethality (LD50) for both the Ad-El A COX and the wt Ad-5 virus. 
Although there was no difference in the LD50 value for both of the viruses, the mice
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treated with the Ad-El A-COX virus started to die much earlier (5 days earlier) than the 
mice treated with wt Ad-5 virus (Figure 7A). The mice that died acutely after systemic Ad- 
El A-COX virus administration showed signs of hepatic toxicity including gross 
pathological changes (liver tissue looked more yellow), histophathological changes and 
elevated liver enzymes in the serum.
The reported LD50 for the conditionally replicating ONYX-015 in the 
immunocompromised nude mice is about 5X109 pfu (Heise et al., 1999a), which is two fold 
higher than the LD50 of the Ad-El A-COX virus measured in the immunocompetent host. 
The anti-vector host immuoresponse associated with the liver toxicity in nude mice is very 
different and probably much less intense than the immunocompetent C57B/6 mice, which 
is probably due to the fact that nude mice do not have all the necessary immune 
components. After systemic administration of the Ad-ElA-COX and Ad-EIA viruses in 
nude mice, we only measured the presence of the El A mRNA by RT-PCR in the liver 
tissues and we were not able to detect any El A mRNA in the mice treated with Ad-El A- 
COX virus (Figure 6A & 6B). These mice also show no signs of systemic toxicity. So, we 
think that the discrepancy between the toxicity results in the immunocompromised and 
immunocompetent murine model is mainly due to the difference in the immune system of 
these two models.
Another possible way to explain the toxicity and the early onset of mortality by the 
recombinant Ad-ElA-COX virus is the absence of the immunoregulatory gene E3 in the 
viral vector. The adenoviral E3 gene products are the most important genes that suppress 
the host immune response against the virus, which regulates many aspects of the host 
immune system and creates an environment ideal for viral replication. Ad E3 gene products
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such as gpl9K block the transport of MHC class I major from the ER to the plasma 
membrane and downregulate CTL response. Another E3 gene product, the 10.4K/14.5K 
protein, down-regulates death receptor and its ligand Fas and TRAIL by receptor 
internalization and inhibits TNF-induced cytolysis and production of chemokines by 
blocking NF-kB signal transduction. Most of the first generation adenoviral vectors are E3 
deleted because E3 is not necessary for viral replication and also to create some space for 
the transgene. So the early onset of the toxicity induced by the Ad-El A-COX virus may be 
due to the absence of the E3 genes. In contrast, the control wt Ad-5 virus may be able to 
suppress the early toxicity induced by the immune system because of the intact E3 gene in 
the viral genome. So, it is probably not fair to compare the toxicity between these two 
viruses due to the difference in the E3 gene. A proper way to evaluate the toxicity of the 
AdElA-COX virus would be a virus with the same first generation viral backbone as 
AdElA-COX virus, but without any COX-2 3’UTR.
We also cannot exclude the possibility that the Ad-El A-COX virus may replicate in some 
specific organ non-selectively than the wt Ad-5 and may induce the toxicity in the 
immunocompetant model. There are anatomical areas, such as the kidney, the central 
nervous system and the seminal vesicles, where COX-2 expression is elevated compared to 
other organs and may support Ad-El A-COX replication. But there was no sign of 
replication for both viruses in major organs such as heart, lung and the kidney. Liver was 
the only organ where we able to detect some non-specific Ad-El A-COX virus replication. 
Mice treated with either of the viruses showed increased amounts of viral titer and viral 
DNA measured in the liver. But the replication kinetics of these two viruses in the liver was 
very different. Compared to wt As-5 virus, the Ad-El A-COX virus showed an increase in
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viral DNA synthesis at 24 hours post injection (Figure 7E), but there was no difference 
between the viral titer at this time point (Figure 7D). We do not know why at 24 hours 
post injection, the recovered viral DNA was higher in the liver of the mice treated with Ad­
El A-COX virus than the wild type Ad-5 virus or why this increased Ad-El A-COX viral 
DNA in the liver do not correlate with the recovered viral titer at this time point. One 
possibility may be that at 24h post administration, the increased viral DNA synthesis in the 
liver of the mice treated with Ad-El A-COX virus is due to the higher replication of that 
virus, but the titer is not changed because of the inability of this virus to control the host 
innate immune response, which also may have cleaned up the vims and resulted in more 
intense hepatotoxicity. Together, these data confirm that there is an early onset of liver 
toxicity after systemic administration of recombinant Ad-El A-COX vims compared to wt 
Ad-5 vims in the immunocompetent murine model.
Host immune response is a major obstacle to the systemic administration of recombinant 
adenovims. Ad vector induced acute inflammation not only reduces the gene transfer 
efficiency and vector persistence, but also causes profound damage to normal tissue and 
significant morbidity in the transduced hosts (Raper et al., 2002). The specific mechanisms 
underlying the acute immune response against the Ad viral vector are not well understood. 
Both viral entry and the adenoviral gene products induce proinflammatory cytokines and 
chemokines cascade that have harmful effects. During viral entry adenovims fiber proteins 
interact with cellular Coxsackie adenovims receptor (CAR) (Bewley et al., 1999) and the 
RGD motifs of the penton base interact with the a vP3 and the a vp5 integrins (Li et al., 
2001a). These interactions activate some key intercellular signaling pathways, which are 
critical for viral endocytosis (Li et al., 1998) and facilitate viral particles transport to the
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nucleus by altering the actin cytoskeleton (Suomalainen et al., 1999). But the host also uses 
the vector activated intercellular signaling pathways as the alarm signals for viral infection 
and induces innate immune responses, the first line of host defense against any viral 
infection. The rapid and potent innate immune reactions induced by the adenoviral vectors 
can have devastating consequences as seen in the clinical trial of gene therapy for ornithine 
transcarbamylase (OTC) deficiency (Raper et al., 2002).
In vitro and in vivo studies have demonstrated that during cell entry, the adenovirus 
activates the intercellular MAPK-signaling cascade for the efficient transport of viral 
particles to the nucleus. The host cells also use the same signaling pathway to trigger early 
inflammation and subsequent antiviral immunity. Within 10 min of Ad-LacZ transduction, 
MAPK dependent IL-8 induction was observed in HeLa cells. Similar studies have showed 
that the activation of p38 MAPK within minutes after adenovirus entry in epithelial cells 
(Suomalainen et al., 1999). A chemical inhibitor against the p38 MAPK signaling pathway 
blocked Ad vector induced chemokine IP-10 expression, providing a link between early 
vector-induced signaling and proinflammatory gene expression (Tibbies et al., 2002). 
MAPK signaling plays an important role in regulating different gene expressions that 
supports both the viral life cycle and the host immune responses. Once activated, MAPKs 
can directly activate transcription factors and transcriptional co-regulator via 
phosphorylation or activate the downstream kinases that can regulate transcription and 
mRNA stability. Crofford and Roessler showed that the adenovirus treatment of the liver 
synoviocytes increased levels of COX-2 mRNA and protein (Crofford et al., 2005). Viral 
gene expression was not required for the early COX-2 induction and inhibition of the p38 
MAPK pathways to suppress the COX-2 expression.
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During the systemic administration of the recombinant viral vector, the host cannot 
distinguish between the infectious virus and the therapeutic virus and therefore inducing 
potent immune responses. Also, the immune responses generated by the host against the 
recombinant adenoviral vectors are more intense than the wild type virus infection because 
of the deletion of E3 immunosuppressive genes. One possibility is that the MAPK 
signaling cascade which is activated during the vector entry process through the interaction 
with the host and the o^ps integrins also creates an environment to stabilize COX-2 
mRNA as a part of the host immune response. Here, we used the COX-2 3’UTR to 
selectively stabilize the mRNA of the adenoviral replicative essential El A gene in the RAS 
transformed environment and thus controlled viral replication in the tumor cells. 
Inflammatory signaling cascades like MAPK, that get activated during the viral entry 
process can also induce inflammatory molecules like COX-2 or the adenoviral gene El A 
that is fused with the COX-2 3’ UTR by stabilizing the mRNA via the AU-rich sequences 
in the 3’UTR. This may lead to the nonspecific stabilization of E1A mRNA in any cells or 
tissues that contain viral entry receptors and are capable of responding to viral infection. So 
the enhanced toxicity observed by the Ad-El A-COX after the systemic administration in 
the immunocompetent model may be due to an inflammatory environment induced by the 
viral vector in the target organ such as liver, which then stabilizes El A mRNA, supporting 
nonspecific virus replication. Also in the immunocompetent animal, the host immune 
response is more intense due to the presence of all the necessary immune components, 
which creates a much more favorable condition to stabilize the mRNA of the 
proinflammatory genes like COX-2 or El A fused with the COX-2 3’UTR.
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Many different genes with the AU-rich 3'UTR confer destabilizing activity on their cognate 
mRNA but their actions are reversed under certain physiological conditions. These include 
hypoxia responsive 3'UTR (Claffey et al., 1998) (Maity & Solomon, 2000), radiation 
responsive elements and 3' UTR which increased mRNA stability in proliferating cells (Lee 
et al., 1998; Maity et al., 1997). In this report, we were able to show that it is possible to 
control transgene expression and viral vector replication by using tumor cell selective 
mRNA stabilization via the COX-2 3’UTR. It will be important to choose these elements 
thoughtfully in order to develop a conditionally replication viral vector. During 
inflammation and cellular transformation, the expression of many inflammatory genes is 
controlled at the level of their mRNA stability. These genes will probably not be the best 
candidates for targeting tumor through their 3’ UTR.
To our knowledge, this is the first time that conditionality of adenoviral replication has 
been conferred solely at the post-transcriptional level of control of El A expression. 
However, based on previous experience with designing tumor cell specific vectors where 
initially unpredicted results can surface upon broader testing, it seems likely that there will 
be apparently suitable tumors (i.e. mutated RAS or elevated P-MAPK activity) in which the 
level of control conferred by the 3’UTR is insufficient to allow completely controlled 
levels of replication. Additionally, there are likely to be anatomical sites, physiological 
conditions and inflammatory environments which are amenable to stabilization of the 
COX-2 3’UTR region (Cao & Prescott, 2002), thereby allowing viral replication at extra- 
tumoral sites where COX-2 is normally induced (Turini & DuBois, 2002). Therefore, we 
envisage that the 3’UTR strategy will be most effective in the context of a mosaics of 
regulatory elements combined to confer multiple levels of specificity to the resultant virus.
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Other targeting strategies such as transcriptional regulation of the El A gene can very 
readily be combined with the COX-2 3’UTR (indeed the COX-2 promoter has itself been 
used to target recombinant vectors (Cao & Prescott, 2002)), as can incorporation of 
molecular features that target tumor cell specific mutations, such as loss of p53 or 
downstream effectors. Thus, multi-component targeting will be most effective at 
generating truly tumor selective vectors, which can be delivered to extra-tumoral sites 
without allowing unacceptable levels of viral replication. Based on our studies here, we 
propose that mRNA (de-) stabilizing elements be considered as one of the component 
cassettes of such mosaically regulated viruses.
The data presented in this chapter from part of the following paper:
Ahmed A, Thompson J, Emiliusen L, Murphy S, Beauchamp DR, Suzuki K, Alemany R, 
Harrington K and Richard G. Vile. A Conditionally Replicating Adenovirus Targeted to 
Tumor Cells Through Activated RAS/P- MAPK-Selective mRNA Stabilization. Nature 
Biotech; 2003 Jul; 21(7): 771-7.
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Chapter 5
Retargeted Intratumoral Expression of a Fusogenic Membrane 
Glycoprotein by Tumor Cell Selective mRNA Stabilization 
Enhances the Efficacy of Replicating Adenovirus Therapy.
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5.1 Introduction
This chapter describes a novel approach to enhance and retarget the oncolytic potency of 
adenovirus vector by combining the ability of the COX-2 3’UTR to stabilize mRNA and 
regulate gene expression specifically in cells with elevated levels of activated Ras/MAPK 
with a viral Fusogenic Membrane Glycoproteins (FMG), which induces tumor cell killing 
through induction of fusion of tumor cells to form large multinucleated syncytia (Fielding 
et al., 2000) (Bateman et al., 2000b). In the previous two chapters, we show that the 469 bp 
COX-2 3’UTR is able to regulate the expression of a viral gene, thus controlling viral 
replication and oncolysis. Here we demonstrate that the FMG mediated fusion and tumor 
cell killing can also be control by the COX-2 3’UTR element and this FMG-induced tumor 
selective syncytia is able to enhance the oncolytic potency of replication competent 
adenoviral vector both in vitro and in vivo.
The use of conditionally replication-competent viruses for the treatment of cancer has been 
more prominently considered due to the problems associated with poor intratumoral spread 
and low transduction efficiency in vivo (Vile et al., 2002). In order to achieve clinically 
relevant therapeutic efficacy, it is essential to improve spread of the therapeutic virus 
within tumors where other cell types, cell matrix, and areas of necrosis exist and viral 
vector tends to be trapped in between the sub-cellular compartment (Sauthoff et al., 2003). 
Many different strategies used to increase efficacy of adenovirus include engineering viral 
genes to enhance virus release and spread, and aiming viruses with additional therapeutic 
genes that might either enhance viral cytotoxicity and/or provide additional therapeutic 
benefits (Ramachandra et al., 2001) (Heise et al., 2000). However, poor intratumoral spread
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remains an important hurdles that need to be overcome before replicating adenoviral vector 
can be used efficiently even against the localized tumor burdens (Vile et al., 2002). 
Previously, several laboratories including ours have shown that tumor cell killing can be 
obtained by gene transfer of the FMG and the FMG-induced tumor cell killing also create a 
immunostimulatory environment, which can enhance the therapeutic efficacy (Bateman et 
al., 2000b) (Higuchi et al., 2000). Moreover, a recent report was able to demonstrate that 
the HIV gpl20 FMG induced fusion facilitates the spread of adenoviral vectors through a 
monolayer of tumor cells and increases viral release from the infected cells (Li et al., 
2001b). Based on these reports, we therefore explored the use of FMG in combination with 
the COX-2 3’UTR to selectively enhance the therapeutic efficacy of the oncolytic 
adenoviral vector. The data presented in this chapter demonstrates that by using the COX-2 
3’UTR mediated, FMG-induced retargeted tumor cell fusion in tandem with the oncolytic 
properties of replicating adenovirus enhance the therapeutic efficacy of both approaches 
synergistically by increasing the release of viral particles from infected cells that are fused 
by FMG and/or the spread of viral particles through the tumor via the syncytia.
5.2 Results
5.2.1 Co-transduction of human tumor cells with sub-therapeutic doses of plasmid 
DNA expressing an FMG and replicating adenovirus leads to extensive tumor cell 
killing in vitro
Transfection of 106 confluent tumor cells from various different lines (Mel624 or Mel888, 
human melanoma; LnCap human prostate carcinoma; U118 or U251 glioma) in vitro with 
0.5pg of plamsid DNA expressing the hyperfusogenic Gibbon Ape Leukemia Virus
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(GALV) FMG (Fielding et al., 2000) (Bateman et al., 2000a) (pCR3.1-GALV) routinely 
led to over 90% of the cells being killed 96 hours following transfection. Similarly, 
infection of these cell lines with wild type adenovirus serotype 5 (Ad5-Wt) at an m.o.i. of 
0.1 led to cytopathicity of over 95% of cells (Figure 1A). To study the interaction of FMG 
expression with Ad5-Wt infection, we selected treatment doses (0.01 |ig plasmid DNA and 
0.001 m.o.i of Ad5-Wt) at which less than 10% of the tumor cell cultures were killed by 
either treatment alone (Figure IB). However, co-transduction with these suboptimal doses 
of both pCR3.1-GALV (0.01 pig) and Ad5-Wt (m.o.i. 0.001) induced significantly increased 
cytotoxicity compared to either treatment alone (>95% cell killing) (Figure IB).
5.2.2 Suboptimal doses of plasmid FMG DNA and replicating adenovirus co-operate 
to eradicate small-established tumors.
To investigate whether these in vitro results also have relevance to in vivo virotherapy, we 
first used direct intratumoral injection of suboptimal doses of Ad5-Wt or pCR3.1-GALV 
into very small established (0.2cm diameter) human tumor xenografts. Three intratumoral 
injections of low doses of either pCR3.1-GALV (0.5|ig/injection) or Ad5-Wt virus at a low 
dose (3xl07 pfu/injection) had no significant effect on tumor cure (Figure 3). However, 
simultaneous co-transduction of tumors with replicating adenovirus stocks and syncytia- 
inducing GALV plasmid DNA led to regression of all tumors under these conditions 
(Figure 3) such that, at the end of the experiments shown in Figure 3 A and B, 10 of 10 
mice were tumor free in the (pGALV + Ad5-Wt) treatment groups.
We confirmed that the therapeutic effects of pCR3.1-GALV and Ad5-Wt co-transduction 
were dependent upon expression of the GALV FMG by including an additional treatment 
group in the experiments of Figure 3. In previous two chapter, we have reported that gene
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expression can be effectively targeted to cells expressing an activated mutant RAS 
oncogene and/or high levels of P-MAPK by ligation of a therapeutic gene to the 
3’Untranslated Region of the Cyclooxygenase 2 gene (COX2-3’UTR). The COX2-3’UTR 
efficiently destabilizes mRNA molecules in cells with low P-MAPK activity but selectively 
restabilises the mRNA molecules and, therefore, protein expression in cells with high P- 
MAPK activity. We constructed an expression plasmid, pCR3.1-GALV-COX (Figure 2) 
in which 469bp of the COX-2 3’UTR destabilizes expression of the GALV FMG in low P- 
MAPK expressing cells (such as the U118 glioma) but selectively restabilises expression in 
high P-MAPK expressing cells (such as U251). Cotransduction of small established U251 
tumor xenografts with Ad5-Wt and pCR3.1-GALV-COX was as effective therapeutically 
as treatment with Ad5-Wt and pCR3.1-GALV (10 of 10 mice tumor free at the end of the 
experiment in Figure 3B); however, treatment of the low P-MAPK tumor U118 with Ad5- 
Wt and pCR3.1-GALV-COX, in which GALV expression is significantly reduced by 
COX-2 3’UTR-mediated destabilization of the mRNA, was no more effective than 
treatment with Ad5-Wt alone (Figure 3A). These results confirm that GALV expression 
can be targeted to tumor cells overexpressing P-MAPK and indicate that the therapeutic 
effects observed with co-transduction of tumors with Ad5-Wt and GALV expressing 
plasmids are dependent upon expression of the FMG. To confirm the in vitro findings of 
enhanced viral spread through co-expression of the pGALV vector, the experiment of 
Figure 3A was repeated except that the tumors were resected two days following injection. 
Tumor cells were dissociated in vitro and analyzed by FACS for expression of the viral 
E1A protein. As can be seen from Figure 3C, even at early times after transduction in 
vivo, significantly enhanced numbers of infected cells were seen in tumors co-transduced
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with replicating virus and pGALV (-8% of the dissociated cells) compared to the virus 
alone (-1%).
5.2.3 Syncytial formation enhances spread of adenoviral vector through a monloayer
The increased potency of GALV transfection in combination with infection by replicating 
virus might be explained simply by enhanced transfection efficiency of tumor cells in the 
presence of lysosomal disrupting adenoviral infection. To address this possibility, we 
measured GFP expression 48 hours following transfection in cultures transfected with 
pCR3.1-GFP plasmid DNA (0.01 jig) in the presence or absence of co-infecting Ad5-Wt 
(moi 0.001). Although results differed slightly for each cell line, the presence of Ad5-Wt 
(at these low m.o.i) increased the transfection efficiency with plasmid DNA by, at most, 
about two fold (typically increasing the number of GFP positive cells from 4% to 6-7% in 
the case of Mel624 cells) (Figure 4A). However, transfection with at least 50 fold more 
plasmid DNA was required to generate levels of cytotoxicity by GALV alone comparable 
to those seen in the combination of low dose pCR3.1-GALV and Ad5-Wt (Figure 1A) 
suggesting that enhanced transfection efficiency alone was not sufficient to explain the co­
operation between GALV transfection and Ad5-Wt infection.
It has recently been reported that syncytial formation enhances the dispersion of adenoviral 
particles through a monolayer in vitro (Li et al., 2001b). Therefore, we examined the ability 
of a replicating adenovirus to mobilize a replication-incompetent Ad-GFP vector from 
human tumor cells into murine B16 melanoma cells in co-culture. Human tumor cells are 
highly susceptible to GALV-mediated cell fusion but B16 murine melanoma cells do not 
express the receptor for GALV and so will not fuse to GALV-expressing cells. In the 
experiment described in Figure 4B, the only way that the GFP reporter gene would
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transduce B16 cells in the mixed cultures would be through mobilization of Ad-GFP from 
the human tumor cells by the replication competent Ad5-Wt virus. The number of GFP- 
transduced B16 cells at the end of the experiment was assessed by FACS analysis. The 
presence of ongoing cell fusion within cultures of human tumor cells significantly 
enhanced mobilization of Ad-GFP for infection of bystander B16 cells when replicating 
Ad5-Wt was present (Figure 4B).
5.2.4 Syncytial cultures produce increased levels of viral titer.
The increased mobilization of the Ad-GFP vector (Figure 4B) in the presence of syncytia 
may be due to an increase in the viral titer released on a per cell basis, an increase in the 
dispersal of the same amount of virus through the culture (Li et al., 2001b), or both. The 
titer of cell free virus released into the supernatants from the cultures of Figure 4B were 
significantly higher in the presence of syncytia relative to the same number of cells in non­
fusing cultures (p<0.03 for U87 cells and p<0.01 for U118 cells) (Table 1). The difference 
in the amount of cell-associated virus (recovered from the cell pellets) was less marked 
between fusing and non-fusing cells but was still significantly enhanced from fusing cells 
(p<0.05 for U87 cells and pc.0.01 for U118 cells) (Table 1). The increase in cell free virus 
may in part be due to the increased lysis of the human tumor cells by FMG-mediated cell 
killing and release of cell associated virus. These data show that presence of fusing cells 
increases both the total amount of virus produced and increases the amount of virus 
released into the culture supernatant, which at least partly will explain the more efficient 
spread of adenovirus through the culture (Figure 4B) (Li et al., 2001b).
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5.2.5 Increased titer associated with syncytia occurs through posttranscriptional 
upregulation of E l A expression.
RtPCR analysis indicated that the increased viral titers described in Table 1 were not due 
to greater levels of transcription of the viral E1A gene within Ad5-Wt-infected, fusing 
human tumor cell cultures (Figure 5A), data confirmed by Northern blotting (not shown). 
In contrast, levels of El A protein were significantly enhanced (up to 10 fold depending 
upon the experiment) within fusing, as opposed to non-fusing, tumor cell cultures (Figure 
5B). These data are consistent with our previous observations (Higuchi et al., 2000), as 
well as those of others (Mi et al., 2000) that as syncytia develop they become highly 
metabolically active (Higuchi et al., 2000) and generate high levels of protein production 
compared to the same number of non-fused cells.
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Figure 1. A. 106 confluent tumor cells (Mel624 shown here) were either transfected using 
the Effectene reagent in vitro with 0.5pg of plamsid DNA expressing the GALV FMG 
(pCR3.1-GALV), were infected with wild type adenovirus serotype 5 (Ad5-Wt) at an m.o.i. 
of 0.1 or were transfected with 0.5pg plasmid DNA admixed with Ad5-Wt (pCR3.1 + Ad5- 
Wt). 96 hours later, surviving cells were counted. B. The same experiment was 
performed using 0.01 pg of plasmid DNA, 0.001 moi of Ad5-Wt or both admixed. With 
the low dose of plasmid DNA, individual pockets of syncytia were formed but these were 
too infrequent to cause wide scale fusion of the entire population of cells and were 
eventually overwhelmed by proliferating tumor cells.
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Figure 2. Construction of the CMV-GALV-COX construct.
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Figure 3. Co-administration of plasmid GALV and Ad5-Wt virus can cure small 
palpable tumors. 5xl06 U118 (A) or U251 (B) tumor cells were injected subcutaneously 
in athymic nude mice. When tumors were palpable (~0.2cm diameter) different groups (10 
mice per group) were injected with PBS (PBS); or with low dose pCR3.1-GALV 
(0.5pg/injection) plasmid DNA (pGALV); or with Ad5-Wt virus (3xl07 pfu/injection) 
(Ad5-Wt); or with pCR3.1-GALV (0.5pg/injection) + Ad5-Wt virus (3xl07 pfu/injection) 
(pGALV+Ad5-Wt). Another group of tumors was also injected with 0.5pg of the plasmid 
pCR3.1 -GALV-COX (Figure 2) along with the Ad5-Wt (pGALV-COX + Ad5-Wt) in 
which 469 bp of the COX-2 3’UTR is ligated downstream of the GALV cDNA (see text). 
Tumor growth was monitored for a further 62 days. Animals were sacrificed when tumor 
size reached 1.0cm in any diameter.
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Figure 3C. The experiment of 3 A and B. above was repeated except that the tumors were 
resected two days following injection with pGALV (GALV), replicating virus (Ad5-wt) or 
pGALV and Ad5-wt (GALV + Ad5-wt). Tumor cells were dissociated in vitro and 
analyzed by FACS for expression of the viral El a protein using a rabbit polyclonal 
antibody against E la (Santa Cruz Biotech. Santa Cruz, CA) and a FTTC labeled anti rabbit 
IgG. As controls for the FACS analysis, uninfected, cultured U251 cells were treated with 
no secondary antibody (Untreated) or with both primary and secondary antibodies 
(Negative). The positive control was U251 cells infected with wild type Ad virus 24 hours 
previously (Positive).
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Figure 4. Co-transduction of human tumor cells with a fusogenic membrane 
glycoprotein and replicating adenovirus increases the spread of virus through the 
culture. A. GFP expression was measured 48 hours following transfection of Mel624 
cultures with pCR3.1-GFP plasmid DNA (0.01 pg) (CMV-GFP) in the presence or absence 
of co-infecting Ad5-Wt (moi 0.001) (Ad5-Wt). B. 106 cells were transfected with pCR3.1- 
GALV plasmid DNA (0.01 pg) to induce syncytia formation or with or pCR3.1-empty as a 
control and/or were infected with a mixture of replicating adenoviral stocks (m.o.i. of 
0.001) mixed with replication defective Ad-GFP (m.o.i. 0.1). 24 hours later, cultures were 
washed 3x in PBS and then 5xl04 B16 cells, pre-labeled with Cell Tracker Orange dye, 
were added to the cultures. Since B16 cells will not be incorporated into syncytia, the only 
way that the GFP reporter gene would transduce these cells would be through mobilization 
of Ad-GFP from the human tumor cells by the replication competent Ad5-Wt. The number 
of GFP transduced B16 cells at the end of the experiment (4 days later) was assessed by 
FACS for double stained (Orange and Green) cells. Similar results were also seen with 
U118 and U251 cells.
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Table 1
(Virus Recovered 
p.f.u/ml on 293 cells)
Original Transduction Treatment
GALV + Ad5-Wt + AdGFP
GALV + — + AdGFP
MOCK + Ad5-Wt + AdGFP
MOCK + —- + AdGFP
Cell Free Cell Associated
U87 U118 U87
9 x 104 2X 105
1 x 106 7 x 105l x l O 3 3 x 103
Table. Syncytial formation is associated with increased viral production. 106 U87 (high 
level of activated MAPK) or U118 (low level of activated MAPK) cells were transfected 
with pCR3.1-GALV plasmid DNA (0.01 pig) to induce syncytia formation or with or 
pCR3.1-empty as a control and/or were infected with a mixture of replicating adenoviral 
stocks (m.o.i. of 0.001) mixed with replication defective Ad-GFP (m.o.i. 0.1), cell culture 
supernatants were recovered and cells were trypsinised, washed in PBS and lysed by three 
cycles of freeze thawing. Viral titers from the supernatants (Cell Free) and from the cell 
pellets (Cell Associated) were then determined by a plaque assay on 293 cells as described 
in material and methods.
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Figure 5. Increased viral titer and spread in syncytial cultures is associated with 
elevated levels of E l A protein but not mRNA. 106 confluent Mel624 tumor cells were 
either transfected using the Effectene reagent in vitro with 0.01 jig of plamsid DNA 
expressing the GALV FMG (pCR3.1-GALV) (lane 1), were infected with wild type 
adenovirus serotype 5 (Ad5-Wt) at an m.o.i. of 0.001 (lane 2) or were transfected with 
0.01 ng plasmid DNA admixed with Ad5-Wt (pCR3.1 + Ad5-Wt) (lane 3). 48 hours later 
RNA was prepared from the cultures and used A. for production of cDNA. Primers 
specific for E1A (5’ -TTCCTCAAGAGGCCACTCTTG-3 ’ and 5’-
CACGCCATGCAAGTTAAACA-3’) were used to assess the amount of El A message 
present in the cultures. Equal loading of samples was assessed by riper for GAPDH. B. In 
addition, protein was prepared from cell lysates and Western Blot analysis used to 
determine the relative levels of expressed El A protein. Equal loading of samples was 
confirmed as shown in the upper panel.
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5.4 Discussion
Oncolytic adenoviruses are a promising new concept for the treatment of cancer. One of the 
most attractive advantage of replicating oncolytic viruses is that a single virus can 
selectively amplify several thousand-fold within a tumor cell and the progeny viruses then 
have the capacity to spread and infect uninfected tumor cells, thus enhancing the 
therapeutic effects. But the early data from both of the clinical trials (Kim et al., 2001) and 
animal models (Sauthoff et al., 2003) indicated that barriers within the tumor prevent viral 
spread, which is a major obstacle for achieving clinically relevant therapeutic efficacy. In 
this chapter, we described a novel approach to enhance the in vivo efficacy of replicating 
adenovirus therapy by combining a fusogenic viral glycoprotein-induced tumor cell fusion 
and also showed that the viral therapy can be retargeted by expressing FMG selectively in 
tumor cells with elevated level of Ras/MAPK via the COX-2 3’UTR element.
Our in vitro studies show that the FMG-induced fusion significantly enhances the oncolytic 
activity of replicating adenovirus. By ligating the GALV FMG with the COX-2 3’ UTR, 
we were able to regulate GALV-induced tumor cell fusion selectively in cells that have 
activated Ras/MAPK signaling cascade. In vivo, we demonstrated that the efficacy of 
intratumoral injection of replicating adenovims is greatly enhanced by the co-injection of 
an FMG-encoding plasmid. This combinatorial approach was sufficient to eradicate very 
small-established tumors at viral doses where injection of the vims, or plasmid alone, was 
not effective. And, the selective expression of GALV by the COX-2 3’UTR element only 
in tumor with elevated level of activated Ras/MAPK was sufficient enough to regulate this 
combined therapeutic approach.
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The enhanced therapeutic effects that observed in this combination therapy were not due to 
increased destruction of the stroma between tumor cells which might act in patient tumors 
to impede virus spread, because the stroma in these experiments are of murine origin which 
do not express fusion competent receptors for the GALV FMG. These data suggest that 
replicating adenoviruses expressing the GALV FMG will be significantly more potent than 
viruses without FMG. In addition, we have shown that targeting of GALV expression to 
tumor cells is possible at posttranscriptional levels as demonstrated in this work. This 
strategies could be combined with pre-existing conditionally replicating adenoviruses 
which have tumor targeting already built in either at the level of transcriptional regulation 
using selective promoters driving essential replicative (Rodriguez et al., 1997) (Hallenbeck 
et al., 1999) or therapeutic genes (Freytag et al., 2002) or at the genetic level using viral 
mutants with tumor cell selective replicating properties (Alemany et al., 2000).
The results from the in vitro studies to understand the interaction between FMG and 
adenovirus replication show that the FMG-mediated syncytial formation significantly 
enhances the efficacy of replicating adenoviral therapy through a combination of 
mechanisms. One of these is a moderate increase in the transfectability of cells with the 
GALV plasmid in the presence of co-infecting adenoviruses. This effect will boost the 
cytotoxicity associated with the FMG-mediated component of the therapy (Bateman, 2002) 
(Diaz et al., 2000). However, quantitatively more significant, the levels of tumor cell that 
expressed the viral El A protein were markedly increased in the presence of FMG-mediated 
cell-cell fusion. Elevated cellular levels of E1A were associated with significantly 
increased total viral titers (total virus produced from infected cells) as well as greater viral 
release from cultures of infected syncytial cultures compared to normal non-fusing
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monolayer. Finally, as a result of all of these effects, and consistent with report using the 
HIV gpl20 FMG (Li et al., 2001b), syncytia also promoted enhanced spread of adenoviral 
particles through the tumor cell cultures. Beside the overall increase in viral titer, syncytial 
formation also increased release of adenoviral particles. This is most probably due in part at 
least to lysis of infected cells thereby releasing intracellular particles, which would 
otherwise remain cell associated. Therefore, the increase level of viral production in 
combination with the accelerated release of viral particles through tumor cell cultures 
would suggest that combination therapy with FMG expression and replicating adenovirus 
infection may overcome some of the problems associated with the use of replicating 
adenovirotherapy, which have been seen to date.
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Chapter 6
A Cell Cycle Dependent Conditionally Replicating Adenoviral 
Vector for Cancer Gene Therapy.
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6.1 Introduction:
We previously showed that successful construction of a conditionally replicating 
adenovirus to target the RAS-MAPK pathway in the cell can be achieved by the 
cyclooxygenase-2 3’-UTR. In order to expand our hypothesis and prove that the 3’UTR 
element from other tumor associated genes can also be used to target tumor cells, in the 
studies presented in this chapter we used the 318 bp 3’UTR element from the DNA 
methyltransferasel gene (DNMT1) and demonstrated in vitro that genes can be selectively 
expressed in rapidly dividing tumor cells. Also, by introducing the DNMT1 3’-UTR in 
between the adenoviral El A coding sequence and the poly A signal, El A expression, and 
subsequently viral replication, becomes restricted to the tumor cells derived from multiple 
tissue types.
DNA methyltransferasel is a major enzyme that is responsible for maintaining the 
methylation pattern from the parent cell into the daughter cell during cell division. The 
expression of DNMT1 is tightly coordinated with the DNA replication (Araujo et al., 1999) 
during cell division (Szyf et al., 1985). Several lines of evidences link DNMT1 with the 
tumorigenic process. First, increased levels of DNMT1 mRNA, protein and activity were 
observed in many different types of cancer. Second, overexpression of DNMT1 in the 
mouse fibroblast NIH3T3 cells caused cellular transformation (Wu et al., 1993). Also the 
DNMT1 promoter regions contain multiple activator protein 1 (AP-1) elements, which can 
be transcriptionally activated by proto-oncogene and mitogenic signals (Girault et al., 
2003). And finally, downregulation of DNMT1 expression by RNA interference, antisense 
or pharmacological inhibitor induced demethylation of DNA and re-expression of various 
tumor suppressor genes (Robert et al., 2003), which lead to inhibition of DNA replication
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(Knox et al., 2000) and cell growth (Laird et al., 1995). Thus, DNMT1 has been suggested 
to play an important role in cancer development.
DNMT1 mRNA levels are significantly downregulated during the Go/ Gi phase of the cell 
cycle, but the abundance of DNMT1 mRNA is dramatically increased after cells enter into 
the S phase (Robertson et al., 2000; Szyf et al., 1991). The 3’-untranslated region (3’-UTR) 
of the DNMT1 mRNA plays an important role in the cell cycle-dependent regulation of 
DNMT1 expression. A 54-nucleotide highly conserved AU-rich element (ARE) within the 
DNMT1 mRNA is responsible for orchestrating cell cycle-dependent DNMT1 expression 
by destabilizing its own mRNA in the quiescent cells {Detich, 2001 #3867}. 40 kd protein 
(p40) interacting with this conserved region of DNMT1 3’UTR may be involved in 
destabilizing DNMT1 mRNA (Detich et al., 2001). As the cell enters into S phase, the 
binding of p40 to the 54-nucleotide element is significantly reduced by some unknown 
mechanisms and the mRNA is restabilized. Because tumor tissues are presumed to contain 
a greater proportion of dividing cells than their normal counterparts and increased DNMT1 
expression is observed in many different tumor samples, targeting cancer via tumor cell 
specific mRNA stabilization by the DNMT1 3’-UTR could be a viable strategy.
In this chapter we are able to show that DNMT 3’UTR element can be used to regulate 
transgenes expression selectively in various tumor cells. By inserting this element in the 
adenoviral genome we were able to control El A expression and viral replication in vitro. 
We were also able to demonstrate that DNMT1 3’UTR-mediated regulation of adenoviral 
replication was correlated with cell cycle dependent DNMT1 protein expression in the 
A549 cancer cell.
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6.2 Results:
6.2.1 DNMT 3’UTR is active in tumor cells
To evaluate tumor cell specific activity of DNMT 3’UTR, a transient transfection of 
luciferase reporter assay was performed. The luciferase activity of the positive control 
plasmid with the SV40 enhancer/promoter (Fig. 1A) in each cell line was considered as 
100%. As shown in Fig. IB, the DNMT 3’UTR containing pGL3 construct showed similar 
luciferase reporter activity compared to the control vector in most of the tumor cell lines 
tested. In contrast, luciferase activity was significantly inhibited (10-12% of control 
vector) in the primary human retina pigment epithelial cells hTERT-RPEl and IMR90. 
The other primary cell line used in this experiment was BEAS-2B, which is a human 
bronchial epithelial cell immortalized by SV-40 large T antigen, and showed similar 
luciferase reporter activity to control plasmid in the presence of DNMT1 3’-UTR. It has 
been reported previously that SV-40 large T antigen transformed cells overexpressed 
DNMT-1 during cellular transformation (Chuang et al., 1997) by stabilizing the DNMT-1 
mRNA at the posttranscriptional level (Slack et al., 1999). So, SV-40 large T antigen may 
also stabilized DNMT1 massages in the BEAS-2B cell and responsible for the increased 
luciferase activity. Western blot analysis of DNMT1 expression in the various tumor and 
primary cell lines revealed that the DNMT1 expression is significantly elevated in most of 
the tumor cell lines tested compared to primary cell lines except BEAS-2B cells.
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6.2.2 The DNMT1 3’-UTR can selectively down-regulate the stable luciferse mRNA in 
primary cells but not in tumor cells
To validate the hypothesis that the cis-acting sequence within the DNMT1 3’-UTR can 
stabilize the mRNA levels in rapidly dividing tumor cells, but destabilize the same mRNA 
in slow growing primary cells, we performed a Northern blot for luciferase mRNA, 
extracted from transiently transfected human primary cells (hTRE) and tumor cells 
(HCT116). In the presence of the DNMT1 3’-UTR, steady-state reporter luciferase mRNA 
expression was significantly inhibited only in the primary cells (Figure 1C). In contrast, in 
tumor cells the DNMT1 3’-UTR did not alter the luciferase mRNA expression. These 
finding suggested that the DNMT1 3’-UTR possesses a potent inhibitory effects on the 
reporter mRNA expression only in primary cells, but not in tumor cells.
6.2.3 Construction of AdDNMT virus
Therefore, we constructed AdDNMT, a conditionally replicating adenovirus where the 
replicative essential viral gene El A was ligated to the DNMT 1-3’UTR using a PCR 
strategy. Figure 2 depicts the genome of the recombinant adenoviruses. The viral DNA was 
isolated by Hirt extraction and the modified sequences were confirmed by PCR (data not 
shown).
6.2.4 AdDNMT induced tumor-specific cytotoxicity
To evaluate the cytolytic activity of the AdDNMT in the context of oncolytic adenovirus, a 
human colorectal cell line HCT116, and the primary cell line hTRE were infected with 
AdDNMT or wild type Ad-5 (wt Ad-5) at an MOI of 1. After 7 days, cells were examined 
for CPE. Figure 4A depicts representative results of selective oncolysis of the AdDNMT 
virus. As expected, wt Ad-5 virus induced cytotoxicity in both tumor and normal cells
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without any specificity. In contrast, the AdDNMT infection induced selective oncolysis in 
the HCT116 tumor cell line, but no significant oncolysis was observed on the normal hTRE 
cell line. The morphology of AdDNMT-infected hTRE normal cells appeared to be very 
similar to the uninfected cells (Figure 4A).
To further monitor the oncolytic activity of Ad-DNMT by the quantitative measurement of 
the cell viability, MTT assays were performed exposing a panel of human primary (hTRE, 
hEPC, HUVAC and IMR90) and tumor cell lines (HCT116, Mel 88, Mel 624, huh7 and 
U251) to AdDNMT or wt Ad-5 virus at MOI of 1. In most of the tumor cell lines tested, the 
oncolytic activity of the AdDNMT virus was as efficient as wt Ad-5 virus, with some 
differences in the kinetics of cell killing between different cell lines (Fig. 3B and 4B). 
While greater than 90% of HCT116 and U251 tumor cells were killed within 6-8 days, 
longer times were required with the Mel 888 and huh-7 cell lines to observe comparable 
levels of cytolysis. But in all the tumor cell lines, AdDNMT and wt Ad-5 virus showed 
very similar kinetics of oncolysis. In contrast, in most of the human primary cell lines, 
AdDNMT showed some toxicity at the earlier time point, but in the later time point 
AdDNMT induced oncolysis was significantly reduced compared to wt Ad-5 virus. The 
cytotoxicity observed by AdDNMT infection at the earlier time points in some primary cell 
lines could be due to the viral particle induced toxicity rather than oncolysis. These 
findings confirmed that AdDNMT mediates selective oncolysis in tumor cells, but the 
oncolysis is significantly reduced in normal cells.
6.2.5 AdDNMT mediated tumor cell-specific E1A expression
To ensure the specificity of DNMT1 3’-UTR, human tumor (HCT116) and primary (hTRE) 
cells were infected with AdDNMT at an MOI of 10. After 48h of incubation, the
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expression of El A protein was evaluated by Western blot. As shown in figure 3C, the 
expression of E1A in AdDNMT infected HCT116 cells was detectable but lower than wt 
Ad-5 infected cells. In contrast, E1A expression was completely undetectable in AdDNMT 
infected primary hTRE cells, thus demonstrating the specificity of DNMT 3’-UTR (Figure 
3C).
6.2.6 Cell cycle dependent DNMT1 expression correlate with AdDNMT replication 
and oncolysis in A549 cells
We observed that the lytic activity of the AdDNMT virus in A549 cells is dependent on the 
seeding density of the A549 cells at the time of AdDNMT infection. If the cell culture 
monolayer of the A549 cells reached full confluence during infection, the oncolytic activity 
of the AdDNMT virus was significantly reduced compared to Wt Ad-5 virus (Figure SC- 
100 % confluent). But if the monolayer was sub-confluent at the time of infection, the 
oncolytic activity of the AdDNMT virus was very similar to the Wt Ad-5 virus. 
Immunoblot analysis revealed that DNMT1 expression was significantly lower in the 
confluent cultures (Figure 5B), which also contained fewer number of cells in the S-phase 
of the cell cycle. Based on these results, we conclude that the oncolytic activity of the 
AdDNMT virus in A549 cells depend on the percentage of cells are in S-phase of the cell 
cycle and also correlate with the cell cycle dependent DNMT1 expression.
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Figure 1. Immunoblot analysis for DNMT-1.
A. Primary
cell lines Cancer cell lines
0-4
Figure 1 A. Level of DNMT 1 expression analyzed by Western blot in the immortalized 
primary cell lines and different cancer cell lines. Equal amount of protein (15 pg) loaded 
into each lane.
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Figure 1. The DNMT 3’UTR destabilizes a reporter mRNA in 
Primary human cells.
B.
SV40p Luc-ORF pA
pGL3-ctrl 1 I— I,- H............ .... I I
3’UTR
pGL3-DNMT 3 ’UTR 1 I— I ~ L . . ^ I
C.
150
125
100
75
50
25
pGL3 CONTROL DNMT1
LnCap
CE L L LINES
□
Figure 1. B. Schematic representation of DNMT1 3’-UTR luciferase reporter plasmids. A 
318-bp PCR product coding for DNMT1 3’-UTR was inserted between the luciferase 
reporter gene and SV40 poly A signal to investigate the selectivity of the DNMT1 3’-UTR. 
C. the DNMT1 3’-UTR activity was assessed by luciferase assays. The DNMT1 3’-UTR 
activity in each cell line was calculated as percentage of the positive control ( pGL3-ctrl). 
The data shown are MEAN ± s.d. (bars) and values (n=3).
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c. The reporter mRNA half life study. 
hTRE HCT116
Luc-
18s-
m m  ^
r nmmmm rnmmmrn
Act D (hr) 0 3 6 9  12 0 3  6 9  12
Luc DNMT 
3’UTR-
18s-
Act D (hr) 0 3 6 9  12 0 3 6 9  12
Figure 1. C. Differential DNMT1 3’UTR decay rates in vitro. The primary cells hTRE 
and the tumor cells HCT116 were transiently transfected 1 pg of pGL3 plasmid with 
reporter luciferase gene and luciferase gene ligated to DNMT 3’UTR. After incubation for 
18 hours, cells were harvested (Act D Oh) or further incubated with 5 pg actinomycin D/ml. 
The cells were harvested every 3 hours for 12 hours and the reporter luciferase mRNA 
levels were determined by Northern blot analysis.
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Figure 2. S ch em a tic  r ep re sen ta tio n  o f  th e  A d D N M T  v e c to r  an d  th e  
th e  A d D N M T -tk  v ecto r  g en om es.
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Fig. 2. Schematic representation of the adenoviral vector AdDNMT.
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Figure 3. Cytopathic effects of AdDNMT on human primary and 
tumor cell line.
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Figure 3C. Immunoblot analysis for E1A protein.
hTRE HCT116
Figure 3. Tumor-selective cytotoxicity of AdDNMT. A, subconfluent tumor cells 
(HCT116) and normal cells (hTRE-RPE) were infected with MOI 1 of AdDNMT or wt 
Ad5 virus. Mock-infected cells were introduced as control. After 7 days, the appearance of 
cytopathic effect (rounding and detachement) was monitored, and documented as 
photographs. B, Monolayers of tumor (HCT116) and normal cells were infected with MOI 
1 of wt Ad5 (■) or AdDNMT (A) virus. MTT assay was performed to measure viable 
cells, and results are the mean of triplicate experiments and expressed as percentage of non­
infected cells. C. . Levels of El A expression in the HCT116 cancer cell lines U87, U118 
and U251 were assayed by Western Blot 15 hours following infection with Ad-EIA or Ad- 
E1A-COX viruses at an m.o.i. of 10. Lane 1 and 5 Mock infected, lane 2 and 6 AdElAp- 
E1A: cells infected with recombinant virus that express E1A gene under E1A promoter,
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lane 3 and 7 Wt-Ad5: cells infected with wild type adenovirus 5 and lane 4 and 8 
AdDNMT: cells infected with recombilant virusthat express E1A gene under E1A 
promoter and fused with DNMT 3’ UTR.
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Figure 4. Oncolytic effect and tumor specificity AdDNMT vector.
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Figure 4. Oncolytic specificity of the AdDNMT vector. Monolayers (A) of normal and 
tumor (B) cells were infected with wt Ad5 (■) or AdDNMT (A) virus at a MOI of 1. MTT 
cytotoxicity assay was performed at the time points shown. The viability of each infected 
culture at each time point is expressed as a percentage of uninfected controls. Each data 
point is the mean of three replicates; bars, ± s.d.
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Figure 5. Cell cycle dependent oncolytic activity of AdDNMT in A549 cell.
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Figure 5. Cell cycle dependent oncolytic activity of AdDNMT in A549 cell. A. Cell cycle 
analysis by flow cytometry of A549 cells plated in different density. B. Immunoblot 
analysis of the DNMT1 protein level in the same population of A549 cells as figure 5A. C. 
Monolayers of A549 cell with different density (as figure 5A) were infected with MOI 1 of 
wt Ad5 (■) or AdDNMT (A) virus. MTT assay was performed to measure viable cells, 
and results are the mean of triplicate experiments and expressed as percentage of non­
infected cells.
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6.4 Discussion:
The studies presented in this chapter provide in vitro evidence supporting the use of tumor 
cell selective mRNA stabilization by the DNMT1 3’UTR for developing a conditionally 
replicating adenovirus vector for cancer treatment. Our results demonstrate that (a) the 
minimal 318 bp DNMT1 3’-UTR can induce tumor cell selective mRNA stabilization of 
El A gene to drive adenovirus replication and oncolysis, (b) the 3’-UTR also causes 
inhibition of the E1A gene expression and adenovirus replication in primary cells derived 
from different tissues, and (c) AdDNMT replication and oncolysis in the A549 tumor cell 
line correlate with cell cycle dependent expression of DNMT1.
The overexpression of the DNMT1 mRNA and protein has been reported in many different 
types of cancers (Etoh et al., 2004; Girault et al., 2003; Nakagawa et al., 2003; Nakagawa 
et al., 2005; Shieh et al., 2005). It is speculated that in cancers, DNMT1 is involved in the 
DNA hypermethylation and maintenance of CpG islands that are not methylated in normal 
cells (Etoh et al., 2004). The ubiquitous expression of DNMT1 in many different types of 
tumor has made the enzyme an attractive pan-tumor target for developing oncolytic 
adenovirus.
The DNMT1 3’UTR used in this report was significantly more active in a variety of cancer 
cell lines with higher expression of DNMT1. By inserting the DNMT1 3’UTR in between 
the luciferase reporter gene and polyA signal, the luciferase activity was 8 to 10-fold 
reduced in normal hTRE-RPE cells, which do not express any DNMT1 (Figure 1). But in 
another primary cell line BEAS-2B, the luciferase activity was not controlled by the 
DNMT1 3’UTR. The BEAS-2B cell line is a normal human bronchial epithelial cell, which 
is immortalized by SV40 large T antigen. It has been reported that the DNMT1 expression
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is a downstream effect of SV40 large T antigen expression and the DNMT1 3’UTR plays 
an important role in DNMT1 expression in cells that express SV40 large T antigen 
(Chuang et al., 1997). We believe that the inability to repress reporter gene activity by the 
DNMT1 3’UTR in the BEAS-2B cells is due to SV40 large T antigen-mediated DNMT1 
mRNA stabilization. On the other hand, DNMT1 3’UTR did not affect the reporter gene 
expression in most of the tumor cell lines that express DNMT1 (Figure 1A and IB). In the 
oncolytic activity measured by the MTT assay, the wild-type Ad5 virus showed a similar 
killing potency in normal and cancer cells, thus lacking tumor cell specificity. In contrast, 
all the tumor cell lines tested, AdDNMT adenovirus induced cell killing as potently as the 
wt Ad-5 virus, but was approximately 10-50 times less effective in normal cells, 
confirming tumor cell-specificity of the DNMT1 3’UTR. We were also able to show that in 
A549 cells, the replication and the oncolytic activity of the AdDNMT virus correlate with 
the DNMT1 protein expression in cells plated with different density. Thus, the A549 cells 
plated in higher density became cytostatic by increasing the number of cells in the Go/ Gi 
phase of the cell cycle (Figure 5A) in the reducing the number of cells metabolically active 
(data not shown). Under these conditions, A549 cells downregulate DNMT1 protein 
expression. The mechanism of DNMT1 downregulation in the confluent A549 cells is not 
yet understood. But we are able to show that in the confluent cultures of A549 cells, the 
oncolytic activity of the AdDNMT virus was significantly reduced compared to the control 
wt Ad-5 adenovirus. In contrast, the semi-confluent A549 cells the oncolytic activity of the 
AdDNMT virus was identical to the wt Ad-5 correlating the correspondingly high levels of 
DNMT1. Thus, from these results we can conclude that the novel DNMT1 3’UTR tested in
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this study can control transgene expression, and viral replication, in a tumor-specific 
manner.
A successful viral vector for cancer gene therapy not only needs to demonstrate the 
therapeutic efficacy by efficiently eliminating all the cancer cells, but also needs to be 
selective enough to use it systemically. Most of the current strategies for developing cancer 
gene therapy vector are not tumor-selective enough to fulfill all the safety requirements for 
systemic use. Major efforts have been directed toward improving or finding new and better 
tumor targeting strategies to achieve higher degree of tumor selectivity and lower the 
toxicity caused by therapeutic vectors. The tumor selective mRNA stabilization by the 
DNMT 3’UTR presented in this study can not only be used as a novel pan-targeting 
approach to control therapeutic or viral gene expression in tumor cells, but it can also be 
used for improving the selectivity of currently available tumor targeting strategies. Many 
tumor specific promoters that are being used for developing oncolytic virus for cancer gene 
therapies are not entirely selective for tumor cells and generally active in one, or at most, a 
few normal tissue types. Due to this leakiness, systemic use of the oncolytic vectors 
developed by these tumor specific promoters is difficult because of the toxicity induced by 
these vectors. Although tumor cells tend to overexpress DNMT1, it has been reported that 
some proliferating normal cells constitutively express DNMT1 (Leonhardt et al., 1992). 
The difference in the mechanisms involved in controlling the expression of DNMT1 in the 
normal proliferating cells and cancer cells is not well understood, but it is a possibility that 
the AdDNMT virus may replicate and show some toxicity in these normal cells. We 
believed that the combination of tumor specific mRNA stabilization mechanisms of the 
DNMT 3’-UTR with a tissue specific promoter could be a solution for developing a safer
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oncolytic vector. The tumor cell specificity of different tumor specific promoters can be 
enhanced by adding the translational specificity of DNMT1 3’UTR, which should help 
each other to express therapeutic gene more selectively in the tumor. The data presented 
here suggest that DNMT 3’UTR mediated tumor specific mRNA stabilization could be use 
as a means to achieve tumor-specific expression of therapeutics, or viral genes, for cancer 
gene therapy.
233
Chapter 7 
Discussion and future direction
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In this thesis, the hypothesis to be tested is that tumor cell selective stabilization of mRNA 
can be used to control therapeutic/viral gene expression in order to develop targeted viral 
vectors for cancer gene therapy. The data presented indicates that linkage to the AU-rich 3’ 
untranslated region (UTR) from a tumor-associated gene, cyclooxygenase-2 (COX-2), of a 
replicative essential viral gene is sufficient to achieve tumor cell selective viral replication 
and oncolysis.
The expression of COX-2, which has been associated with poor prognosis in many 
different types of tumor and is a downstream effect of RAS-mediated transformation 
(Sheng et al., 2001). Upregulation of COX-2 in the transformed environment is partly 
mediated by a selective stabilization of the COX-2 mRNA (Sheng et al., 2000) (Dixon et 
al., 2000) and the AU-rich region of the 3’UTR of COX-2 mRNA is essential for 
stabilizing the COX-2 mRNA in an activated RAS-MAPK-dependent manner (Lasa et al., 
2000). So, we hypothesized that tumor selective transgene expression can be achieved by 
using an AU-rich stabilization element such as the COX-2 3’UTR in a viral vector for 
cancer gene therapy. Our hypothesis relies on the proven ability of the COX-2 3’UTR 
region to destabilize a message in the quiescent environment, but restabilize the same 
mRNA in the presence of the appropriate oncogenic stimuli.
The initial studies were designed to clone the AU-rich element from the 3’ UTR of the 
tumor-associated gene COX-2 and evaluate it’s the ability to regulate gene expression in 
transformed and non-transformed cells. 469 base pairs of the COX-2 3’UTR was cloned 
(Dixon et al., 2000) and inserted downstream of the replicative essential adenoviral gene 
El A, which was driven by the human CMV to generate the CMV-E1A-COX construct. 
The effect of the COX-2 3’UTR insertion on El A expression was characterized in a model
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system where exactly matched rat intestinal epithelial cell lines (RIE-iRAS), differing only 
in the expression of an activated inducible variant of the H-Ras oncogene were used (Sheng 
et al., 2000). Plasmid transfection of the adenoviral E1A gene, with or without, the COX-2 
3’UTR in the RIE-iRAS cells, followed by infection with an ElA-deleated, replication- 
incompetent adenoviral vector expressing GFP reporter gene (Ad-GFP) highlighted a 
number of points. First of all, transient expression of E1A (CMV-E1A) in RIE-iRAS cells 
was able to support the replication and mobilization of the incoming Ad-GFP vector, which 
was independent of the inducible expression of Ras oncogene. In contrast, cells transfected 
with CMV-E1A-COX plasmid were able to support replication and mobilization of the Ad- 
GFP vector only when RIE-iRAS cells were previously induced to express activated Ras. 
Secondly, experiments designed to assess viral titers showed a clear difference between the 
titer of Ad-GFP released with, or without, inducible RAS signaling in the RIE-iRAS cells 
transfected with CMV-E1A-COX plasmid. And finally, inhibition of Mitogen-activated 
protein kinase (MAPK) activation, a downstream effectors molecule for Ras signaling 
cascade, greatly reduced the ability of CMV-E1A-COX to support Ad-GFP replication and 
mobilization even in the presence of inducible activated Ras. From these experiments, we 
were able to conclude that, at least in vitro, the COX-2 3’UTR is able to control gene 
expression, which was highly dependent on oncogenic Ras signaling.
To test whether the regulation of gene expression by the COX-2 3’UTR is sufficient to 
control viral replication, we incorporated the CMV-E1A and CMV-E1A-COX cassettes 
into ElA-deleted adenoviral genomes. The production of recombinant adenovirus 
expressing these cassettes was performed using standard methods and the recoverable titer 
of adenovirus expressing CMV-E1A (Ad-EIA) or CMV-E1 A-COX (Ad-El A-COX) was
very similar to the wild type Ad-5 titer. The replication selectivity of the Ad-EIA and the 
Ad-ElA-COX virus were tested in the model cell culture system RIE-iRAS cells. 
Replication and oncolysis of the Ad-El A-COX virus was heavily dependent upon the 
expression of the inducible activated Ras and consistently produced an excess of 3 log 
more viruses compared to the same cultures without any inducible activated Ras. Ad-El A- 
COX virus replication in the Ras induced RIE-iRas cells was also inhibited (about 2 log 
inhibition) by blocking MAPK activation with a chemical inhibitor, which again validated 
the requirement for activated Ras/MAPK intracellular signaling in COX-2 3’UTR mediated 
regulation of gene expression. We were also able to show that the oncolytic activity of the 
Ad-El A-COX virus in different human tumor cell lines correlated very closely with the 
cell lines’ MAPK activity status. In vivo in two human tumor xenograft models with 
elevated levels of activated MAPK (U87 and U251), the Ad-El A-COX virus showed 
similar therapeutic efficacy as the wild type Ad-5 virus, but showed no significant 
therapeutic effects in the tumor model with very minimal activated MAPK (U118). Taken 
together, these data suggest that El A expression can be regulated in an adenoviral genome 
by the COX-2 3’UTR and Ad-El A-COX virus is oncolytic both in vitro and in vivo against 
human tumors with elevated level of activated RAS-MAPK signals.
Results from the toxicity and the biodistribution studies in the immunocompetent 
murine model show that the systemic administration of Ad-ElA-COX virus induces some 
hepatic toxicity compared to the wild type Ad-5 virus. Although the lethal dose 50 (LD50) 
for both of the viruses were very similar, the mice treated with Ad-El A-COX virus had 
elevated levels of liver enzyme in the blood and showed abnormal liver histopathology 
with increased immune infiltrate. This toxicity was not associated with the organ-specific
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non-selective replication of the Ad-El A-COX virus because the amount of virus recovered 
from the liver of the mice treated with the Ad-El A-COX were lower than the mice treated 
with the wild type Ad-5 virus. However, at the early time point (24 h post i.v. challenge) 
we observed an increased amount of viral DNA and El A protein in the livers of the Ad- 
E1A-COX treated group compared to the wt Ad-5 group. It is possible that this early 
elevation of viral DNA and protein could trigger a stronger innate immune response, which 
then would lead to hepatic toxicity. It is known that during cell entry, the interaction 
between the adenoviral entry receptors (fiber knob and penton base (Roelvink et al., 1998)) 
and the cellular entry receptors (CAR and avp 3 and ocyp 5 (Wickham et al., 1993)) 
activates various intercellular signaling pathways including the MAPK signaling cascade 
(Bruder et al., 1997) (Tibbies et al., 2002). Based on this, one working hypothesis is that 
the activation of a MAPK pathway during the initial adenoviral interaction with the cellular 
entry receptors might alter the resting cell microenvironment and therefore even hyper- 
stabilize the viral E1A protein ligated to the COX-2 3’UTR. This hypothesis is recently 
supported by Crofford et al, showing that the initial interaction between adenovirus and 
liver synoviocytes is sufficient to increase COX-2 expression both at the mRNA and 
protein levels, and MAPK signaling is vital for this COX-2 induction (Crofford et al.,
2005). Taken together, results from the initial in vivo toxicity show that the 3’UTR needs 
to be selected very carefully in order to develop tumor selective conditionally replicating 
viral vectors. The 3’UTR from different genes will have different restrictions, which will 
depend on the level of expression of that gene in the tumor microenvironment and the 
expression profile in the normal physiological condition (Denigo et al., 2000). Also, the 
kind of vector used to target tumor will be important for the selection of the 3’UTR
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elements. It will be probably wise to avoid genes involved in inducing innate immune 
response for developing retargeted adenoviral vectors, because adenovirus is known to 
induce potent innate immune responses (Muruve, 2004), which may compromise the 
selectivity of the 3’UTR element. Recently, several reports show that in order to develop 
safe and less toxic adenoviral vectors for cancer therapy, multiple viral genes expression 
need to be regulated (Irving et al., 2004). One possible way to reduce the Ad-ElA-COX 
induced liver toxicity after systemic administration will be to use the COX-2 3’UTR 
element to regulate multiple adenoviral genes. For example, the adenoviral late 
transcription unit will be a very attractive candidate for this targeting approach as the late 
transcription unit encodes approximately 15-20 different mRNAs, all of which derive from 
a single pre-mRNA by differential splicing (Young, 2003). Most of the late gene products 
are viral structural proteins and essential for virion assembly (Rux & Burnett, 2004). If an 
mRNA stabilizing element, such as COX-2 3’UTR, can be inserted down stream of the late 
transcription unit, all of these late gene products can be regulated by one single tumor 
selective element and may lead to improved tumor selectivity and reduced toxicity.
To our knowledge, this is the first example of achieving tumor-selective gene expression, 
and development of a conditionally replicating adenovirus, through a tumor specific post- 
transcriptional mRNA stabilization element. There are several issues that need to be 
addressed in order to optimize post-transcriptional targeting strategies for more efficient 
tumor targeting. First of all, we have no knowledge about the minimal level of activated 
RAS-MAPK signaling required for achieving sufficient stabilization of the transgene 
mRNA in order to target tumor cells through the COX-2 3’UTR. This will give us a clearer 
idea about the kind of cancer that can be targeted with the Ad-El A-COX vector. One
!
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possible way to investigate this will be using a more sensitive inducible system such as 
repaying regulated, where transgene can be expressed in a dose-responsive manner 
(Pollock et al., 2002) and use these systems to generate stable cell line where constitutively 
activated Ras or MAPK expression can be more tightly controlled. Also, the receptor 
tyrosine kinase (RTK) family of proteins such as epidermal growth factor receptor (EGFR) 
is an upstream signaling molecule of Ras/MAKP signaling cascade and plays an important 
role in cancer pathogenesis. Several reports postulate a link between the EGFR 
upregulation and subsequent COX-2 induction in different cancers (Yuan et al., 2005) and 
the activation of EGFR signaling pathway can induce COX-2 expression by stabilizing the 
COX-2 mRNA (Matsuura et al., 1999). So the RTK overexpressed tumor cell can be a 
suitable target for the Ad-El A-COX virus and we need to test the level of different RTK 
expression in different cancer cells and try to correlate with the oncolytic selectivity of Ad- 
El A-COX virus. Second of all, we did not optimize the length of the COX-2 3’UTR 
element needed to achieve the maximum levels of tumor selectivity. The 469 bp COX-2 
3’UTR used in this study was based on the published data by Dixon et al (Dixon et al., 
2000) who reported the position of the six AU-rich sequence motifs (AUUUA) in the 469 
bp of the COX-2 3’UTR. Several other AU-rich motifs located outside of the 469 bp COX- 
2 3’UTR have also been identified. It will be logical to include the rest of the 1000 bp AU- 
rich motifs from the COX-2 3’UTR in our tumor targeting strategy to see whether we can 
improve the tumor selectivity of this element. And finally, what kind of viral vector will be 
the best fit for these pos-transcriptional targeting strategies that will give us the maximum 
control and tumor selectivity for viral replication. To use mRNA stabilization as a mean to 
control viral gene expression and tumor selective viral replication, it is possible that
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oncolytic RNA viral vectors such as vesicular steatites virus (VSV) or measles virus may 
be better than DNA viruses because the whole viral RNA genome could be restabilized or 
destabilized by the 3’UTR element and that may enhance the selectivity of tumor cell 
specific viral replication. But the most challenging thing for using the RNA virus in this 
targeting approach will be the production of high titer recombinant vectors. It may be 
necessary to alter the producer cell by introducing the appropriate intercellular signals such 
as activated Ras/MAPK signaling, so the viral genome can be stabilized in the producer 
cell and will allow to generate high titer therapeutic viral vectors.
In order to expand the tumor targeting strategy using selective mRNA stability with other 
tumor associated genes, we cloned a second 3’UTR element from the DNA 
methyltransferase 1 (DNMT1) gene, an important enzyme responsible for maintaining the 
cellular epigenetic pattern from parent cell to daughter cell during cell division (Chen & Li,
2006). Several studies have linked this enzyme with tumorogenesis (Szyf, 2002). Increased 
DNMT1 expression in various transformed environments is associated with abnormal cell 
cycle (Szyf, 2001) and increased rate of cell division in tumor cells as compared to their 
normal counterparts. In dividing cells, the stability of the DNMT1 mRNA is dramatically 
increased after the cell entry into the S phase and the 3’UTR of the DNMT1 mRNA is 
crucial for this cell cycle dependent increased mRNA turnover (Detich et al., 2001) 
(Robertson et al., 1999). Because most cancerous tissues contain a higher percentage of 
dividing cells compared to normal tissues (Robertson et al., 2000), we thought it might be 
possible to express therapeutic/viral genes selectively in rapidly dividing tumor cells by 
using the DNMT1 3’UTR. By inserting the DNMT1 3’UTR element downstream of 
adenoviral E1A gene we showed that the E1A gene can be expressed selectively in cancer
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cells and a recombinant adenovirus (AdDNMT) generated by using the E1A-DNMT 
3’UTR construct was able to replicate selectively in various tumor cells. The oncolytic 
activity of the AdDNMT virus was significantly reduced in three immortalized primary cell 
lines in the tissue culture. The oncolytic activities also correlated with DNMT1 protein 
expression and the percentage of cells that were in the S phase of the cell cycle. These in 
vitro data support the conclusion that the DNMT1 3’UTR is able to control transgene 
expression and adenoviral replication selectively in tumor cells. Currently we are 
evaluating the selectivity of the AdDNMT virus in the in vivo animal model.
One of the major obstacles to effective therapeutic use of replicating viruses as anti­
cancer agents is the poor intra-tumoral spread of the released virus where other cell types, 
cell matrix and areas of necrosis exist (Sauthoff et al., 2003). Even after local 
administration into the tumor, the virus usually gets trapped between various compartments „ 
composed of these different cell-types (Heise et al., 1999b). To overcome this problem, we 
exploited a viral fusogenic membrane glycoprotein (FMG), which is a cytotoxic gene that 
induces cell killing through induction of tumor cell fusion by forming large multinuclear 
syncytia. Our laboratory previously demonstrated that the gene transfer of FMG in a 
xenograft tumor model inhibits tumor growth (Bateman et al., 2000a). A recent report also 
showed that the HIV gpl20 -mediated syncytia formation facilitates the dispersal and 
increases the infection efficiency of an adenoviral vector in vitro (Li et al., 2001b). Also, an 
oncolytic herpesvirus expressing Gibbon Ape Leukemia Virus (GALV) hyperfusogenic 
FMG enhances the therapeutic efficacy of the oncolytic virus in vivo (Fu et al., 2003). 
Based on these results, we hypothesized that the FMG expression during viral replication 
inside the tumor might enhance the therapeutic efficacy of the oncolytic viral therapy by
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increasing both the release of the viral particles from the infected cells and the spread of the 
viral particles through out the tumor via the syncytia. We were able to show that GALV 
induced syncytia enhances viral titer and spread of adenoviral vector through a monolayer. 
In the presence of GALV induced syncytia, the titer of the virus released into the culture 
medium is two logs higher than without syncytia. Increased viral titer in syncytia was 
associated with the upregulation of adenoviral El A protein expression through unknown 
post-transcriptional mechanisms. We do not know whether the FMG-induced syncytia 
affect the expression level of the other viral proteins both in early and late phases. It has 
been previously reported by our laboratory that transgene expression can be upregulated in 
syncytia culture due to the increased metabolic activity induced by syncytia formation, 
which can convert the syncytia into transient protein production factories (Bateman, 2002; 
Higuchi et al., 2000). We were also able to show that a combination of different doses of 
FMG gene therapy with replicating adenovirotherapy leads to regression of both small and 
large established tumor xenografts. Moreover, this combined therapy can be effectively 
targeted to cells expressing activated oncogenic signals (RAS/MAPK) by ligation of the 
FMG to the 3’ untranslated region of the COX-2 gene. We believe that FMG expression 
needs to be regulated transcriptionally, or post-transcriptionally, in order to avoid toxicity. 
For safety purpose, it may be wise to keep the FMG expression separate from virus 
replication, but it could be difficult to get approval from the regulatory committee to use 
two separate therapeutic arms (intratumoral FMG+ adenoviral therapy) as a therapy for 
cancer. Therefore, I proposed to develop a conditionally replicating adenovirus expressing 
FMG selectively in the tumor. In addition, we have no notion about the time, or amount, of 
FMG expression required for the maximum interaction between the viral life cycles and the
FMG-induced syncytia, which will give us the optimal synergistic enhancement of the 
therapeutic efficacy. These questions can be addressed by developing a replicating 
adenovirus that expresses FMG at different stages of the viral life cycle by using different 
internal viral promoter (FMG expresses at the early phase of the viral life cycle by the El A 
promoter or expresses at the late phase of the viral life cycle by using the viral major late 
promoter (Wills et al., 1994)). Taken together, we used FMG-induced syncytia to enhance 
the in vivo therapeutic efficacy of an oncolytic adenovirus for the treatment of cancer. The 
FMG-induced syncytia not only act as a potent cytotoxic and immunostimulatory gene for 
cancer gene therapy, but also improve oncolytic viral replication, intratumoral spread and 
production, which enhance the oncolytic properties of the conditionally replicating 
adenovirus.
The application of gene therapy in the treatment of diseases like cancer is currently 
limited due to our inability to efficiently target systemic metastasis. Because different types 
of cancer have diverse biological properties, and since even the most efficient targeting 
strategy currently available has its limitations, it is unrealistic to imagine that an individual 
targeting approach will eventually emerge as the most efficient way to target cancer. 
Besides, most of the tumor specific elements currently used to target cancer cells have 
proven to be leaky due to their expression in the normal anatomical site (Zeh & Bartlett, 
2002). Moreover, most tumors contain a very heterogeneous population of transformed 
cells (Bignold, 2003) (Khong & Restifo, 2002). Targeting cancer with an individual tumor 
specific element will create selection pressures, which will drive the cancer to become 
resistant to therapy (Konson et al., 2004). So, a successful cancer gene therapy approach 
will likely rely on the ability to combine different targeting strategies to create highly
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specialized “mosaic” vectors that safely incorporate different targeting strategies to address 
specific features of each type of cancer (Borovjagin et al., 2005). We think that the post- 
transcriptional targeting strategy of using the 3’UTR will be most efficient in combination 
with other tumor targeting approaches such as transcriptional or transductional targeting. 
One unique feature of the tumor selective mRNA stabilization element such as COX-2 
3’UTR is that we can regulate individual gene expression both at the transcriptional and 
post-transcriptional levels. This may help us target systemic cancer more selectively and 
reduce toxicity from the therapeutic viral vectors.
In summary, this thesis described tumor cell selective mRNA stabilization as a novel 
means to achieve tumor specific therapeutic gene expression. By using two different 
3’UTR mRNA stability elements, we were able to regulate three different transgenes 
selectively in tumor cells. Incorporation of the COX-2 3’UTR in the adenovirus genome 
was sufficient enough to control viral replication and oncolysis both in vitro and in vivo. 
Many other genes have been reported to use tumor cell selective mRNA stabilization as a 
mean to control their expression in the tumor microenvironment. Therefore, targeting 
cancer through tumor cell selective mRNA stabilization could be a viable strategy, which 
may have broad applicability and potential in vector development for cancer gene therapy.
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